| 15;17 translocation FISH | TR1517 | Not detected |
| 1p and 19q deletion by FISH | | Ratio > 0.8 (no deletion) |
| 5-Fluorocytosine | 5FC | < 1.0 µg/mL |
| 5-Hydroxyindoleacetic acid, 24 hour urine | 5HQT |
| 24 hour urine |
|
|
2-10 years |
< 8.0 mg/d |
|
> 10 years |
< 6.0 mg/d |
|
| 5-Hydroxyindoleacetic acid, random urine | 5HQTR |
| 2-10 years |
≤ 12.0 mg/g creatinine |
|
> 10 years |
≤ 10.0 mg/g creatinine |
|
| 7-Dehydrocholesterol | DHC7 | See Additional Information |
| ABL Kinase domain mutations | KDSQ | None detected |
| ABO and Rh Typing | ABRH | |
| ABO only | ABO | |
| ABO/Rh Confirmation (New test) | CHEK | |
| Acanthamoeba & Naeglaria, Direct exam | P409 | Negative |
| Acetaminophen | AAPH |
| Therapeutic |
10-20 mg/L |
|
Toxic |
> 150 mg/L (4 hours post ingestion) |
|
| Acetylcholine Receptor Binding Antibody | ACRA |
| Negative |
≤ 0.30 nmol/L |
|
Equivocal |
0.31-0.49 nmol/L |
|
Positive |
≥ 0.50 nmol/L |
|
| Acid Hemolysis | AHEM | Negative |
| Acid Phosphatase, Total | APHT | 0.0-4.3 U/L |
| Activated Partial Thromboplastin Time | PTT |
| Age |
Normal range |
|
Full term infant, 0-5 day old |
25.0-60.0 seconds |
|
Full term infant, 6 days-3 months |
24.0-50.0 seconds |
|
>3 months |
22.2 - 33.0 seconds |
An infant reference range has not been experimentally determined using our current PTT reagent. The PTTs of normal infants are longer than those of adults due to lower factor levels in the first months of life; the infant reference ranges provided (5 days, 3 months) are based on published literature (Ref: Andrew M et al. Blood 1987; 70-165). This publication further indicates that although trending longer, PTT values at 3 months may not differ statistically from adult values. If there is concern for clotting factor deficiency or inhibitor in an infant, factor activity assays should be requested if clinically indicated. |
| Acylcarnitine Profile | ACYLP | see table |
| Acylglycine Profile | AGLY |
| 2-Ethylmalonic Acid |
0.5-20.2 µg/mg creatinine |
|
2-Methylsuccinic Acid |
0.4-13.8 µg/mg creatinine |
|
Glutaric Acid |
0.6-15.2 µg/mg creatinine |
|
Isobutyrylglycine |
< 0.01-11.0 µg/mg creatinine |
|
n-Butyrylglycine |
0.1-2.1 µg/mg creatinine |
|
2-Methylbutyrylglycine |
0.3-7.5 µg/mg creatinine |
|
Isovalerylglycine |
0.3-14.3 µg/mg creatinine |
|
n-Hexanoylglycine |
0.2-1.9 µg/mg creatinine |
|
n-Octanoylglycine |
0.1-2.1 µg/mg creatinine |
|
3-Phenylpropionylglycine |
< 0.01-1.1 µg/mg creatinine |
|
Suberylglycine |
< 0.01-11.0 µg/mg creatinine |
|
trans-Cinnamoylglycine |
0.2-14.7 µg/mg creatinine |
|
Dodecanedioic Acid (12 DCA) |
0.1-1.1 µg/mg creatinine |
|
Tetradodecanedioic Acid (14 DCA) |
< 0.01-1.0 µg/mg creatinine |
|
Hexadodecanedioic Acid (16 DCA) |
< 0.01-1.0 µg/mg creatinine |
|
| Adenosine Deaminase & Purine Nucleoside Phosphorylase Enzymes (New test) | ADAPQ | |
| Adenovirus Antibody | ADEN | |
| Adenovirus DNA | ADVP | |
| Adrenocorticotropic hormone | ACTH |
| ≥18 years |
6-50 ng/L |
|
3-17 years |
9-57 ng/L |
|
<3 years |
Not established |
Reference ranges adopted from Quest Diagnostics as determined in adult and pediatric groups using the same methodology (Siemens Immulite 2000 chemiluminescent assay). The Quest adult reference range was verified by in house testing of 10 male and 23 female lab volunteers. Owing to circadian variation in ACTH levels, the reference ranges are only applicable to samples collected between 0700 and 1000 hours. |
| Alanine transaminase | ALT | Male
|
0 - 17 years |
20-60 U/L |
|
≥18 years |
12-60 U/L |
Female:
|
0 - 3years |
20-60 U/L |
|
4 years - 17 years |
20-50 U/L |
|
≥18 years |
11-50 U/L |
Note:
1. Normal range for children 0 to <18 years adapted from "Pediatric Reference Intervals", 6th edition, AACC Press, 2007, method 4.
2. Normal range for adults was determined by testing 269 male and female healthy blood donors at UCSF. |
| Albumin (Microalbumin), 24 hour urine | AU24 | 24 hour collection:
|
Normal |
< 30 mg/D |
|
Microalbuminuria |
30-299 mg/D |
|
Nephropathy |
> 300 mg/D |
|
| Albumin (Microalbumin), spot urine | AUR | Random urine:
|
Normal |
< 30 mg/g creatinine |
|
Microalbuminuria |
30-299 mg/g creatinine |
|
Nephropathy |
> 300 mg/g creatinine |
|
| Albumin, Body Fluid | ALBB | |
| Albumin, CSF | ALBC | 6.6-44.2 |
| Albumin, Serum / Plasma | ALB |
| 0-7 days |
1.9-4.0 g/dL |
|
8 days – 11 months |
2.7-4.8 g/dL |
|
1 year – 17 years |
3.1-4.8 g/dL |
|
≥18 years |
3.5-4.8 g/dL |
Note:
1. Normal range for infants 0-7 day old adopted from "Pediatric Reference Ranges", 6th edition, AACC Press, 2007, method 4 Bromcresol purple (BCP)
2. Normal range for children 8 days to less than 18 years old adopted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
3. Normal range for adults was determined by testing 271 male and female healthy blood donors at UCSF. |
| Aldolase | ADSE | Pediatric males & females:
|
< 24 months |
3.4-11.8 U/L |
|
2-17 years |
3.4-8.6 U/L |
|
| Aldosterone, serum | ALDT | ≥ 18 year olds:
|
Upright 8:00-10:00 am |
≤ 28 ng/dL |
|
Upright 4:00-6:00 pm |
≤ 21 ng/dL |
|
Supine 8:00-10:00 am |
3-16 ng/dL |
Pediatric:
|
1-12 months |
2-70 ng/dL |
|
1-4 years |
2-37 ng/dL |
|
5-9 years |
≤ 9 ng/dL |
|
10-13 years |
≤ 21 ng/dL |
|
14-17 years |
≤ 35 ng/dL |
|
Premature infants (31-35 weeks) |
≤ 144 ng/dL |
Tanner Stages:
|
II-III Males |
1-13 ng/dL |
|
II-III Females |
2-20 ng/dL |
|
IV-V Males |
3-14 ng/dL |
|
IV-V Females |
4-32 ng/dL |
|
| Aldosterone, urine | ALDU | On a typical diet containing 100-300 mmol Sodium per day:
|
2-7 years |
≤ 5.7 µg/d |
|
8-11 years |
≤ 10.2 µg/d |
|
12-16 years |
≤ 15.6 µg/d |
|
≥ 18 year olds |
≤ 2.3-21.0 µg/d |
Post-fludrocortisone or IV saline suppression: < 5.0 µg/d |
| Alkaline Phosphatase | ALKP |
| Age |
Male |
Female |
|
< 1 month |
75-316 U/L |
48 - 406 U/L |
|
1 month - 11 months |
82 - 383 U/L |
124 - 341 U/L |
|
1 - 4 years |
110 - 302 U/L |
60 - 321 U/L |
|
5 - 9 years |
110 - 341 U/L |
118 - 360 U/L |
|
10 - 11 years |
103 - 373 U/L |
103 - 373 U/L |
|
12 - 13 years |
83 - 382 U/L |
83 - 382 U/L |
|
14 - 15 years |
67 - 372 U/L |
67 - 372 U/L |
|
16 - 18 years |
47 - 171 U/L |
45 - 171 U/L |
|
≥18 years |
31 - 95 U/L |
31 95 U/L |
Note:
1. Normal range for infants 0 to <1 year adopted from "Pediatric Reference Ranges", 6th edition, AACC Press, 2007, method 3
(p-Nitrophenylphosphate)
2. Normal range for children 1 to less than 16 years old adopted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
3. Normal range for children 16 to <18 years old adopted from "Pediatric Reference Ranges", 6th edition, AACC Press, 2007, method 3 (p-Nitrophenylphosphate)
4. Normal range for adults was determined by testing 271 male and female healthy blood donors at UCSF. |
| Alkaline Phosphatase, Bone-specific | BSAP | ≥ 18 year old males:
|
18-29 Years |
8.4-29.3 µg/L |
|
30-39 Years |
7.7-21.3 µg/L |
|
40-49 Years |
7.0-18.3 µg/L |
|
50-68 Years |
7.6-14.9 µg/L |
≥ 18 year old females:
|
18-29 Years |
4.7-17.8 µg/L |
|
30-39 Years |
5.3-19.5 µg/L |
|
40-49 Years |
5.0-18.8 µg/L |
|
50-76 Years |
5.6-29.0 µg/L |
|
Premenopausal (35-45 Years) |
5.0-18.2 µg/L |
Pediatrics:
Males
|
2-24 Months |
25.4-124.0 µg/L |
|
6-9 Years |
41.0-134.6 µg/L |
|
10-13 Years |
43.8-177.4 µg/L |
|
14-17 Years |
13.7-128.0 µg/L |
Females:
|
2-24 Months |
25.4-124.0 µg/L |
|
6-9 Years |
41.0-134.6 µg/L |
|
10-13 Years |
24.2-154.2 µg/L |
|
14-17 Years |
10.5-75.2 µg/L |
|
| Alpha Subunit of Glycoprotein Hormones | ASUB |
| Males |
≤ 0.6 ng/mL |
|
Premenopausal females |
≤ 1.5 ng/mL |
|
Postmenopausal females |
0.9-3.3 ng/mL |
|
Pregnancy (1st & 2nd Trimest) |
1.8-360 ng/mL |
|
Hypothyroid patients |
≤ 3.7 ng/mL |
|
| Alpha Thalassemia Gene Mapping (New test) | ATHSB | Negative
No alpha globin gene deletions detected.
No alpha globin gene triplication detected |
| Alpha Thalassemia mutations | ATHL | Negative. No alpha globin gene deletions detected. |
| Alpha Thalassemia point mutations | HBCS | No Mutation Detected |
| Alpha-1-Antitrypsin, Phenotyping | ATPN | 90% of Normals are MM |
| Alpha-1-Antitrypsin, clearance | A1AC |
|
| Alpha-1-Antitrypsin, random stool | A1AF | ≤ 54 mg/dL |
| Alpha-1-Antitrypsin, serum | A1AT | 79-207 mg/dL |
| Alpha-Fetoprotein, CSF | AFPCSF | < 1.5 ng/mL
Reference range in newborns is not established. |
| Alpha-Fetoprotein, serum | AFPT | < 8.1 µg/L |
| Alpha-Galactosidase Activity, Leukocytes | AGA | > 23 nmol/h/mg protein |
| Alpha-fetoprotein, amniotic fluid (with reflex to Acetylcholinesterase and Hgb F) | AFPX |
| MOM |
< 2.00 |
|
Acetylcholinesterase |
Neg |
|
Fetal Hemoglobin |
Neg |
|
| Alternative Pathway Activity | MOLT | 77-159 Units/mL |
| Aluminum, plasma | ALUM |
| Non-dialysis patient |
≤ 7 µg/L |
|
Dialysis patient |
< 40 µg/L |
|
| Amikacin | AMIKP (Peak), AMIKT (trough), AMIKRN (random) |
| Peak |
20.0 - 30.0 µg/mL |
|
Trough |
< 8.0 µg/mL |
|
| Amino Acids, CSF, Quantitative | AACSF | |
| Amino Acids, Urine, Quantitative | AAQU | See report |
| Aminolevulinic acid dehydratase, RBC | ALAD |
| Normal |
>3.9 nmol/L/sec |
|
Indeterminate |
3.5-3.9 nmol/L/sec |
|
Decreased |
<3.5 nmol/L/sec |
|
| Amiodarone | AMIO |
| Therapeutic for each |
1.5-2.5 mg/L |
|
Toxic:Amiodarone |
> 2.5 mg/L |
|
Desethyl-amiodarone |
> 2.0 mg/L |
|
| Amitriptyline | AMTR | 100-250 µg/L for sum of drug and metabolite |
| Ammonia | NH3 |
| < 30 days |
< 50 µmol/L |
|
≥ 30 days |
< 35 µmol/L |
Note: Reference ranges determined by validating the assay manufacturer's reference range in 24 adult laboratory staff and by adapting the newborn reference range from method number 2 in Soldin et al. Pediatric Reference Intervals, 6th edition, 2007 |
| Amphetamine Screen, Urine | AMPU | Negative
Note: a negative result indicates that this class of drugs is not present, or they are present at a concentration below the cut-off concentration of 1000 µg/L |
| Amphetamine confirmation, urine | AMPC | Not detected |
| Amylase, Body Fluid | AMYB | |
| Amylase, Serum / Plasma | AMY |
| 0 - 5 months |
5 - 65 U/L |
|
6 months - 2 years |
12 - 113 U/L |
|
3 years – 5 years |
26 – 163 U/L |
|
6 years - 11 years |
27 - 113 U/L |
|
12 years - 17 years |
30 - 126 U/L |
|
≥18 years |
23 -144 U/L |
Serum reference range established June 20, 2011 by testing samples from 120 male and female blood donors.
Pediatric reference ranges adapted from Tietz, Fundamentals of Clinical Chemistry, 5th ed., 2001 and from Clifford et al, Clinica Chimica Acta 412 (2011)788-790. |
| Amylase, random urine | AMYUR | < 650 U/L |
| Amylase, timed (2 hour) urine | AMYU | 1-17 U/hour |
| Anaerobic Culture | | |
| Anaplasma phagocytophilium, Antibodies (IgG & IgM) | ANAPL |
| IgG |
< 1:64 titer |
|
IgM |
< 1:20 titer |
|
| Androstanediol Glucuronide, 3 alpha- | AGLU |
Tanner Stages II-III:
|
Males |
19-164 ng/mL |
|
Females |
33-244 ng/dL |
≥ 18 year olds:
|
Males |
260-1500 ng/dL |
|
Females |
60-300 ng/dL |
|
| Androstenedione | ASDN | Pediatric:
|
1-12 months |
6-78 ng/dL |
|
1-4 years |
5-51 ng/dL |
|
5-9 years |
6-115 ng/dL |
|
10-13 years |
12-221 ng/dL |
|
14-17 years |
22-225 ng/dL |
|
Premature infants (31-35 weeks) |
≤ 480 ng/dL |
|
Term infants |
≤ 290 ng/dL |
Tanner Stages:
|
II-III Males |
17-82 ng/dL |
|
II-III Females |
43-180 ng/dL |
|
IV-V Males |
57-150 ng/dL |
|
IV-V Females |
7-68 ng/dL |
≥ 18 year old male:
|
18-30 years |
50-220 ng/dL |
|
31-50 years |
40-190 ng/dL |
|
51-60 years |
50-220 ng/dL |
≥ 18 year old female:
|
Follicular |
35-250 ng/dL |
|
Mid-cycle |
60-285 ng/dL Luteal |
30-235 ng/dL |
|
Postmenopausal |
20-75 ng/dL |
|
| Aneuvysion FISH | CYFDB | Normal. See Additional Information |
| Angiotensin Converting Enzyme, CSF | ACEC | ≤ 15 U/L |
| Angiotensin Converting Enzyme, serum | ACE |
| Pediatric 6 mo-17 years |
13-100 U/L |
|
Adults 19-61 years |
9-67 U/L |
|
| Anion Gap (Information only) | | 4-14
Normal range was determined by testing 412 male and female healthy adult blood donors at UCSF. |
| Anti-Cardiolipin Antibody, IgA | ACLA |
| Normal |
< 10 APL U/mL |
|
Equivocal |
10-15 APL U/mL |
|
Positive |
> 15 APL U/mL |
|
| Anti-Cardiolipin Antibody, IgG | ACLG |
| Normal |
< 15.0 GPL units |
|
Equivocal |
15.0-20.0 GPL units |
|
Moderate positives |
20.1-80.0 GPL units |
|
High positives |
> 80.0 GPL units |
|
| Anti-Cardiolipin Antibody, IgM | ACLM |
| Normal |
< 12.5 MPL units |
|
Equivocal |
12.5-20.0 MPL units |
|
Moderate positive |
20.1-80.0 MPL units |
|
High positive |
> 80.0 MPL units |
|
| Anti-Cyclic Citrullinated Peptide Antibody (IgG) | CYCP |
| Negative |
< 20 Units |
|
Weak Positive |
20.0-39.9 Units |
|
Moderate Positive |
40.0-59.9 Units |
|
Strong Positive |
> 59.9 Units |
|
| Anti-IgA | AIGA |
| Negative |
≤ 52.0 Units |
|
Positive |
> 52.0 Units |
|
| Anti-Mullerian Hormone (New test) | AMH | Females
|
<14 years |
0.30-11.21 ng/mL |
|
14-19 years |
Not established |
|
20-29 years |
0.65-16.40 ng/mL |
|
30-39 years |
0.16- 8.43 ng/mL |
|
40-49 years |
< 5.20 ng/mL |
|
> 49 years |
< 2.05 ng/mL |
Males
|
< 1 year |
101.90-262.00 ng/mL |
|
1- 6 years |
87.30-243.80 ng/mL |
|
7-11 years |
34.30-230.10 ng/mL |
|
12-17 years |
< 135.45 ng/mL |
|
> 17 years |
1.45 - 15.27 ng/mL |
|
| Anti-Neutrophil Antibodies | | |
| Anti-Nuclear Antibodies | ANA | Negative titer < 40 |
| Anti-Phospholipid Antibody Panel | APLA | |
| Anti-Streptolysin O | ASO | ≤ 200 IU/mL |
| Anti-phospholipid Syndrome Information | | |
| Antibodies to Extractable Nuclear Antigens | AENA | For both anti-SM and anti-SM/RNP:
|
Negative |
< 20 Units |
|
Weak Positive |
20-39 Units Index |
|
Moderate Positive |
40-80 Units |
|
Strong Positive |
> 80 Units |
|
| Antidiuretic Hormone | AVP |
| Antiduretic Hormone |
1.0 - 13.3 pg/mL |
|
Serum osmolality |
283-301 mmol/kg |
|
| Antimicrobial Susceptibility, Agar Dilution | B048 | |
| Antimicrobial Susceptibility, Disc | B046 | |
| Antimicrobial Susceptibility, E test | B047 | |
| Antimicrobial Susceptibility- Routine MICs | B045 | |
| Antimicrobial Synergy Study | B043 | |
| Antimicrobial susceptibility testing | | |
| Antimicrobicidal Susceptibility | B042 | |
| Antiplasmin Activity | A2PI |
| Newborn |
≥ 50% |
|
≥ 18 year old |
80-140% |
30-36 wk premature infants may not reach
adult levels for up to 90 days of age |
| Antithrombin Activity | AT |
| 0-3 months |
Not established (See Additional Information) |
|
Adult (> 3 mo.) |
79-120% |
|
| Apt Test | APT | Adult |
| Argatroban Assay | ARGA | Therapeutic anticoagulation: 0.5-2.0 µg/mL (mcg/mL)
Note: these values may not be applicable to intra-operative anticoagulation. See 'Additional information' |
| Array CGH, Family F/U | PCGH | Normal |
| Array CGH, constitutional | ACGHC | Normal |
| Array CGH, prenatal | ACGHP | Normal |
| Arsenic, 24 hour urine | ASU | < 81 µg/L (Varies w/diet) |
| Arsenic, blood | ASB | ≤ 60 µg/L |
| Arsenic, random urine | ASUR |
| Non-exposed ≥ 18 year old |
≤ 50 µg/g creatinine |
|
| Arylsulfatase A | ASUL | > 2.4 U/L |
| Ascaris lumbricoides eggs | P401 | |
| Ascaris lumbricoides larvae | P412 | |
| Ascaris lumbricoides worm | P404 | |
| Ascorbic Acid | ASCA | 0.20-1.90 mg/dL |
| Aspartate transaminase | AST |
| 0-7 days |
24-100 |
|
8-30 days |
20-72 |
|
1 month - 11 months |
13-65 |
|
1 year - 5 years |
18-63 |
|
≥ 6 years |
17-42 |
Note:
1. Normal range for infants 0-1 year adapted from "Pediatric Reference Intervals", 6th edition, AACC Press, 2007, method 1.
2. Normal range for 1 to 6 year old children adapted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
3. Normal range for children >6 years adapted using adult normal ranges after comparison of Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345 and adult normal ranges.
4. Normal range for adults was determined by testing 270 male and female healthy blood donors at UCSF. |
| Aspergillus Antibodies | ASPG | Negative |
| Aspergillus species Culture | P259A | |
| Aspirin Tolerance Test | ASPT |
| Pre-ASA |
< 11 min |
|
Post-ASA |
< 11 min. |
|
| Avian Influenza A | P319 | Negative |
| B-Cell Crossmatch by Cytotoxicity (For Donor) (New test) | ILBXCD | |
| B-Cell Crossmatch by Cytotoxicity (Recipient) (New test) | ILBXCR | |
| B-Cell Crossmatch by Cytotoxicity w/ DTT (Recipient) (New test) | ILBXDT | |
| B-Type Natriuretic Peptide | BNP |
| Age |
Male |
Female |
|
< 45 |
< 25 pg/mL |
< 48 pg/mL |
|
45-54 |
< 40 pg/mL |
< 73 pg/mL |
|
55-64 |
< 73 pg/mL |
< 82 pg/mL |
|
65-74 |
< 64 pg/mL |
< 96 pg/mL |
|
> 74 |
< 79 pg/mL |
< 181 pg/mL |
|
| B-cell Phenotyping Profile (New test) | MOLT | |
| B-tryptase | BTRP | See Additional Information |
| B. pertussis/parapertussis PCR | P355 | Not Detected |
| BCR/ABL Quantitative by PCR | BCRABL | No BCR-ABL fusion transcripts. |
| BCR/ABL translocation FISH | TR922 | Not detected |
| BK virus, DNA, Quantitative, plasma | BKV | Not detected |
| BK virus, DNA, Quantitative, urine | BKVU | Not detected |
| BRAF V600E Mutation testing by RT-PCR | | No mutation detected |
| BRCA Mutations | MOLT | No Mutation Detected |
| Babesia microti Antibodies (IgG & IgM) | BABES |
| Babesia Ab IgG |
< 1:64 titer |
|
babesia Ab IgM |
< 1:20 titer |
|
| Bacterial Culture, Abscess | | |
| Bacterial Culture, Blood, Aerobic & Anaerobic | P062 | |
| Bacterial Culture, Body Fluid | P077 | |
| Bacterial Culture, CSF | P076 | |
| Bacterial Culture, Duodenal aspirate | P081 | |
| Bacterial Culture, Genital | P070 | |
| Bacterial Culture, Head & Neck | P067 | |
| Bacterial Culture, Miscellaneous | P113 | |
| Bacterial Culture, Nasopharyngeal | | |
| Bacterial Culture, Normally Sterile Tissue | P078 | |
| Bacterial Culture, Referral culture | P026 | |
| Bacterial Culture, Respiratory | P063 | |
| Bacterial Culture, Stool | P166 | |
| Bacterial Culture, Surgical drainage | P079 | |
| Bacterial Culture, Urine w/ gram stain | P059S | See Additional Information |
| Bacterial Culture, Urine w/o gram stain | P059 | |
| Bacterial Culture, Wound Aerobic & Anaerobic w/gram stain | P081 | |
| Bacterial Culture, Wound, Aerobic only | P080 | |
| Barbiturate confirmation, urine | BARC | Not detected |
| Barbiturates Screen, Urine | BARB | Negative
Note: a negative result indicates that this class of drugs is not present, or they are present at a concentration below the cutoff concentration of 200 µg/L |
| Bartonella species Antibodies | BART |
| Negative |
< 1:64 for IgG |
|
Negative |
< 1:16 for IgM |
|
| Basic Metabolic Panel (New test) | CBMP | See individual test entries |
| Beckwith-Wiedemann Syndrome | MOLT | 0.45-0.54 |
| Benzodiazepine confirmation, urine | BENC | Not detected |
| Benzodiazepines Screen, Urine | BENZ | Negative
Note: a negative result indicates that this class of drugs is not present, or they are present at a concentration below the cutoff concentration of 200 µg/L |
| Beta Amyloid 42/Tau Protein Analysis, CSF (New test) | | |
| Beta Globin Gene Deletions by PCR | BDEL | Negative for deletions |
| Beta Thalassemia mutations (incl. HbS, HbC, HbE) | BTHL | Negative |
| Beta-2 Microglobulin, urine | B2MU |
| Normal |
≤ 132 µg/g creatinine |
|
OSHA Industrial Reference range |
300 µg/g creatinine |
|
| Beta-2-Microglobulin, serum | B2MI | < 2.35 mg/L |
| Beta-2-glycoprotein Antibody, IgA | B2GA | ≤ 20 SAU |
| Beta-2-glycoprotein Antibody, IgG | B2GPG | < 21 SGU |
| Beta-2-glycoprotein Antibody, IgM | B2GPM | < 21 SMU |
| Beta-D-glucan | BDGLU | < 60 pg/mL |
| Beta-Hydroxybutyrate (New test) | BHOB | 0.02 - 0.27 mmol/L |
| Beta-globin DNA Sequencing | BGSQ | Negative |
| Bile Acids, Total (New test) | BILET | Fasting sample 0 - 10 µmol/L |
| Bilirubin, Direct | BILD |
| < 1 week |
<0.9 mg/dL |
|
≥ 1 week |
<0.3 mg/dL |
Note:
1. Normal range for neonates 0-1 week adopted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
2. Normal range for adults was determined by testing 271 male and female healthy blood donors at UCSF. Adult range adopted for pediatric patients >1 week. |
| Bilirubin, Total | BILT | 0.2-1.3 mg/dL
Normal range was determined by testing 268 male and female healthy adult blood donors at UCSF. |
| Bilirubin, Total, Body Fluid | BILTBF | |
| Biopterin (Newborn Screening follow-up only) | | |
| Biotinidase | BIOTI | 3.3-8.7 nmole/min/mL |
| Blastomycosis Antibody | BLAS | Negative |
| Bleeding Time | BT |
| Age |
Normal |
|
0-4 months old |
< 3 min |
|
> 4 months old |
< 11 min |
|
| Blood Gas Panel Information | | |
| Blood Gases |
| Parnassus (NCPL) |
NGAS |
|
Mount Zion |
ORBG |
|
| Analyte |
Ages |
Arterial |
Venous |
|
pH |
All |
7.35-7.45 |
7.31-7.41 |
|
pCO2 |
< 1 year |
27-41 mmHg |
41-51 mmHg |
|
pCO2 |
≥ 1 year |
32-48 mmHg |
41-51 mmHg |
|
pO2 |
< 30 days |
80-100 mmHg |
35-40 mmHg |
|
pO2 |
≥ 30 days |
83-108 mmHg |
35-40 mmHg |
|
HCO3- |
All |
22-27 mmol/L |
|
Base Excess (BE) |
All |
-2 to 2 |
|
Oxygen saturation (SaO2) |
All |
95-99% |
|
| Blood Smear Morphology | MORP | Normal |
| Blood Smear Preparation | SLID | |
| Body Surface Area | BSA | |
| Bone Marrow Collection and Examination | | |
| Bone Marrow Culture | | |
| Bone Marrow Storage | BMST | |
| Bordetella pertussis Antibody (IgG/IgA) | BPAB |
| PT IgG |
< 45 IU/mL |
|
PT IgA |
< 10 IU/mL |
|
FHA IgG |
< 90 IU/mL |
|
FHA IgA |
< 50 IU/mL |
|
| Borrelia burgdorferi, infected tick | | Negative |
| Botulism Toxin, Adults and Children > 12 months old | P319 | Negative |
| Botulism Toxin, Children < 12 months old | P319 | Negative |
| Brilliant Cresyl Blue Stain | BCB | Negative |
| Brucella antibodies (IgG, IgM) | BRUCI | < 0.80 U
Interpretive criteria:
|
Negative |
< 0.80 U |
|
Equivocal |
0.80-1.09 U |
|
Positive |
≥ 1.10 U |
|
| Bullous pemphigoid Antibodies (New test) | BPPAB | < 9.0 U |
| Buprenorphine, urine (New test) | BUPU | < 5 ng/mL |
| Bupropion | BUPR | 25-100 ng/mL |
| Burkholderia cepacia culture | P119 | |
| Burkholderia pseudomallei Antibodies (IgG & IgM) | MOLT |
| Negative IgG |
< 64 titer |
|
Negative IgM |
< 40 titer |
|
| Busulfan Pharmacokinetics, Adult (Non-Research) (New test) | BUSUA, BUSAR2, BUSAR3, BUSAR4 |
| Area Under the Curve |
900-1500 µmol*min |
|
Steady state concentration (Css) |
600-900 ng/mL |
|
| Busulfan Pharmacokinetics, Pediatric (Non-Research) (New test) | BUSUP, BUSRP2, BUSRP3, BUSRP4, BUSRP5, BUSRP6 |
| Area Under the Curve |
900-1350 µmol*min |
|
Steady state concentration (Css) |
600-900 ng/mL |
|
| C-Reactive Protein | CRP | < 6.3 mg/L |
| C-Reactive protein, Highly Sensitive | CRPH |
| Tertile |
CRP mg/L |
Cardiovascular Risk |
|
1 |
< 1.0 |
Low |
|
2 |
1.0-3.0 |
Moderate |
|
3 |
> 3.0 |
High |
|
| C-telopeptide (New test) | CTX | Pediatric:
|
Age |
Males |
Females |
|
5-9 years |
574-1849 pg/mL |
574-1849 pg/mL |
|
10-13 years |
519-2415 pg/mL |
519-2415 pg/mL |
|
14-17 years |
435-2924 pg/mL |
242-1291 pg/mL |
Adult:
|
Age |
Males |
Females |
|
18-29 years |
87-1200 pg/mL |
64-640 pg/mL |
|
30-39 years |
70-780 pg/mL |
60-650 pg/mL |
|
40-49 years |
60-700 pg/mL |
40-465 pg/mL |
|
50-68 years |
87-345 pg/mL |
Not available |
|
| C1 Esterase Inhibitor Deficiency panel | C1EI | C1EI activity (by decay of C1r):
|
Normal |
> 67% |
|
Equivocal |
41-67% |
|
Abnormal |
< 41% |
|
C1EI quantitation |
11-26 mg/dL |
|
C1q quantitation |
5.0-8.6 mg/dL |
|
| C90rf72 Repeat Expansion (New test) | ALSC9 | Negative for the hexanucleotide repeat expansion (1-30 repeats) |
| CD3 dose estimation | CD3D | Not applicable |
| CEBPA Mutation | CEBPA | Negative for mutation |
| CSF IgG Synthesis Rate | | |
| CYP2C19 Genotype | 2C19 | Wildtype 2C19 (*1/*1) |
| Cadmium | CADM |
| Non-smokers |
|
< 1.7 µg/L |
|
≥ 18 year old smokers |
< 5.0 µg/L OSHA reference range |
< 5.0 µg/L Potentially toxic |
30 µg/L |
|
| Caffeine | CAFF |
| Therapeutic |
8-20 mg/L Potentially Toxic |
> 50 mg/L |
|
| Calcitonin | CATN |
| ≥ 18 year old males |
≤ 10 pg/mL |
|
≥ 18 year old females |
≤ 5 pg/mL |
Pediatrics (Males and Females):
|
< 6 months |
≤ 41 pg/mL |
|
6 months-3 years |
≤ 14 pg/mL |
|
3-17 years |
≤ 6 pg/mL |
|
| Calcitonin Stimulation Test | CATN x mult | Normal response:
|
Pentagastrin alone |
Male |
Female |
|
1 or 2 min |
≤ 106 pg/mL |
≤ 29 pg/mL |
|
at 5 min |
≤ 106 pg/mL |
≤ 23 pg/mL |
|
Ca++ & Pentagastrin |
Male |
Female |
|
at 1 min |
≤ 324 pg/mL |
≤ 41 pg/mL |
|
at 2 min |
10-491 pg/mL |
≤ 70 pg/mL |
|
at 5 min |
8-343 pg/mL |
≤ 39 pg/mL |
|
at 10 min |
≤ 112 pg/mL |
≤ 23 pg/mL |
|
| Calcium, Ionized, post-filter (New test) | PCAI | |
| Calcium, Ionized, serum/plasma | CAI |
| 0-1 month |
1.00-1.50 mmol/L |
|
1-6 months |
0.95-1.50 mmol/L |
|
≥ 6 months |
1.16-1.36 mmol/L |
|
| Calcium, Ionized, whole blood (MtZ Only) | CAIB |
| < 6 months |
0.95-1.50 mmol/L |
|
≥ 6 months |
1.15-1.29 mmol/L |
|
| Calcium, total, 24 hour urine | CAU | Usually 100-300 mg/D |
| Calcium, total, Serum / Plasma | CA |
| < 1 year |
9.0-10.9 mg/dL |
|
≥ 1 year |
8.8-10.3 mg/dL |
Note:
1. Normal range for children 0-1 year adopted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
2. Normal range for adults used for children >1 year. Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345 for 1-3 year olds and Tietz', "Fundamentals of Clinical Chemistry" 5th ed, 2001, for 2-12 year olds showed reference intervals comparable to adult range.
3. Normal range for adults was determined by testing 270 male and female healthy blood donors at UCSF. |
| Calcium, total, random urine | CAUR | |
| Calprotectin, fecal (New test) | CPRN | ≤ 162.9 µg/g |
| Cancer Antigen 125 | C125 | < 36 U/mL in females. Not established in males, See Additional Information |
| Cancer Antigen 15-3 | CA15 | < 33 U/mL |
| Cancer Antigen 19-9 | CA19 | < 36 U/mL |
| Cancer Antigen 27.29 | CA27 | < 39 U/mL |
| Cannabinoids confirmation, urine | THCC | Not detected |
| Carbamazepine | CZP |
Source: Carbamazepine: Drug information copyright 1978-2012, Lexicomp, Inc. Accessed at UpToDate www.uptodate.com August 2012. |
| Carbohydrate deficient transferrin, for Alcohol Abuse | CDTA | 0.00-0.10 |
| Carbohydrate deficient transferrin, for Metabolic errors | CDT | Congenital disorders of glycosylation:
|
Mono-oligosaccharide/Di-oligosaccharide |
≤ 0.10 |
|
A-oligosaccharide/Di-oligosaccharide |
≤ 0.05 |
|
| Carbon Dioxide, Total | CO2 |
| 0 - 15 years |
16 – 30 mmol/L |
|
≥ 16 years |
22 – 32 mmol/L |
1. Normal range for 0 to 15 year old children adapted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
2. Normal range for >18y adults was determined by testing 271 male and female healthy blood donors at UCSF. Adult range adapted for children 16-18 years |
| Carcinoembryonic Antigen | CEA | < 3.8 µg/L |
| Carcinoembryonic Antigen, Pancreatic cyst fluid | CEAP | |
| Carnitine, plasma | CARN |
| Total carnitine |
20-71 µmole/L |
|
Free carnitine |
18-69 µmole/L |
|
Acyl/Free ratio |
0.1-0.4 |
|
| Carnitine, urine | UCARN |
| Free Carnitine, Urine |
10-270 nmol/mg Cr |
|
Total Carnitine, Urine |
75-500 nmol/mg Cr |
|
Acyl/Free Carnitine Ratio, Urine |
0.5-5.0 ratio |
|
| Carotene | CARO |
| PEDIATRIC 9 mo-6 years |
< 48 µg/dL 7-17 years |
< 95 µg/dL |
|
≥ 18 year old Males |
4-51 µg/dL Females |
6-77 µg/dL |
|
| Catecholamines, Fractionated, random urine | UCAFR | |
| Cell Count and Differential, body fluid | CCDB | |
| Cell Count and Differential, CSF | CCDC |
| Appearance |
Clear |
|
Xanthochromia |
Negative |
|
WBC |
< 6 x106/L |
|
RBC |
None |
|
Neutrophils |
None |
|
| Ceroid Lipofucinosis | | |
| Ceruloplasmin | CERU | 19-68 mg/dL |
| Chimerism Testing – CD14/15 Cell Subset (New test) | ILNH14 | |
| Chimerism Testing – CD19 Cell Subset (New test) | ILNH19 | |
| Chimerism Testing – CD3 Cell Subset (New test) | ILNH3 | |
| Chimerism Testing – CD33 Cell Subset (New test) | ILNH33 | |
| Chimerism Testing – CD34 Cell Subset (New test) | ILNH34 | |
| Chimerism Testing – CD56 Cell Subset (New test) | ILNH56 | |
| Chimerism Testing – CD71 Cell Subset (New test) | ILNH71 | |
| Chimerism Testing – Granulocyte Cells Subset (New test) | ILNHGR | |
| Chimerism Testing – Informatives (Recipient and Donor) (New test) | ILNH1 | |
| Chimerism Testing – Whole Blood or Bone Marrow (New test) | ILNH2 | |
| Chlamydia Antibody (MIF) | CPNI (C. pneumoniae (TWAR)), CTRI (C. tranchomatis), CPSI (C. psittaci) |
| Antibody |
Negative Titer |
|
IgG |
<1:64 |
|
IgA |
<1:16 |
|
IgM |
<1:10 |
|
| Chlamydia Culture | P699 | No Chlamydia isolated |
| Chlamydia trachomatis DNA Detection, Cervix or Urethral | P702 | Negative |
| Chlamydia trachomatis DNA detection from Throat & Rectal Samples (New test) | P360 | Not detected |
| Chloramphenicol | MOLT |
| Therapeutic peak |
10-20 mg/L |
|
Potentially toxic |
> 25 mg/L |
|
| Chloride, 24 hour urine | CLU | Usually 50-250 mmol/D |
| Chloride, Body Fluid | CLB | |
| Chloride, Serum / Plasma | CL |
| 0-17 years |
97-108 mmol/L |
|
≥ 18 years |
97-108 mmol/L |
1. Normal range for >18y adults was determined by testing 271 male and female healthy blood donors at UCSF.
2. Pediatric range same as adults as referenced in Soldin, "Pediatric Reference Intervals" 6th ed. 2007, Methods 1,2,3. |
| Chloride, random urine | CLUR | |
| Chloride, stool | CLST | |
| Chloride, sweat | SWCL | For infants up to and including 6 months of age:
|
CF unlikely |
< 30 mmol/L, |
|
Intermediate |
30-59 mmol/L, |
|
Indicative of CF |
≥ 60 mmol/L. |
For individuals older than 6 months of age:
|
CF unlikely |
< 40 mmol/L, |
|
Intermediate |
40-59 mmol/L, |
|
Indicative of CF |
≥ 60 mmol/L. |
Reference ranges adopted from:
Farrell PM, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-S14 |
| Cholesterol Testing & CHD Risk | | |
| Cholesterol, HDL | HDL | HDL Cholesterol:
|
Acceptable |
> 39 mg/dL |
|
Higher risk |
< 40 mg/dL |
|
Lower risk |
> 59 mg/dL |
Total Cholesterol:HDL Cholesterol ratio:
Non-HDL Cholesterol values for adults (> 19 y/o):
|
Optimal |
< 130 mg/dL |
|
Near or above optimal |
< 160 mg/dL |
|
Borderline high-risk |
160-189 mg/dL |
|
High-risk |
> 189 mg/dL |
|
Very high-risk |
> 219 mg/dL |
|
| Cholesterol, LDL | LDL | Children and Adolescents (< 20 y/o):
|
Acceptable |
< 110 mg/dL |
|
Borderline high |
110-129 mg/dL |
|
High |
> 129 mg/dL |
Adults: (≥ 20 y/o):
|
Optimal |
< 100 mg/dL |
|
Near or above optimal |
100-129 mg/dL |
|
Borderline high-risk |
130-159 mg/dL |
|
High-risk |
160-189 mg/dL |
|
Very high-risk |
> 189 mg/dL |
|
| Cholesterol, Total | CHOL | Children and Adolescents (< 20 y/o):
|
Acceptable |
< 170 mg/dL |
|
Borderline |
170-199 mg/dL |
|
High |
> 199 mg/dL |
Adults (≥ 20 y/o):
|
Desirable |
< 200 mg/dL |
|
Borderline |
200-239 mg/dL |
|
High |
> 239 mg/dL |
|
| Cholesterol, VLDL | | |
| Cholinesterase - Genetic variants | CGV | Cholinesterase, serum:
|
Male |
3342-7586 IU/L |
|
Female |
2673-6592 IU/L |
|
Dibucaine number |
81.6-88.3% Inhibition |
|
| Cholinesterase, RBC and Plasma | CPR |
| RBC Cholinesterase |
9572-15031 IU/L Plasma cholinesterase: |
|
Male |
3334-7031 IU/L |
|
Female |
2504-6297 IU/L |
|
| Chromium, 24 hour urine | MOLT | ≤ 2 µg/L |
| Chromium, plasma | CHRO | ≤ 3.5 µg/L |
| Chromium, random urine | CHROR |
| Chromium |
<2.0 ng/mL |
|
Chromium:Creatinine ratio |
<5 |
|
| Chromogranin A | CGA | 1.9-15.0 ng/mL |
| Chromosome Analysis, Amniotic Fluid (includes Alpha-fetoprotein, amniotic fluid) | CYAFB | 46,XY normal male
46,XX normal female |
| Chromosome Analysis, Blood, High Resolution | CYHR | 46,XY normal male
46,XX normal female |
| Chromosome Analysis, Chorionic Villi | CYCV | 46,XY normal male
46,XX normal female |
| Chromosome Analysis, POC or tissue biopsy, routine | CYTIS | 46,XY normal male
46,XX normal female |
| Chromosome Analysis; Pediatric Leukemia (New test) | LCYT | |
| Chromosome analysis, Adult Leukemia | CYTLL | |
| Chronic Lymphocytic Leukemia FISH | MOLT | Negative for each marker |
| Chronic Lymphocytic Leukemia, IgVH Mutation Status | MOLT | |
| Cimetidine | MOLT | 0.5-2.5 mg/L |
| Citrate, 24 hour urine | CITU | 100-1300 mg/d |
| Citrate, random urine | CITUR | Pediatric:
|
< 1 month |
NOT ESTABLISHED |
|
|
1-11 months |
235 – 4069 mg/g creatinine |
|
1 – 9 years |
11 – 1136 mg/g creatinine |
|
10 – 17 years |
55 – 845 mg/g creatinine |
≥ 18 year olds:
|
Females |
125-900 mg/g creatinine |
|
Males |
65-650 mg/g creatinine |
|
| Citrate, serum | MOLT | 1.7-3.0 mg/dL (85-156 µmol/L) |
| Clomipramine | CLMP |
| Clomipramine |
50-250 µg/L |
|
DM-clomipramine |
150-350 µg/L |
|
Total |
200-600 µg/L |
|
| Clonazepam | CLON |
| Therapeutic |
30-60 µg/L |
|
Potentially toxic |
> 70 µg/L. |
|
| Clorazepate | NORDP | 0.1-2.0 ug/mL |
| Clostridium difficile | P328 | Negative for C. difficile |
| Cobalt, blood (New test) | COBL | ≤ 1.8 µg/L |
| Cocaine Screen, Urine | COCU | Negative
Note: a negative result indicates that cocaine metabolite is not present, or it is present at a concentration below the cutoff concentration of 300 µg/L |
| Cocaine metabolite confirmation, urine | COCAC | Not detected |
| Coccidia exam | P407 | Negative |
| Coccidioides immitis Antibody, Complement fixation | COCF | Negative |
| Coccidioides immitis Antibody, Immunodiffusion, serum | COCC | Negative |
| Cold Agglutinins | CAGG | Negative titer < 20 |
| Colorado Tick Fever Antibodies (IgG & IgM) | MOLT |
| Negative IgG |
< 16 titer |
|
Negative IgM |
< 20 titer |
|
| Complement C3, serum | C3 | 71-159 mg/dL |
| Complement C4, serum | C4 | 13-30 mg/dL |
| Complement, Total, serum | CH50 | 22-40 CH50 units/mL |
| Complete Blood Count (includes Platelet Count) | CBC | Click on links below for normal value information.
White cell count
Red cell count
Hemoglobin
Hematocrit
Red cell indices
Platelet count
White cell differential |
| Complete Blood Count with 5-part Differential | CBCD | Click on links below for normal value information.
White cell count
Red cell count
Hemoglobin
Hematocrit
Red cell indices
Platelet count
White cell differential |
| Comprehensive Metabolic Panel (New test) | CMP | See individual test entries |
| Connexin 30 | CNXN30 | |
| Convalescent Serum | | |
| Coombs, Direct, Polyspecific | DCT | Negative |
| Coombs, Indirect | ICT | Negative |
| Cooximetry | COOX |
| Hemoglobin |
see Hemoglobin entry |
|
Oxyhemoglobin |
93-100% |
|
Carboxyhemoglobin |
0.5-1.5% |
|
Methemoglobin |
0.0-1.5% |
|
Oxygen saturation |
95-99% |
|
Art. O2 content: |
16-22 vol% |
|
A-V DO2 |
3.5-5 vol% |
|
A-a DO2 |
varies with FiO2 |
|
| Copper, 24 hour urine | COPU | 15-60 µg/24 hours |
| Copper, plasma | COP |
| 0-2 years |
12-67 µg/dL |
|
3-10 years |
27-153 µg/dL |
|
Adult males |
70-140 µg/dL |
|
Adult females |
85-155 µg/dL |
|
| Copper, random urine | COPUR | Normals based on second void AM urine:
|
Males |
6.4-14.3 µg/g creatinine |
|
Females |
6.7-18.6 µg/g creatinine |
|
| Copper, tissue | COPT | 10-35 µg/g dry weight of liver |
| Cortisol, Unconjugated, urine | CRTF |
| < 1 year old |
Not established |
|
1-4 years old |
0.9-8.2 µg/24 hours |
|
5-9 years old |
1.0-30.0 µg/24 hours |
|
10-13 years old |
1.0-45.0 µg/24 hours |
|
14-17 years old |
3.0-55.0 µg/24 hours |
|
≥ 18 years old |
4.0-50.0 ug/24 hours |
|
| Cortisol, free, serum (New test) | CRTFS |
| Adult: |
|
|
|
8:00 A.M.-10:00 A.M. |
0.07-0.93 µg/dL |
|
4:00 P.M.-6:00 P.M. |
0.04-0.45 µg/dL |
|
10:00 P.M.-11:00 P.M. |
0.04-0.35 µg/dL |
|
| Cortisol, serum | CORT |
| AM (0700-0900 hours) |
4-22 µg/dL |
|
PM (1500-1700 hours) |
3-17 µg/dL |
Reference range adopted from vendor performed studies and verified by running lab personnel |
| Coumadin | MOLT | 1.0-10.0 ug/mL
|
| Coxiella burnetii Antibodies, IgG & IgM | QFEV | Negative titer < 16 |
| Creatine kinase - MB fraction | MBMU | 0-6 µg/L |
| Creatine kinase, total | CK | Male:
|
0-4 years |
41-277 U/L |
|
5-9 years |
54-269 U/L |
|
10-14 years |
38-255 U/L |
|
≥ 15 years |
50-388 U/L |
Female:
|
0-4 years |
34-204 U/L |
|
5-9 years |
44-189 U/L |
|
10-14 years |
28-170 U/L |
|
≥ 15 years |
37-241 U/L |
1. Normal range for 1 to 15 year old children adapted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
2. Normal range for adults was determined by testing 270 male and female healthy blood donors at UCSF. Adult range adopted for children 15-18 years. |
| Creatine, serum | CRTE | ≤ 1.0 mg/dL |
| Creatine, urine | CRTU |
| Males |
< 0.15 g/24 hours |
|
Females |
< 0.25 g/24 hours |
|
| Creatinine Clearance | CRCL |
| Age |
Male and Female |
|
0-7 days |
17-60 mL/min/1.73 m2 |
|
8-30 days |
26-68 mL/min/1.73 m2 |
|
1-2 months |
30-86 mL/min/1.73 m2 |
|
3-5 months |
39-114 mL/min/1.73 m2 |
|
6-11 months |
49-157 mL/min/1.73 m2 |
|
12-23 months |
62-191 mL/min/1.73 m2 |
|
2-12 years |
89-165 mL/min/1.73 m2 |
|
Age |
Male |
Female |
|
13-29 years |
88-146 mL/min/1.73 m2 |
81-134 mL/min/1.73 m2 |
|
30-39 years |
82-140 mL/min/1.73 m2 |
75-128 mL/min/1.73 m2 |
|
40-49 years |
75-133 mL/min/1.73 m2 |
69-122 mL/min/1.73 m2 |
|
50-59 years |
68-126 mL/min/1.73 m2 |
64-116 mL/min/1.73 m2 |
|
60-69 years |
61-120 mL/min/1.73 m2 |
58-110 mL/min/1.73 m2 |
|
≥70 years |
55-113 mL/min/1.73 m2 |
52-105 mL/min/1.73 m2 |
Pediatric reference ranges from Holliday, Malcolm A; Barratt, T. Martin and Vernier, Robert L. Pediatric Nephrology, 2nd edition Williams & Wilkins and Edelmann, Chester M. Jr. Pediatric Kidney Disease vol 1, Little Brown & Company, Boston MA. Adult reference ranges from Tietz Textbook of Clinical Chemistry 2nd edition,W.B. Saunders Company |
| Creatinine, 24 hour (or timed) urine | CRU | Age (years):
|
< 1 |
8-20 mg/kg/D |
|
1-11 |
8-22 mg/kg/D |
|
12-15 |
8-30 mg/kg/D |
|
Male 16-89 years |
14-26 mg/kg/D |
|
Female 16-89 years |
11-20 mg/kg/D |
|
> 90 years |
> 9 mg/kg/D |
|
| Creatinine, Body Fluid | CRB | None established. If urine leakage into a body cavity has occurred, the concentration of creatinine in the body fluid may be within the concentration range of creatinine found in urine. Random urine creatinine concentrations are typically between 80 mg/dL to 150 mg/dL and can range from approximately 20 mg/dL to 300 mg/dL (see Barr, DB et al. Environmental Health Perspectives 113:192-200, 2005). |
| Creatinine, Serum / Plasma | CRG | Creatinine:
|
Age |
Male |
Female |
|
< 1 year |
0.30-0.70 mg/dL |
0.30-0.70 mg/dL |
|
1-18 years |
0.30-0.90 mg/dL |
0.30-0.90 mg/dL |
|
≥ 19 years |
0.71-1.22 mg/dL |
0.52-1.06 mg/dL |
eGFR:
|
≥ 18 years |
> 60 mL/min/1.73 m2 |
|
< 18 years |
Not calculated (See Addtl. Info.) |
1. Pediatric reference ranges adapted from Beckman's published "Pediatric Reference Range Guidelines for Synchron Systems, Bulletin 9345.
2. Normal range for adults was determined by testing 270 male and female healthy blood donors at UCSF. |
| Creatinine, random urine | CRUR | See Additional Information |
| Crossmatch | XM-Standard
XMAG-w/ Coombs
XMPW-w/ prewarming to 37C
XMPG-w/ Ployethylene Glycol (PEG) | See Additional Information |
| Cryofibrinogen (New test) | CRYF | Negative |
| Cryoglobulin | CRYQ | < 0.12 g/L |
| Cryoprecipitate Factor 8 Activity | CRFA | Brought from Blood Centers of the Pacific |
| Cryopreservation of cells | CYTOFZ | |
| Cryptococcus neoformans, Antigen | P253 | Negative |
| Cryptosporidum parvum | P407 | Negative |
| Crystals, duodenal fluid or bile | CBD | Negative |
| Crystals, synovial fluid | CJF | Negative |
| Cutaneous Antibodies | No test code, see Processing instructions | Negative titer < 1:10 |
| Cyanide | CYAN |
| Normal |
< 0.1 mg/L |
|
Potentially toxic |
> 0.5 mg/L |
|
| Cyclospora | P407 | Negative |
| Cyclosporine A | CYCL |
| Therapeutic trough |
50-500 µg/L |
|
| Cystic Fibrosis CBAVD Poly T Mutation | POLT | 5T allele not detected |
| Cystic Fibrosis, Full CFTR gene sequencing | MOLT | No mutation detected |
| Cystic Fibrosis, PCR for common mutations | MCFM | No mutation detected |
| Cysticercosis Antibody | TSABS | < 0.90 |
| Cysticercosis Antibody, CSF (IgG) | TSCSF | Negative |
| Cystine, Quantitative, 24 hour urine | CUQNT |
| 0-9 years |
6-48 µmol/24 hours |
|
10-13 years |
10-94 µmol/24 hours |
|
14-17 years |
17-102 µmol/24 hours |
|
> 17 years |
24-184 µmol/24 hours |
|
| Cystine, Quantitative, random urine | CUQT |
| 0-30 days |
24.0-75.5 mmol/mol creatinine |
|
1-23 months |
7.7-80.2 mmol/mol creatinine |
|
2-18 years. |
2.8-14.1 mmol/mol creatinine |
|
≥ 18 years. |
4.9-23.7 mmol/mol creatinine |
|
| Cytochrome P450 2D6 | MOLT | Wildtype *1/*1 |
| Cytomegalovirus Antibody, IgM | CMVIGM | Negative |
| Cytomegalovirus DNA, Quantitative PCR | CMVQT | Not detected |
| Cytomegalovirus DNA, Quantitative, Non-blood samples | CMVMIS | Not detected |
| Cytomegalovirus Genotyping | CMVAVR | |
| Cytomegalovirus antibody, IgG | CMVAB | Negative |
| Cytomegalovirus culture | P320 | Negative |
| Cytotoxicity Antibody Screen (New test) | ILCAS | |
| D-Xylose Absorption, serum | XYL1 |
| Fasting |
< 7 mg/dL |
|
≥ 18 year olds- After a 25 g dose |
29-72 mg/dL |
|
After a 5 g dose |
8-28 mg/dL Children |
15.8-39.6 mg/dL |
|
| D-Xylose Absorption, urine | MOLT |
| ≥ 18 year old |
> 4.0 g excreted in 5 hours after a 25 g dose |
|
≥ 18 year old |
> 1.2 g after a 5g dose |
|
Child |
16-33% of the ingested dose |
|
| DEACTIVATED Homogentisic Acid, Qualitative | AKU | Negative |
| DEACTIVATED Plague Serology | IDAB | |
| DEACTIVATED Thyroglobulin | TGLB | 1.4-33.6 µg/L |
| DNA Extraction and Hold (New test) | DNAX | |
| DNA Preparation & Storage (New test) | ILCPP | |
| DNAase B Antibody | ADAB | <187 U/mL |
| Dehydroepiandrosterone | DHEA |
| 1-5 years |
<68 ng/dL |
|
6-7 years |
<111 ng/dL |
|
8-10 years |
<186 ng/dL |
|
11-12 years |
<202 ng/dL |
|
13-14 years |
<319 ng/dL |
|
15-16 years |
39-481 ng/dL |
|
17-19 years |
40-491 ng/dL |
|
20-50 years |
31-701 ng/dL |
|
| Dehydroepiandrosterone Sulfate | DHES |
| Age |
Males |
Females |
|
18-29 years |
110-510 ug/dL |
45-320 ug/dL |
|
30-39 years |
110-370 ug/dL |
40-325 ug/dL |
|
40-49 years |
45-345 ug/dL |
25-220 ug/dL |
|
50-59 years |
25-240 ug/dL |
15-170 µg/dL |
|
60-69 years |
< 186 ug/dL |
< 186 ug/dL |
|
70-90 years |
< 76 µg/dL |
< 90 µg/dL |
Note: the reference ranges have been adopted from Quest Diagnostics-San Juan Capistrano based on correlation studies and same methodology. |
| Dehydroepiandrosterone Sulfate, Pediatric | PDHES | Premature Infants
|
26-28 weeks, day 4 |
123-882 |
|
31-35 weeks, day 4 |
122-710 |
Full Term Infants
|
3 days |
88-356 |
|
1-12 months |
5-111 by first month |
|
|
5-48 by six months |
Prepubertal
|
1-5 years |
< 5-57 |
|
6-7 years |
9-72 |
|
8-10 years |
13-115 |
|
Tanner Stage |
Males |
Females |
|
I |
13-83 |
19-144 |
|
II |
42-109 |
32-129 |
|
III |
48-200 |
32-226 |
|
IV |
102-385 |
58-260 |
|
V |
120-370 |
44-248 |
|
| Deletion 13Q FISH (New test) | DEL13Q | Absent |
| Deletion 17P FISH (New test) | DEL17P | Absent |
| Deletion 20q (New test) | DEL20Q | No deletion detected |
| Delta-Aminolevulinic Acid Quantitative, 24 hour urine | ALAQ | < 4.5 mg/24 h |
| Delta-Aminolevulinic Acid Quantitative, random urine | ALAQR | Pediatric:
|
1 - 8 years |
2.3-6.2 mg/g creat |
|
9 - 17 years |
1.5-5.3 mg/g creat |
≥ 18 years:
|
Females |
<5.4 mg/g creat |
|
Males |
<1.8 mg/g creat |
|
| Dengue Antibodies, IgG & IgM | DENGF |
|
| Deoxycorticosterone | DOC |
| Cord blood |
111-372 ng/dL |
|
1 wk-12 months |
7-49 ng/dL |
|
Pre-pubertal child (1-10 y/o) |
2-34 ng/dL |
|
≥ 18 year olds [0800 hours] |
2-19 ng/dL |
|
| Deoxycortisol, 11-, nonspecific | CNSP |
| Normal |
< 1 µg/dL |
|
Post-stimulation |
> 7 µg/dL |
|
| Deoxycortisol, 11-, specific | CSPE |
| Cord blood |
295-554 ng/dL Premature infants |
48-579 ng/dL |
|
Full-term infants-3 days |
13-147 ng/dL |
|
1-12 months |
< 156 ng/dL |
|
Pre-pubertal child (1-10 y/o) [0800 hours] |
20-155 ng/dL |
|
≥ 18 year olds [0800 hours] |
12-158 ng/dL |
|
| Desipramine | DESI |
| Therapeutic |
50-300 µg/L when given as parent drug |
|
| Desmoglein 1 and 3 Antibodies (New test) | DSG | DESMOGLEIN 1
|
Negative |
<14.0 U |
|
Indeterminate |
14.0-20.0 U |
|
Positive |
>20.0 U |
DESMOGLEIN 3
|
Negative |
<9.0 U |
|
Indeterminate |
9.0-20.0 U |
|
Positive |
>20.0 U |
|
| Dexamethasone Suppression Test | | See Additional Information |
| Dexamethasone Suppression Test, High-Dose | | See Additional Information |
| Dexamethasone Suppression Test, Low-Dose | | See Additional Information |
| Diazepam | MOLT | Therapeutic: 0.1-2.5 mg/L for the SUM of the parent drug and its metabolite |
| Differential Time to Positivity | P062 | No growth |
| Digitoxin | DIGT |
| Therapeutic |
10-30 ng/mL |
|
Potentially toxic |
> 30 ng/mL |
|
| Digoxin | DIG | Therapeutic: 0.5-2.0 µg/L |
| Dihydrotestosterone | DHT |
| Age |
Male |
Female |
|
Cord Blood |
< 2-8 ng/dL |
< 2-8 ng/dL |
|
Premature Infants |
10-53 ng/dL |
2-13 ng/dL |
|
Full-term Newborns |
5-60 ng/dL |
< 2-15 ng/dL |
|
30-60 days |
12-85 ng/dL |
< 3 ng/dL |
|
7 months -Tanner Stage 1 |
< 3 ng/dL |
< 3 ng/dL |
|
Tanner Stage 2 |
3-17 ng/dL |
5-12 ng/dL |
|
Tanner Stage 3 |
8-33 ng/dL |
7-19 ng/dL |
|
Tanner Stage 4 |
22-52 ng/dL |
4-13 ng/dL |
|
Tanner Stage 5 |
24-65 ng/dL |
3-18 ng/dL |
|
≥ 18 year old |
30-85 ng/dL |
4-22 ng/dL |
|
| Diphtheria Antitoxin | DIPH | Protective ≥ 0.01 IU/mL |
| Diphtheria Culture | P126 | Negative |
| Disaccharidases | DSCS |
| Lactase |
15.0-45.5 µM gluc/min/g prot |
|
Maltase |
25-69.9 µM gluc/min/g prot |
|
Palatinase |
100-224.4 µM gluc/min/g prot |
|
Sucrase |
5-26.3 µM gluc/min/g prot |
|
| Disopyramide | DISO | Therapeutic: 2-5 mg/L |
| Diuretic Screen and Identification | DIUS | |
| Donath landsteiner (New test) | MOLT | Negative |
| Donor Infectious Disease Screen +NAT | PTXID | |
| Donor Platelet Count | DPLT | See Additional Information |
| Double-Stranded DNA Antibody | ADNA |
| Negative |
< 30 IU/mL |
|
Equivocal |
30-75 IU/mL |
|
Positive |
>75 IU/mL |
|
| Doxepin | DOX | Therapeutic: 150-250 µg/L for SUM of Doxepin and Nordeoxepin |
| Drug screening - Volatiles | MOLT | |
| Drug screening, Comprehensive (Send-out, TAT 10 days) | ABUS | No compounds detected |
| Drugs of Abuse Screen (In-house; Not for drug monitoring) | DAU | Negative
(Note: a negative result indicates that the specific class of drugs is not present, or is present at a concentration below that of the cut off concentration. See each drug class for specific concentration cut-offs). |
| Duplication 1Q FISH (New test) | DUP1Q | Absent |
| E. coli O157 | P157 | |
| EGFR Amplification by FISH | | Ratio: 1.03 +/- 0.15 |
| EWSR1 FISH (New test) | | |
| Echinococcus granulosa Antibody (IgG) | ECHINO | Negative |
| Ectoparasites, Identification of | P416 | |
| Ehrlichia chaffeensis Antibodies (IgG & IgM) | EHRL |
| IgG |
< 1:64 titer |
|
IgM |
< 1:20 titer |
|
| Electrolytes, serum or plasma | LYTE |
| Sodium |
134-143 mmol/L |
|
Potassium 0-2 weeks |
4.0-6.0 mmol/L |
|
Potassium > 2 weeks |
3.4-4.9 mmol/L |
|
Chloride |
98-107 mmol/L |
|
Total CO2 |
23-32 mmol/L |
|
| Entamoeba histolytica Antigen | MOLT | Not detected |
| Entamoeba histolytica antibody (IgG) | AMOEB | Negative
Not detected < 1.00
Detected ≥ 1.00 |
| Enteropathogenic E coli | | |
| Enterovirus PCR | P319 | Not Detected |
| Eosinophils, nasal smear | EON | Negative |
| Eosinophils, sputum | EOSP | Negative |
| Eosinophils, urine | UEOS | Negative |
| Epidemiology (Survey) Culture | P039 | |
| Epstein-Barr virus Antibodies-IgA Anti-VCA only | EBVCA | Negative titer < 10 |
| Epstein-Barr virus DNA, Quantitative, blood | EBVQT | Not detected |
| Epstein-Barr virus DNA, Quantitative, non-blood samples | EBVMIS | Not detected |
| Epstein-Barr virus, Antibodies | EBV |
| IgM anti-VCA |
|
Neg |
|
Anti-EBNA |
Neg |
|
| Erythrocyte Porphyrin (New test) | ERYP | 0-35 µg/dL |
| Erythropoietin | ERP | Pediatric:
|
3 weeks-2 months |
5.0-13.0 mIU/mL |
|
3 months-16 years |
9.0-28.0 mIU/mL |
|
≥ 18 year olds |
4.1-19.5 mIU/mL |
|
| Estradiol | E2P |
| Age |
Male |
Female 1-9 years |
≤ 4 pg/mL |
≤ 16 pg/mL |
|
10-11 years |
≤ 12 pg/mL |
≤ 65 pg/mL |
|
12-14 years |
≤ 24 pg/mL |
≤ 142 pg/mL |
|
15-17 years |
≤ 31 pg/mL |
≤ 283 pg/mL |
Adult males (> 17 years) ≤ 29 pg/mL
Adult females (>17 years)
|
Follicular Stage |
39-375 pg/mL |
|
Mid Cycle Stage |
94-762 pg/mL |
|
Luteal Stage |
48-440 pg/mL |
|
Postmenopausal |
≤ 10 pg/mL |
|
| Estrone, serum | E1P | Pediatric Females:
|
Prepubertal 1-9 years |
≤ 34 pg/mL |
|
10-11 years |
≤ 72 pg/mL |
|
12-14 years |
≤ 75 pg/mL |
|
15-17 years |
≤ 188 pg/mL |
Pediatric Males:
|
Prepubertal 1-9 years |
< 10 pg/mL |
|
10-11 years |
≤ 12 pg/mL |
|
12-14 years |
≤ 28 pg/mL |
|
15-17 years |
≤ 64 pg/mL |
Post-pubertal Female:
|
Follicular Stage |
10-138 pg/mL |
|
Mid-cycle Stage |
49-268 pg/mL |
|
Luteal Stage |
16-173 pg/mL |
|
Post-Menopausal female |
≤ 65 pg/mL |
|
≥ 18 year old male |
≤ 68 pg/mL |
|
| Ethanol, Urine | ALCO | Not detected |
| Ethanol, serum or plasma | ALC | Negative < 0.005 g/dL |
| Ethosuximide | ETHO |
| Therapeutic |
40-100 mg/L |
|
Potentially toxic |
> 150 mg/L |
|
| Ethotoin | ETHT |
| Therapeutic |
8.0-20.0 mg/L Toxic |
> 60 mg/L |
|
| Ethyl glucuronide with confirmation | EGESC |
| Ethyl glucuronide |
< 500 ng/mL |
|
Ethyl sulfate |
< 100 ng/mL |
|
| Euglobulin Clot Lysis Time | EUCL | > 60 minutes |
| Everolimus | EVRO |
| Therapeutic |
3-8 ng/mL |
|
Potentially toxic |
> 12 ng/mL |
|
| FISH for Translocation 8:21 (New test) | TR821 | No translocation |
| FLT3 Mutations, Qualitative PCR (New test) | FLT3 | Negative |
| FTA-ABS | FTAC | Nonreactive |
| Factor 10 Activity, Chromogenic | FXCH |
| Normal |
73-158% activity |
|
Therapeutic range for patients on coumadin |
11-42% |
|
| Factor 10 Activity, Routine | F10 |
| 0-4 days |
12-68% |
|
5 days to 30 days |
19-79% |
|
1 month – 3 months |
31-87% |
|
3 months - 6 months |
35-107% |
|
6 months – 1 year |
38-118% |
|
1-5 years |
58-116% |
|
6-10 years |
55-101% |
|
11 – 17 years |
50-117% |
|
≥ 18 year old |
71-143% |
UCSF HAS NOT ESTABLISHED NORMAL REFERENCE RANGES FOR FACTOR LEVELS FOR CHILDREN <18 YEARS OLD. The table above gives age-adjusted reference ranges for Pediatric Factor 10 Levels as percentages. The values are expressed by the upper and lower boundary encompassing 95% of the population.
These values are based upon these references:
Andrew M. et al. Development of the Human Coagulation System in the Full Term Infant. Blood 1987 70:165
Andrew M, et al. Maturation of the Hemostatic System During Childhood. Blood October 1992, 80(8): 1998-2005
Values are converted from the original tables, which express values as units/ml. Original tables provide values for infants at 1 day, 5 days, 30 days, 90 days, and 180 days of age as well as for children 1-5 years, 6-10 years, and 11-16 years. The published tables have been converted to the reference range shown. |
| Factor 11 Activity | F11 |
| Day 1 |
10-66% |
|
Day 5 |
23-87% |
|
Day 30 |
27-79% |
|
Day 90 |
41-97% |
|
Day 180 |
38-134% |
|
≥ 18 year old |
72-161% |
Pediatric Reference (Day 1 – 180): Andrew, M et al. Development of the human coagulation system in the full-term infant. Blood. 70:165-72). |
| Factor 12 Activity | F12A | Age
|
Newborn - Day 4 |
13-93% |
|
Day 5 - 1 Month |
11-83% |
|
1 Month - 3 Months |
17-81% |
|
3 Months - 6 Months |
25-109% |
|
6 Months - 1 Year |
39-115% |
|
1 Year - 5 Years |
64-129% |
|
6 Years - 10 years |
60-140% |
|
11 Years - 16 Years |
34-137% |
|
≥ 17 Years |
50-150% |
|
| Factor 13 Activity | F13A | 57-192% |
| Factor 2 Activity | F2 |
| 0-4 days |
26-70% |
|
5-30 days |
33-93% |
|
1-3 months |
34-102% |
|
3-6 months |
45-105% |
|
6 months – 1 year |
60-116% |
|
1-5 years |
71-116% |
|
6-10 years |
67-107% |
|
11-17 years |
61-104% |
|
≥ 18 years |
81-127% |
UCSF HAS NOT ESTABLISHED NORMAL REFERENCE RANGES FOR FACTOR LEVELS FOR CHILDREN <18 YEARS OLD. The table above gives age-adjusted reference ranges for Pediatric Factor 2 Levels as percentages. The values are expressed by the upper and lower boundary encompassing 95% of the population.
These values are based upon these references: Andrew M. et al. Development of the Human Coagulation System in the Full Term Infant. Blood 1987 70:165
Andrew M, et al. Maturation of the Hemostatic System During Childhood. Blood October 1992, 80(8): 1998-2005
Values are converted from the original tables, which express values as units/ml. Original tables provide values for infants at 1 day, 5 days, 30 days, 90 days, and 180 days of age as well as for children 1-5 years, 6-10 years, and 11-16 years. The published tables have been converted to the reference range shown. |
| Factor 5 Activity | F5 |
| 0-4 days |
36-108% |
|
5 days to 30 days |
45-145% |
|
1 month – 3 months |
62-134% |
|
3 months - 6 months |
48-132% |
|
6 months – 1 year |
55-127% |
|
1-5 years |
79-127% |
|
6-10 years |
63-116% |
|
11 – 17 years |
55-99% |
|
≥ 18 years |
67-154% |
UCSF HAS NOT ESTABLISHED NORMAL REFERENCE RANGES FOR FACTOR LEVELS FOR CHILDREN <18 YEARS OLD. The table above gives age-adjusted reference ranges for Pediatric Factor 5 Levels as percentages. The values are expressed by the upper and lower boundary encompassing 95% of the population.
These values are based upon these references:
Andrew M, et al. Maturation of the Hemostatic System During Childhood. Blood October 1992, 80(8): 1998-2005
Andrew M. et al. Development of the Human Coagulation System in the Full Term Infant. Blood 1987 70:165
Values are converted from the original tables, which express values as units/mL. Original tables provide values for infants at 1 day, 5 days, 30 days, 90 days, and 180 days of ages as well as for children 1-5 year, 6-10 years, and 11 - 16 years. The published tables have been converted to the reference range shown.
|
| Factor 7 Activity | F7 |
| 0-4 days |
28-104% |
|
5 days to 30 days |
35-143% |
|
1 month – 3 months |
42-138% |
|
3 months - 6 months) |
39-143% |
|
6 months – 1 year |
47-127% |
|
1-5 years |
55-116% |
|
6-10 years |
52-120% |
|
11 – 17 years |
58-115% |
|
≥ 18 years |
54-169% |
UCSF HAS NOT ESTABLISHED NORMAL REFERENCE RANGES FOR FACTOR LEVELS FOR CHILDREN <18 YEARS OLD. The table above gives age-adjusted reference ranges for Pediatric Factor 7 Levels as percentages. The values are expressed by the upper and lower boundary encompassing 95% of the population.
These values are based upon these references:
Andrew M. et al. Development of the Human Coagulation System in the Full Term Infant. Blood 1987 70:165
Andrew M, et al. Maturation of the Hemostatic System During Childhood. Blood October 1992, 80(8): 1998-200
5
Values are converted from the original tables, which express values as units/ml. Original tables provide values for infants at 1 day, 5 days, 30 days, 90 days, and 180 days of age as well as for children 1-5 years, 6-10 years, and 11-16 years. The published tables have been converted to the reference range shown.
|
| Factor 8 Activity | F8 | 43-168%
Note: During infancy, Factor VIII values can be greater than those observed in adults. Nevertheless, a value of approximately 50% was noted as the lower limit of normal for full term infants from birth to 6 months. (Reference: Andrew M. et al. Blood 1987 70:165). |
| Factor 8 Activity, Chromogenic | F8CH | 65-179% Avtivity |
| Factor 9 Activity | F9 |
| 0-4 days |
15-91% |
|
5 days to 30 days |
15-91% |
|
1 month – 3 months |
21-81% |
|
3 months - 6 months |
21-113% |
|
6 months – 1 year |
36-136% |
|
1-5 years |
47-104% |
|
6-10 years |
63-89% |
|
11 – 17 years |
59-122% |
|
≥ 18 years |
60-160% |
UCSF HAS NOT ESTABLISHED NORMAL REFERENCE RANGES FOR FACTOR LEVELS FOR CHILDREN <18 YEARS OLD. The table above gives age-adjusted reference ranges for Pediatric Factor 9 Levels as percentages. The values are expressed by the upper and lower boundary encompassing 95% of the population.
These values are based upon these references:
Andrew M. et al. Development of the Human Coagulation System in the Full Term Infant. Blood 1987 70:165
Andrew M, et al. Maturation of the Hemostatic System During Childhood. Blood October 1992, 80(8): 1998-2005
Values are converted from the original tables, which express values as units/ml. Original tables provide values for infants at 1 day, 5 days, 30 days, 90 days, and 180 days of age as well as for children 1-5 years, 6-10 years, and 11-16 years. The published tables have been converted to the reference range shown. |
| Factor Inhibitor Screen | INHB | Negative |
| Factor Inhibitor Titer | FIT | <0.1 BU |
| Factor V (F5) Leiden Mutation | FVR | Negative |
| Fanconi's Anemia with DEB | FANC | |
| Fat Stain | P408 | Neural fat not increased; Total fat not increased |
| Fatty Acids, Nonesterified | NEFA |
| Newborn |
0-2.30 mmol/L |
|
1-12 months |
0.50-1.60 mmol/L 1-7 years |
0.60-1.50 mmol/L 8-17 years |
0.20-1.10 mmol/L ≥ 18 year old |
0.09-0.82 mmol/L |
|
| Fatty Acids, Very Long Chain , Saturated plus Phytanic acid | VLCF |
|
|
Normal |
X-linked ALD hemizygote |
X-linked ALD Heterozygote |
Zellweger Syndrome |
|
C26:0 |
µg/mL |
0.24 (0.14) |
1.30 (0.45) |
0.68 (0.29) |
3.93 (1.50) |
|
C26:1 |
µg/mL |
0.11 (0.04) |
0.34 (0.16) |
0.23 (0.10) |
4.08 (2.30) |
|
Phytanic acid |
µg/mL |
0.54 (0.29) |
0.57 (0.46) |
0.45 (0.22) |
0.40 (0.28) |
|
Pristanic acid |
µg/mL |
0.05 (0.04) |
0.06 (0.06) |
0.06 (0.03) |
0.09 (0.16) |
|
C22:0 |
µg/mL |
29.76 (6.45) |
18.50 (5.10) |
19.41 (4.08) |
8.66 (4.97) |
|
C24:0 |
µg/mL |
22.88 (4.88) |
32.25 (8.20) |
24.89 (5.42) |
17.51 (8.64) |
|
C22:1 (n-9) |
µg/mL |
1.61 (0.45) |
1.19 (0.66) |
1.33 (0.41) |
1.73 (0.65) |
|
Erucic acid |
|
|
|
|
|
|
C24/C22 |
µg/mL |
0.78 (0.10) |
1.71 (0.23) |
1.30 (0.19) |
2.07 (0.28) |
|
C26/C22 |
µg/mL |
0.01 (0.003) |
0.07 (0.03) |
0.04 (0.02) |
0.50 (0.16) |
|
| Fc epsilon receptor antibody | CUI | |
| Fecal Fat, Quantitative | FATF |
| Breast fed infant |
< 1 |
|
Child 0-6 years |
< 2 |
|
≥ 18 year old-normal diet |
< 7 |
|
≥ 18 year old-low-fat diet |
< 4 |
|
| Fecal Occult Blood Test | FOBT | Negative |
| Ferritin | FERR |
| Males |
22-322 µg/L |
|
Females |
10-291 µg/L |
Reference ranges adopted from Quest Diagnostics based on split Pt. comparison testing using the same instrument/methodology (Siemens Centaur) |
| Fetal Bleed Screen | FBLD | Negative |
| Fetal Cells, Quantitative | FETC | See Additional Information |
| Fetal Fibronectin | FFN | Negative |
| Fetal Lung Maturity Panel (Lamellar Body Count & Phosphatidyl glycerol) (New Test) | LBCPGA | LBC:
|
> 50 x 10e9/L |
Mature |
|
15 - 50 x 10e9/L |
Transitional |
|
< 15 x 10e9/L |
Immature |
PG:
|
| Fibrin D-Dimers | FDD | <400 ng/mL |
| Fibrin Monomer | FIBM | Negative |
| Fibrinogen, Antigenic | FIBAG | 180-350 mg/dL |
| Fibrinogen, Functional | FIB | 202-430 mg/dL |
| Fibrinogen/Fibrin Degradation Products | FFDP | < 5 mcg/mL |
| Filaria IgG4 Antibody | MOLT | < 1.00 |
| Filaria species | P409M | Negative |
| First Trimester Screen | FTS | |
| Flecainide | FLEC |
| Therapeutic |
0.20-1.00 mg/L |
|
Toxic |
> 1.00 mg/L |
|
| Folate, RBC | FOLR | 280-791 µg/L of RBC hemolysate
Reference range adopted from reagent manufacturer performed studies and verified by running normal samples collected from outpatients with a normal FBS, Hematocrit and MCV. |
| Follicle Stimulating Hormone | FSH |
| Adult males (≥ 18 years) |
0.6-14.7 IU/L |
Adult females (≥ 18 years):
|
Follicular phase |
2.5-10.2 IU/L |
|
Mid-cycle peak |
3.4-33.4 IU/L |
|
Luteal phase |
1.5-9.1 IU/L |
|
Pregnant |
< 0.3 IU/L |
|
Post-Menopausal |
23.0-116.3 IU/L |
|
| Follicle Stimulating Hormone, Pediatric | PFSH |
| Males |
|
|
0-9 years/prepubertal* |
< 3.00 mIU/mL |
|
10-13 years/early prepubertal |
0.30-4.00 mIU/mL |
|
14-17 years |
0.40-7.40 mIU/mL |
|
Females |
|
|
0-8 years/prepubertal* |
0.50-4.50 mIU/mL |
|
9-13 years/early prepubertal |
0.40-6.50 mIU/mL |
|
14-17 years |
0.80-8.50 mIU/mL |
*See Additional Information |
| Fondaparinux | FONDA | See additional information |
| Fragile X | FRX | Results are reported as "No Mutation Detected", "Pre-mutation Present" or "Full Mutation Present".
Number of CGG repeats is also reported.
|
Result |
CGG Repeats |
|
Normal |
< 45 |
|
Intermediate |
45-54 |
|
Premutation |
55-200 |
|
Full mutation |
>200 |
|
| Free Catecholamines, Fractionated, 24-hour Urine | UCAF | Epinephrine
|
3-8 years |
1-7 µg/d |
|
9-12 years |
≤ 8 µg/d |
|
13-17 years |
≤ 11 µg/d |
|
> 17 years |
2-24 µg/d |
Norepinephrine
|
3-8 years |
5-41 µg/d |
|
9-12 years |
5-50 µg/d |
|
13-17 years |
12-88 µg/d |
|
> 17 years |
15-100 µg/d |
Dopamine
|
3-8 years |
80-378 µg/d |
|
9-12 years |
51-474 µg/d |
|
13-17 years |
51-645 µg/d |
|
> 17 years |
52-480 µg/d |
Total Nor + Ep
|
3-8 years |
9-51 µg/d |
|
9-12 years |
9-71 µg/d |
|
13-17 years |
13-90 µg/d |
|
> 17 years |
26-121 µg/d |
|
| Free Catecholamines, Fractionated, plasma | CATP | Pediatric patient supine:
Children age 3-15 years:
|
Epinephrine |
≤ 464 pg/mL |
|
Norepinephrine |
≤ 1251 pg/mL |
|
Dopamine |
< 60 pg/mL |
≥ 18 year olds patient supine:
|
Epinephrine |
< 50 pg/mL |
|
Norepinephrine |
112-658 pg/mL |
|
Dopamine |
< 10 pg/mL |
|
Total |
123-671 pg/mL |
≥ 18 year old patient upright (not recommended):
|
Epinephrine |
< 95 pg/mL |
|
Norepinephrine |
217-1109 pg/mL |
|
Dopamine |
< 20 pg/mL |
|
Total |
242-1125 pg/mL |
Pediatric normals from: J Chromatogr 1993 617:304-307 |
| Free Kappa & Lambda light chains, urine | FRULC | |
| Free Sialic Acid, urine | MOLT | Negative |
| Free T3, Adult | FT3 |
| Adults (18 years and older) |
2.6-5.7pmol/L |
For children, order test Free T3, Pediatric (code PFT3)
Adult reference ranges adopted from manufacturer reference range studies (95% CI) and verified in-house using blood donor (N=124) (excluding autologous donors) on no medications and negative for anti-Tg and TPO antibodies. |
| Free T3, Pediatric | PFT3 |
| < 1 year |
Not Established |
|
1-9 years |
337-506 pg/dL |
|
10-13 years |
335-480 pg/dL |
|
14-18 years |
287-455 pg/dL |
|
| Free T4 | FT4 |
| Age |
Male (pmol/L) |
Female (pmol/L) |
|
1-3 days |
10-36 |
11-25 |
|
4-30 days |
6-30 |
8-25 |
|
1-12 months |
10-26 |
11-24 |
|
1-5 years |
11-21 |
12-19 |
|
Age |
Male & Female |
|
6-10 years |
11-19 |
|
>10 years |
10-18 |
Pediatric reference ranges adopted from Pediatric Reference Intervals seventh edition (Soldin, Steven J. et al) and Canadian Laboratory Initiative on Reference Interval Database (CALIPER) Clin Biochem 2009;42:885-991
Adult 95% reference range from the manufacturer (personal communication, Abbott Labs) was verified by running 148 non-autologous donor samples from subjects on no medications and neg. for TgAb and TPO Ab |
| Free T4 (by dialysis) | FT4D |
| Prematures, 25-30 weeks, first week of life |
0.5-3.3 ng/dL |
|
Prematures, 31-36 weeks, first week of life |
1.3-4.7 ng/dL |
|
Cord blood, > 37 weeks |
1.2-2.2 ng/dL |
|
Birth-4 days |
2.2-5.3 ng/dL |
|
2 weeks-2 years |
0.8-2.0 ng/dL |
|
3-20 years |
1.0-2.4 ng/dL |
|
21-87 yr |
0.8-2.7 ng/dL |
Pregnancy:
|
First trimester |
0.9-2.0 ng/dL |
|
Second trimester |
0.8-1.5 ng/dL |
|
Third trimester |
0.8-1.7 ng/dL |
|
| Fructosamine | FRUT | 190-270 µmol/L |
| Fungal Culture, Blood or Bone marrow | P258 | |
| Fungal Culture, Coccidiodes (CSF) | P256N | No Coccidiodes isolated |
| Fungal Culture, dermatophytes | P257 | |
| Fungal Culture, other fungi | P256 | No fungus isolated |
| Fungal Culture, yeast | P259Y | |
| GAD-65 Autoantibodies | GAD | ≤ 1.0 U/mL |
| GM-1 Antibodies, IgG and IgM (New test) | GM1AB | < 1:800 |
| GT1b Antibodies, IgM | MOLT |
| Normal |
< 600 |
|
Elevated |
600 |
|
Very High |
1000 |
|
| Galactomannan Antigen | GMAN |
| Negative |
<0.5 Index |
|
Positive |
≥0.5 Index |
|
| Galactose | GALAC | Age:
|
1-7 days |
<5.4 mg/dL |
|
8-14 days |
<3.6 mg/dL |
|
>14 days |
<2.0 mg/dL |
|
| Galactose-1-Phosphate Uridyl Transferase, RBC | G1PUT | > 18.4 U/g Hgb |
| Galactose-1-Phosphate, RBC | GAL1P |
| Non-galactosemic |
5-49 mcg/g of hemoglobin (<1 mg/dL) |
|
Galactosemic on galactose restricted diet |
80-125 mcg/g of hemoglobin (1-4 mg/dL) |
|
Galactosemic on unrestricted diet |
>125 mcg/g of hemoglobin (>4 mg/dL) |
|
| Gamma-Glutamyl Transpeptidase | GGT |
| Age |
Male |
Female |
|
0 - 7 days |
25-168 U/L |
18-148 U/L |
|
8 days - 30 days |
23-174 U/L |
16-140 U/L |
|
1 month - 3 months |
16-147 U/L |
16-140 U/L |
|
4 months - 6 months |
5-93 U/L |
13-123 U/L |
|
7 months - 11 year |
8-38 U/L |
8-59 U/L |
|
1 year - 4 years |
2-15 U/L |
2-15 U/L |
|
5 years - 9 years |
6-16 U/L |
6-19 U/L |
|
10 years - 17 years |
7-26 U/L |
8-23 U/L |
|
≥ 18 years |
10-69 U/L |
7-37 U/L |
1. Normal range for children 0 to <5 year adopted from Soldin, Steven J., "Pediatric Reference Ranges", 6th edition, AACC Press, 2007, method 4
2. Normal range for children 5 to less than 18 years old adopted from Beckman Coulter's
"Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
3. Normal range for adults was determined by testing 271 male and female healthy blood donors at UCSF. |
| Ganglioside Antibodies | MOLT | |
| Gastric Acidity, Titratable | GAA |
| Free HCl output |
0.0-40.0 mEq/L |
|
Total (titratable) acidity |
10.0-60.0 mEq/L |
Basal acid output (BAO) is normally < 5 mmol/h and peak output 5-40 mmol/h. |
| Gastric Parietal Cell Antibody | GPCA |
| Negative |
≤ 20.0 Units |
|
Equivocal |
20.1-24.9 Units |
|
Positive |
≥ 25.0 Units |
|
| Gastrin | GAST |
| < 5 years |
Not established |
|
5-17 years |
13-64 pg/mL |
|
≥ 18 year old |
≤ 100 pg/mL |
Note: reference ranges apply to fasting samples only. |
| Gentamicin | GENPK (Peak), GENTH (Trough), GENRN (Random) |
| Therapeutic peak |
5-10 mg/L |
Trough levels:
|
Standard dosing |
< 2 mg/L (< 1 mg/L optimum) |
|
Once daily, high dose |
< 1 mg/L (< 0.3 mg/L optimum) |
|
ICN extended interval dosing |
< 2 mg/L (< 1.5 mg/L optimum) |
|
CF extended interval dosing |
< 1 mg/L |
Source of reference range: UCSF/SFGH/VASF joint guidelines for antimicrobial use in adults.
Click here for link |
| Giardia lamblia Antigen | P413 | Negative |
| Gliadin Antibodies (IgG and IgA) | GLIA |
| Gliadin antibody (IgG) |
Negative |
< 20 Units |
|
|
Weak Positive |
20-30 Units |
|
|
Positive |
> 30 Units |
|
Gliadin Antibody (IgA) |
Negative |
< 20 Units |
|
|
Equivocal |
20-30 Units |
|
|
Positive |
> 30 Units |
|
| Glomerular Basement Membrane Antibody | AGBM |
| Negative |
< 3.0 EU/mL |
|
Positive |
≥ 3.0 EU/mL |
|
| Glucagon | GLGN |
| Cord Blood |
≤ 215 pg/mL |
|
Day 1 |
≤ 240 pg/mL |
|
Day 2 |
≤ 400 pg/mL |
|
Day 3 |
≤ 420 pg/mL |
|
Days 4-14 |
≤ 148 pg/mL |
|
Adults |
≤ 60 pg/mL |
|
| Glucose Loading Screen | GLT1 | 1 hour post-50 g po glucose, without regard to whether patient had been fasting: 70 -139 mg/dL |
| Glucose Tolerance Test, Non-pregnant | OGT2 |
| Normal |
< 140 mg/dL |
|
Impaired glucose tolerance |
140-199 mg/dL |
|
Diabetes mellitus |
> 199 mg/dL* |
* If confirmed on another day by repeat OGT, or a diagnostic elevation of the fasting or non-fasting glucose. |
| Glucose Tolerance Test, Pregnancy | OGTP |
| Fasting |
< 95 mg/dL |
|
1 hour |
< 180 mg/dL |
|
2 hour |
< 155 mg/dL |
|
3 hour |
< 140 mg/dL |
|
| Glucose, 24 hour urine | GLUU | < 0.5 g/D |
| Glucose, Body fluid | GLBF | |
| Glucose, CSF | GLC | 40-70 mg/dl |
| Glucose, fasting | FBS |
| Normal |
70-99 mg/dL |
|
Impaired fasting glucose ("pre-diabetes") |
100-125 mg/dL |
|
Diabetes mellitus |
> 125 mg/dL |
|
| Glucose, non-fasting | GLU | Pediatrics:
|
< 1 month |
55-115 mg/dL |
|
1 month - 1 year |
55-123 mg/dL |
|
1 year - 17 years |
56-145 mg/dL |
Adults (≥ 18 years old):
|
Normal |
70-199 mg/dL |
|
Impaired glucose tolerance |
140-199 mg/dL* |
|
Diabetes mellitus |
> 199 mg/dL** |
* measured 2 hour postprandial
** AND Sx of diabetes such as polyuria, polydipsia or unexplained weight loss
1. Normal range for infants 0 to <1 month adapted from Soldin, Steven J., "Pediatric Reference Intervals", 6th edition, AACC Press, 2007, method 1.
2. Normal range for 1 month to <18 years adapted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
3. ADA guidelines used for adults. |
| Glucose, random urine | GLUR | Negative |
| Glucose, whole blood | NGLU | Pediatrics:
|
< 1 month |
55-115 mg/dL |
|
1 month - 1 year |
55-123 mg/dL |
|
1 year - 17 years |
56-145 mg/dL |
Adults (≥ 18 years old):
|
Normal |
70-199 mg/dL |
|
Impaired glucose tolerance |
140-199 mg/dL* |
|
Diabetes mellitus |
> 199 mg/dL** |
* measured 2 hour postprandial
** AND Sx of diabetes such as polyuria, polydipsia or unexplained weight loss
1. Normal range for infants 0 to <1 month adapted from Soldin, Steven J., "Pediatric Reference Intervals", 6th edition, AACC Press, 2007, method 1.
2. Normal range for 1 month to <18 years adapted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
3. ADA guidelines used for adults. |
| Glucose-6-Phosphate Dehydrogenase Screen, RBC, quantitative | G6PD | 4.6-13.5 U/g Hgb |
| Glycine, CSF:Plasma ratio | | CSF/plasma ratio: 0.02-0.05 |
| Gram Stain | P057 | |
| Growth Hormone | GH |
| Adult males |
< 3.1 µg/L |
|
Adult females |
< 8.1 µg/L |
Reference range was adopted from Siemens Immulite 2000 vendor performed studies and verified in-house by running adult donor samples (excluding autologous donors) on 20 male and 20 female samples.
Pediatric reference ranges are not available for this immunoassay platform.
For children, order Growth Hormone, Ultrasensitive (test code PGHB) |
| Growth Hormone, Pediatric | PGHB |
| Age |
|
|
1-2 days |
5-53 ng/mL |
|
2-7 days |
5-27 ng/mL |
|
31 days-11 months |
2-10 ng/mL |
|
|
|
|
Post-overnight fast |
|
|
Children |
0-6 ng/mL |
|
≥ 18 year olds |
0-6 ng/mL |
|
| HCV & HIV NAT | NAT | Nonreactive |
| HER2/neu FISH | ERBB2; Her2/NEU | Normal range for breast tumors without amplification in this laboratory is an ERBB-2:chromosome 17 ratio of <1.8. ERBB-2 amplification is defined as a ratio of > 2.2. A ratio of 1.8-2.2 is interpreted as equivocal.
This test is most useful as an adjunct to immunohistochemical analysis of ERB-B2 protein expression (Herceptest) to clarify the interpretation of 1+ and 2+ results. |
| HIV 1,2 Antibody Screen | HIVA | Negative |
| HIV Antibody Screen Confirmation | HIVWB |
| Negative |
No reactivity |
|
Indeterminate |
Reactivity that doesn't meet criteria for positive test. |
|
Positive |
reactivity to 2 or more of: p24, gp41, gp120/160 |
|
| HIV Genotyping | MOLT | |
| HIV Phenotyping | MOLT | See Additional Information |
| HIV, Rapid Antibody Screen | HIVR | Negative |
| HIV-1 DNA, Qualitative, by PCR - for patients < 6 month of age | MOLT | Negative |
| HIV-1 RNA, Quantitative, by Real time PCR | HIVRT | < 40 copies/mL
< 1.60 log copies/mL |
| HIV-2 Confirmation | HIV2WB | Negative |
| HLA Antibody Screening – Mixed Beads (New test) | ILANS | |
| HLA Antibody Specificity – Class I | ILLS1 | |
| HLA Antibody Specificity – Class II | ILLS2 | |
| HLA Antibody Testing – Class I PRA | ILPRA1 | |
| HLA Antibody Testing – Class II PRA | ILPRA2 | |
| HLA-A High Resolution Typing (New test) | ILSEA | |
| HLA-A Typing – Intermediate Resolution (New test) | ILALD | |
| HLA-ABC Typing – Intermediate Resolution (New test) | ILSSP | |
| HLA-B High Resolution Typing (New test) | ILSEB | |
| HLA-B Typing – Intermediate Resolution (New test) | ILBLD | |
| HLA-B*1502 Typing (New test) | IL1502 | |
| HLA-B*5701 Typing (New test) | IL5701 | |
| HLA-B27 Typing (New test) | ILB27 | |
| HLA-C High Resolution Typing (New test) | ILSEC | |
| HLA-C Typing – Intermediate Resolution (New test) | ILCLD | |
| HLA-DPA1 High Resolution Typing (New test) | ILDPA | |
| HLA-DPB1 High Resolution Typing (New test) | ILDPB | |
| HLA-DQA1 High Resolution Typing (New test) | ILDQA | |
| HLA-DQB1 High Resolution Typing (New test) | ILDQB | |
| HLA-DR/DQ Typing – Intermediate Resolution (New test) | ILEXG | |
| HLA-DRB1 High Resolution Typing (New test) | ILSED | |
| HLA-DRB3/4/5 High Resolution Typing (New test) | ILDDX | |
| HTLV-I/II Antibody | HTLV12 | Negative |
| Haloperidol | HALO |
| Therapeutic |
5-15 ug/L |
|
Toxic |
> 50 ug/L |
|
| Hantavirus Antibodies (IgG & IgM) | HANTA |
| ≤ 1.10 |
Antibody not detected |
|
> 1.10 |
Antibody detected |
|
| Hantavirus, Antigen | MOLT | Negative |
| Haptoglobin | HAPT | 36-195 mg/dL |
| Heart-Reactive Antibody | MOLT | |
| Heat Shock Protein Antibody | MOLT | Not present |
| Helicobacter pylori Antigen | HPAG | Not detected |
| Helicobacter pylori Culture | P131 | |
| Helicobacter pylori IgG Antibody | HELI |
| Negative |
< 20.1 Units |
|
Equivocal |
20.1-24.9 Units |
|
Positive |
> 24.9 Units |
|
| Helper, Suppressor and Total T cells | THI |
| Population |
% Lymphs |
Absolute count |
|
CD4 T Cells |
31-60% |
410-1590 x106cells/L |
|
CD8 T Cells |
13-41% |
190-1140 x106cells/L |
|
CD3 (total T) Cells |
55-84% |
690-2540 x106cells/L |
CD4 / CD8 (Helper/Supressor) ratio: 0.8-4.2
Note: Reference values are for ≥ 18 year olds. For pediatric ranges please see:
Kotylo, PA, et al. 1993. Reference ranges for Lymphocyte Subsets in Pediatric Patients. Am. J. Clin. Pathol 100:111-115
Lin, S-C., et al. 1998. Age-Related Changes in Blood Lymphocytes of Chinese Children. Ped. Allergy Immunol. 9:215-220
Melaranci, C., et al. 1992. T. Cell Subpopulations in Pediatric Healthy Children: age-normal values. J. Clin. Lab. Immunol. 30:143-149 |
| Hematocrit (NCPL) | NLHCT | Hct:
|
0-7 days |
45-67% |
|
8-14 days |
42-66% |
|
2-4 weeks |
39-63% |
|
1-2 months |
31-55% |
|
2-3 months |
28-42% |
|
3-6 months |
29-41% |
|
6-24 months |
33-39% |
|
2-5 years |
34-40% |
|
5-12 years |
35-45% |
|
Male 12-15 years |
37-49% |
|
Male 15-18 years |
38-49% |
|
Male > 18 years |
41-53% |
|
Female > 12 years |
36-46% |
Calculated Hgb:
|
0-7 days |
14.5-22.5 g/dL |
|
8-14 days |
13.5-21.5 g/dL |
|
2-4 weeks |
12.5-20.5 g/dL |
|
1-2 months |
10.0-18.0 g/dL |
|
2-3 months |
9.0-14.0 g/dL |
|
3-6 months |
9.5-13.5 g/dL |
|
6-24 months |
11.0-13.5 g/dL |
|
2-5 years |
11.2-13.5 g/dL |
|
5-8 years |
11.4-15.5 g/dL |
|
8-12 years |
11.6-15.5 g/dL |
|
| Hematocrit, Body Fluid-Automated | BHCT | RBCs are not normally present |
| Hematocrit, Body Fluid-Manual | BHCTM | RBCs are not normally present |
| Hematocrit, automated | HCT, HCTM, CBC, CBCD, ORHT, LBGH |
| 0-7 days |
45-67% |
|
8-14 days |
42-66% |
|
2-4 weeks |
39-63% |
|
1-2 months |
31-55% |
|
2-3 months |
28-42% |
|
3-6 months |
29-41% |
|
6-24 months |
33-39% |
|
2-5 years |
34-40% |
|
5-12 years |
35-45% |
|
Male 12-15 years |
37-49% |
|
Male 15-18 years |
38-49% |
|
Male > 18 years |
41-53% |
|
Female > 12 years |
36-46% |
|
| Hematocrit, spun | NSH |
| 0-7 days |
45-67% |
|
8-14 days |
42-66% |
|
2-4 weeks |
39-63% |
|
1-2 months |
31-55% |
|
2-3 months |
28-42% |
|
3-6 months |
29-41% |
|
6-24 months |
33-39% |
|
2-5 years |
34-40% |
|
5-12 years |
35-45% |
|
Male 12-15 years |
37-49% |
|
Male 15-18 years |
38-49% |
|
Male > 18 years |
41-53% |
|
Female > 12 years |
36-46% |
|
| Hemochromatosis, Hereditary | HHEM | No mutation detected. |
| Hemoglobin | HGB, CBC, CBCD, LBGH |
| 0-7 days |
14.5-22.5 g/dL |
|
8-14 days |
13.5-21.5 g/dL |
|
2-4 weeks |
12.5-20.5 g/dL |
|
1-2 months |
10.0-18.0 g/dL |
|
2-3 months |
9.0-14.0 g/dL |
|
3-6 months |
9.5-13.5 g/dL |
|
6-24 months |
11.0-13.5 g/dL |
|
2-5 years |
11.2-13.5 g/dL |
|
5-8 years |
11.4-15.5 g/dL |
|
8-12 years |
11.6-15.5 g/dL |
|
Male 12-15 years |
12.3-16.0 g/dL |
|
Male 15-18 years |
12.6 -17.0 g/dL |
|
Male > 18 years |
13.6-17.5 g/dL |
|
Female 12-15 years |
11.8-15.5 g/dL |
|
Female > 15 years |
12.0-15.5 g/dL |
|
| Hemoglobin A1c | HBA1 | Non-Diabetic: 4.3-5.6% |
| Hemoglobin, Free, Plasma | FHGB | ≤ 6.9 mg/dL |
| Hemoglobinopathy Evaluation | HBEP |
|
Hgb F |
Hgb A2 |
Hgb A |
|
0-1 months |
50-90% |
< 2% |
10-50% |
|
1-2 months |
30-80% |
< 3% |
20-70% |
|
2-3 months |
10-55% |
< 3% |
40-90% |
|
3-4 months |
5-30% |
< 3% |
65-95% |
|
4-6 months |
< 20% |
< 3% |
> 77% |
|
6-12 months |
< 10% |
< 3% |
> 87% |
|
1-2 years |
< 5% |
< 3.2% |
> 92% |
|
2+ years |
< 2% |
< 3.3% |
> 94% |
|
| Hemophilia A Inversion | INVN | Negative |
| Hemosiderin Stain, urine | HMSU | Negative |
| Heparin Laboratory/Dosing Algorithm post-initial bolus therapy | | |
| Heparin Level (Low Molecular Weight Heparin) | HEP | Therapeutic (4 hours post dose):
Enoxaparin:
|
Q12 dosing |
0.5-1.0 U/mL |
|
Qday dosing |
1.0-2.0 U/mL |
|
Prophylactic dosing |
0.2-0.4 U/mL |
Dalteparin:
|
Q12 dosing |
0.6 U/mL |
|
Qday dosing |
1.05 U/mL |
Tinzaparin:
These are general guidelines only. Detailed recommendations for heparin therapy and monitoring are available through the UCSF Comprehensive Hemostasis and Antithrombotic Service (CHAS), which can be contacted at pager 443-4023. |
| Heparin Level (Unfractionated heparin) | UFHEP | Therapeutic:
|
UFH by infusion |
0.3-0.7 anti-Xa U/mL |
|
| Heparin-PF4 Complex Antibodies (Revised Test) | HIPAB | Heparin-Induced PLT AB: Negative
Patient O.D.: <0.400
|
| Hepatitis A Antibody, Total | HAVG | Negative |
| Hepatitis A, IgM Antibody | HAVM | Negative |
| Hepatitis B Core Antibody, IgM | CORM | Negative |
| Hepatitis B Core Antibody, Total | CORE | Negative |
| Hepatitis B DNA, Qualitative NOT ORDERABLE | | |
| Hepatitis B DNA, Quantitative by PCR | HBVRT | Target not detected (< 10 IU/mL) |
| Hepatitis B Surface Antibody, Qualitative | HBAB | Negative |
| Hepatitis B Surface Antibody, Quantitative | HBSQT | |
| Hepatitis B Surface Antigen | HBAG | Negative |
| Hepatitis B Virus Drug Resistance & BCP/Precore Mutations (New test) | HBVDRG | |
| Hepatitis B e Antibody | AHBE | Negative |
| Hepatitis B e Antigen | HBE | Negative |
| Hepatitis C Antibody | HCV | Negative |
| Hepatitis C Antibody, Confirmation | HCVC | |
| Hepatitis C Fibrosure | HCVF | Reference ranges for individual tests:
Alanine aminotransferase (ALT)
|
Male |
0-55 IU/L |
|
Female |
0-40 IU/L |
|
A2-macroglobulin |
110-276 mg/dL |
Apolipoprotein A-1
|
Male |
110-180 mg/dL |
|
Female |
110-205 mg/dL |
Bilirubin, total
Newborns term and near term:
|
24 hours old |
0.0-8.0 mg.dL |
|
48 hours old |
0.0-13.2 mg/dL |
|
72 hours old |
0.0-15.6 mg/dL |
|
96 hours old |
0.0-16.6 mg/dL |
|
≥ 1 month old |
0.0-1.2 mg/dL |
|
Adults |
0.0-1.2 mg/dL |
Gamma glutamyl transpeptidase (GGT)
|
Male |
0-65 IU/L |
|
Female |
0-60 IU/L |
Metavir scale:
Fibrosis stage (Fibro test):
|
F0 - no fibrosis |
0.00-0.21 |
|
F0-F1 |
0.21-0.27 |
|
F1 - portal fibrosis |
0.27-0.31 |
|
F1-F2 |
0.31-0.48 |
|
F2 - bridging fibrosis with few septa |
0.48-0.58 |
|
F3 - bridging fibrosis with many septa |
0.58-0.72 |
|
F3-F4 |
0.72-0.74 |
|
F4 - cirrhosis |
0.74 - 1.00 |
Activity grade (ActiTest):
|
A0 - no activity |
0.00-0.17 |
|
A0-A1 |
0.17-0.29 |
|
A1 - minimal activity |
0.29-0.36 |
|
A1-A2 |
0.36-0.52 |
|
A2 - moderate activity |
0.52-0.60 |
|
A2-A3 |
0.60-0.62 |
|
A3 - severe activity |
0.62-1.00 |
|
| Hepatitis C RNA, Quantitative by Real Time PCR | HCVRT | Target not detected (< 12 IU/mL or < 1.08 log IU/mL) |
| Hepatitis C virus Genotyping | HCVG | |
| Hepatitis D Antibody | HDV | Negative |
| Hepatitis E Antibody, IgM | HEVM | Not detected |
| Herpes Simplex 1,2 Antibody, IgG | HSVP | Negative (Index < 0.90) |
| Herpes simplex 1,2 virus Antibody, IgM (New test) | HSVM12 | Negative |
| Herpes simplex Antigen (DFA) | P347 | Negative |
| Herpes simplex Culture | P325 | |
| Herpes simplex Drug Susceptibility Testing | P319 | |
| Herpes simplex, DNA | Amniotic fluid: P319
Other samples: P337 | Not detected |
| Heterophile Agglutination | MONO | Negative |
| Histamine, plasma | HIST | 0.1-1.8 ng/mL
|
| Histamine, urine | HISTU |
| Normal |
0.006 - 0.131 mg/24 hours |
|
| Histone Antibody (New test) | HISTO | < 1.0 U |
| Histoplasma capsulatum Antibody Immunodiffusion | HSTO | Negative |
| Histoplasma capsulatum Antibody, by Complement Fixation | HICFB | < 1:8 |
| Histoplasma capsulatum Antigen (New test) | HISTAG |
| <0.7 |
Negative |
|
0.7-2.9 |
Borderline |
|
>2.9 |
Moderate to strong positive |
|
| Hold Array CGH | HACGH | Normal |
| Hold Specimen | HSFD | |
| Homocysteine, Total | HCYS |
| ≤ 70 years |
4-14 umol/L |
|
> 70 years |
6-20 umol/L |
|
| Homovanillic Acid, 24 hour urine | HVA |
| 3-8 years |
0.5-6.7 mg/d |
|
9-12 years |
1.1-6.8 mg/d |
|
13-17 years |
1.4-7.2 mg/d |
|
> 17 years |
1.6-7.5 mg/d |
|
| Homovanillic Acid, random urine | HVAR | Homovanillic acid in random urine:
|
Birth-6 months |
9.1-36 mg/g creatinine |
|
7-11 months |
11.2-33 mg/g creatinine |
|
1-2 years |
8.5-38 mg/g creatinine |
|
3-8 years |
2.1-23 mg/g creatinine |
|
9-12 years |
1.1-12 mg/g creatinine |
|
≥ 18 year olds |
1.4-5.3 mg/g creatinine |
Creatinine in random urine:
|
Birth-6 months |
0.02-0.32 g/L |
|
7-11 months |
0.02-0.36 g/L |
|
1-2 years |
0.02-1.28 g/L |
|
3-8 years |
0.2-1.49 g/L |
|
9-12 years |
0.02-1.83 g/L |
|
≥ 18 year olds |
0.27-3.00 g/L |
|
| Human Chorionic Gonadotropin Testing | | |
| Human Chorionic Gonadotropin for Pregnancy, Urine ≥ 18 year old (New test) | HCGUA | Negative (non-pregnant) |
| Human Chorionic Gonadotropin for Pregnancy, Urine < 18 year old (New test) | HCGUPE | Negative (non-pregnant) |
| Human Chorionic Gonadotropin for Pregnancy, serum, ≥ 18 year old (Adult) | HCGPA |
| Normal (Non-pregnant) |
< 5 IU/L |
HCG ranges for normal pregnancy quoted by the manufacturer of the assay from the literature are:
|
0.2-1 weeks |
5-50 IU/L |
|
1-2 weeks |
50-500 IU/L |
|
2-3 weeks |
100-5,000 IU/L |
|
3-4 weeks |
500-10,000 IU/L |
|
4-5 weeks |
1000-50,000 IU/L |
|
5-6 weeks |
10,000 – 100,000 IU/L |
|
6-8 weeks |
15,000-200,000 IU/L |
|
8-12 weeks |
10,000-100,000 IU/L |
|
| Human Chorionic Gonadotropin for Pregnancy, serum, < 18 year old (Pediatric) | HCGPP |
| Normal (Non-pregnant) |
< 5 IU/L |
HCG ranges for normal pregnancy quoted by the manufacturer of the assay from the literature are:
|
0.2-1 weeks |
5-50 IU/L |
|
1-2 weeks |
50-500 IU/L |
|
2-3 weeks |
100-5,000 IU/L |
|
3-4 weeks |
500-10,000 IU/L |
|
4-5 weeks |
1000-50,000 IU/L |
|
5-6 weeks |
10,000 – 100,000 IU/L |
|
6-8 weeks |
15,000-200,000 IU/L |
|
8-12 weeks |
10,000-100,000 IU/L |
|
| Human Chorionic Gonadotropin for Tumor, CSF | BHCGC | < 1.5 IU/L |
| Human Chorionic Gonadotropin for Tumor, serum | HCGT |
| Males |
< 3 IU/L |
|
Females |
< 6 IU/L |
|
| Human Herpes virus 7, DNA | HHV7 | |
| Human Herpes virus 8, DNA | HHV8 | Not detected |
| Human Herpesvirus 6, DNA | HHV6 | |
| Human Papilloma Virus High-Risk DNA Types | HPV | Not detected |
| Huntington's Disease Triplet Repeat | HUNT | Normal |
| Hydroxycorticosteroids, 17- | 17HS | Reference ranges not established for infants < 1 year old.
|
Male & Female |
Normal Range |
|
1-2 years |
0.5 - 2.5 mg/24 hr |
|
3-4 years |
1.0- 4.0 mg/24hr |
|
5-6 years |
1.0 - 4.8 mg/24hr |
|
7-8 years |
1.0 - 5.6 mg/24hr |
|
9-10 years |
1.0 - 7.0 mg/24hr |
|
11-12 years |
1.5 - 8.0 mg/24hr |
|
Age |
Male |
Female |
|
13-16 years |
2.0 - 6.0 mg/24hr |
2.8 - 6.8 mg/24hr |
|
17-20 years |
3.0- 10.0 mg/24hr |
2.0- 7.0 mg/24hr |
|
> 20 years |
3.0 -10.0 mg/24hr |
2.0 - 6.0 mg/24hr |
|
| Hydroxypregnenolone, 17- | HPRE |
| Cord blood |
50-2121 ng/dL |
|
Premature infants |
64-2380 ng/dL |
|
Full-term infants-3 days |
10-829 ng/dL |
|
1-6 months |
36-763 ng/dL |
|
6-12 months |
42-540 ng/dL |
|
Pre-pubertal child (1-10 y/o) |
15-221 ng/dL |
|
Pubertal age groups |
44 -235 ng/dL |
|
≥ 18 year olds |
53-357 ng/dL |
|
| Hydroxyprogesterone, 17- | 17HP |
| Premature Infants (31 – 35 weeks) |
≤ 360 ng/dL |
|
Term Infants (3 days) |
≤ 420 ng/dL |
Pediatric:
|
1 – 12 months |
11 – 170 ng/dL |
|
1 – 4 years |
4 – 115 ng/dL |
|
5 – 9 years |
≤ 90 ng/dL |
|
10 – 13 years |
≤ 169 ng/dL |
|
14 – 17 years |
16 – 283 ng/dL |
Pregnancy:
|
First Trimester |
78 – 457 ng/dL |
|
Second Trimester |
90 – 357 ng/dL |
|
Third Trimester |
44 – 578 ng/dL |
≥ 18 year old males:
|
8-30 years |
32-307 ng/dL |
|
31-40 years |
42-196 ng/dL |
|
41-50 years |
33-195 ng/dL |
|
51-60 years |
37-129 ng/dL |
|
≥ 18 year old females: |
|
|
Follicular phase |
≤ 185 ng/dL |
|
Mid-cycle phase |
≤ 225 ng/dL |
|
Luteal phase |
≤ 285 ng/dL |
|
Postmenopausal |
≤ 45 ng/dL |
|
| Hypersensitivity Pneumonitis Panel | HPTA | Negative |
| IGF-1, Adult (New test) | AIGF1 | Age
|
18-19.9 years |
108-548 |
|
20-24.9 years |
83-456 |
|
25-29.9 years |
63-373 |
|
30-39.9 years |
53-331 |
|
40-49.9 years |
52-328 |
|
50-59.9 years |
50-317 |
|
60-69.9 years |
41-279 |
|
70-79.9 years |
34-245 |
|
>80 years |
34-246 |
|
| IGF-Binding Protein 3 | BP3 |
| Premature |
Range |
Mean |
|
0-1 month |
0.3-1.4 mg/L |
0.9 mg/L |
|
2-3 months |
0.9-2.3 mg/L |
1.6 mg/L |
|
4-5 months |
0.4-2.2 mg/L |
1.5 mg/L |
|
6-11 months |
1.0-2.3 mg/L |
1.5 mg/L |
|
Full term |
Range |
Mean |
|
0-1 months |
0.4-1.7 mg/L |
0.9 mg/L |
|
2-3 months |
0.5-2.1 mg/L |
1.3 mg/L |
|
4-5 months |
0.6-2.4 mg/L |
1.4 mg/L |
|
6-11 months |
0.5-2.4 mg/L |
1.4 mg/L |
|
|
|
|
|
|
Range |
Mean |
|
1-4 years |
0.8-3.0 mg/L |
2.1 mg/L |
|
5-6 years |
1.5-3.4 mg/L |
2.4 mg/L |
|
7-8 years |
2.1-4.2 mg/L |
3.0 mg/L |
|
9-11 years |
2.0-4.8 mg/L |
3.3 mg/L |
|
12-13 years |
2.1-6.2 mg/L |
3.8 mg/L |
|
14-15 years |
2.2-5.9 mg/L |
4.2 mg/L |
|
16-18 years |
2.5-4.8 mg/L |
3.5 mg/L |
|
19-30 years |
2.0-4.2 mg/L |
3.0 mg/L |
|
31-70 years |
1.9-3.6 mg/L |
2.7 mg/L |
|
| IGF-I, Pediatric | PIGF1 | Newborns and Infants
|
Age |
Term (ng/mL) |
Preterm (ng/mL) |
|
Birth |
15-109 |
21-93 |
|
1 day-2 months |
15-109 |
23-163 |
|
3-4 months |
7-124 |
23-171 |
|
5-6 months |
7-93 |
15-132 |
|
7-12 months |
15-101 |
15-179 |
Children
|
Age |
Male Range (ng/mL) |
Female Range (ng/mL) |
|
1-2 years |
30-122 |
56-144 |
Male Pubertal Ranges by Tanner Stage
|
Age |
Tanner 1 (ng/mL) |
Tanner 2 & 3 (ng/mL) |
Tanner 4 & 5 (ng/mL) |
|
3 years |
20-141 |
|
|
|
4 years |
25-157 |
|
|
|
5 years |
30-174 |
|
|
|
6 years |
37-192 |
|
|
|
7 years |
44-211 |
|
|
|
8 years |
52-231 |
39-264 |
|
|
9 years |
61-252 |
52-304 |
|
|
10 years |
71-275 |
67-347 |
|
|
11 years |
82-299 |
86-393 |
277-673 |
|
12 years |
93-324 |
106-443 |
265-652 |
|
13 years |
106-350 |
130-497 |
241-612 |
|
14 years |
120-377 |
156-554 |
220-574 |
|
15 years |
127-391 |
185-616 |
199-537 |
|
16 years |
|
201-648 |
180-501 |
|
17 years |
|
|
161-467 |
|
18 years |
|
|
144-434 |
Female Pubertal ranges by Tanner Stage
|
Age |
Tanner 1 ng/mL) |
Tanner 2 (ng/mL) |
Tanner 3 (ng/mL) |
Tanner 4 & 5 (ng/mL) |
|
3 years |
26-162 |
|
|
|
|
4 years |
32-179 |
|
|
|
|
5 years |
39-198 |
|
|
|
|
6 years |
47-217 |
|
|
|
|
7 years |
55-238 |
|
|
|
|
8 years |
64-259 |
89-369 |
|
|
|
9 years |
74-282 |
96-399 |
192-568 |
|
|
10 years |
85-306 |
104-431 |
192-568 |
279-664 |
|
11 years |
97-332 |
112-466 |
192-568 |
268-646 |
|
12 years |
110-358 |
121-504 |
192-568 |
248-612 |
|
13 years |
|
131-545 |
192-568 |
229-579 |
|
14 years |
|
136-566 |
192-568 |
211-547 |
|
15 years |
|
|
192-568 |
194-516 |
|
16 years |
|
|
|
177-487 |
|
17 years |
|
|
|
162-458 |
|
18 years |
|
|
|
147-430 |
Adults
|
Age |
Male (ng/mL) |
Female (ng/mL) |
|
19-20 years |
281-510 |
217-475 |
|
21-30 years |
155-432 |
87-368 |
|
31-40 years |
132-333 |
106-368 |
|
41-50 years |
121-237 |
118-298 |
|
51-60 years |
68-245 |
53-287 |
|
61-70 years |
60-220 |
75-263 |
|
71-80 years |
36-215 |
54-205 |
|
| IGF-II | IGF2 |
| Prepuberty |
334-642 µg/L |
|
Puberty |
245-737 µg/L |
|
≥ 18 year old |
288-736 µg/L |
|
| IL28B Genotype (New test) | IL28B | C/C Genotype |
| Ibuprofen | IBUP |
| Normal |
0-49 mg/L |
|
Potentially toxic |
50-74 mg/L |
|
Toxic |
> 75 mg/L |
|
| Ig Heavy-Chain Gene Rearrangement | MOLT | Negative |
| IgA, serum | IGA |
| Cord blood |
1-4 mg/dL |
|
1 month |
1-53 mg/dL |
|
2 months |
3-47 mg/dL |
|
3 months |
5-46 mg/dL |
|
4 months |
4-73 mg/dL |
|
5 months |
8-84 mg/dL |
|
6 months |
8-68 mg/dL |
|
7-9 months |
11-90 mg/dL |
|
10-12 months |
16-84 mg/dL |
|
1-3 years |
14-159 mg/dL |
|
4-5 years |
25-154 mg/dL |
|
6-10 years |
33-236 mg/dL |
|
> 10 years |
89-581 mg/dL |
|
| IgD, serum | IGD | < 179 mg/L |
| IgE, Specific | IGES, BTRAST |
| Undectectable Ab |
< 0.35 KU/L |
|
Low level Ab |
0.35-0.70 KU/L |
|
Moderate level Ab |
0.71-3.50 KU/L |
|
High level Ab |
3.51-17.5 KU/L |
|
Very High level Ab |
> 17.5 KU/L |
|
Asm. % Ref |
Interpretation |
|
< 70 |
None detected |
|
70-109 |
Very low positive |
|
110-219 |
Low positive |
|
220-599 |
Moderate positive |
|
60-1999 |
High positive |
|
2000-5999 |
Very high positive |
|
> 5999 |
Extremely high positive |
Note: LabCorp Reference range for B&T patrients
< 0.08 KU/L |
| IgE, serum | IGE |
| Age |
IU/mL |
|
0-1 years |
<30 |
|
1-2 years |
<50 |
|
2-3 years |
<46 |
|
3-9 years |
<53 |
|
≥18 years |
<88 |
Pediatric reference ranges have not been validated by the UCSF Clinical Laboratories. Expected values for ages 10-18 are the same as adult (<88 IU/mL), but no information regarding this age group was available from the manufacturer. |
| IgG Index, CSF | IGGI and IGGIS |
| CSF IgG |
0.3-4.3 mg/dL |
|
CSF Albumin |
5.4-31.8 mg/dL |
|
Serum IgG |
672-1760 mg/dL |
|
Serum Albumin (> 10 yer old) |
3400-4700 mg/dL |
|
IgG Index, CSF |
0.3-0.6 |
|
| IgG Subclasses 1-4 | GSUB |
|
IgG1 |
IgG2 |
IgG3 |
IgG4 |
|
0-1 year |
194-182 mg/dL |
23-300 mg/dL |
19-85 mg/dL |
0.5 -78 mg/dL |
|
2-3 years |
315-945 mg/dL |
38-225 mg/dL |
17-68 mg/dL |
1.0-54 mg/dL |
|
4-5 years |
308-945 mg/dL |
61-345 mg/dL |
10-122 mg/dL |
2.0-112 mg/dL |
|
6-7 years |
288-918 mg/dL |
44-375 mg/dL |
16-85 mg/dL |
0.4-98 mg/dL |
|
8-9 years |
432-1020 mg/dL |
72-430 mg/dL |
13-85 mg/dL |
2.0-95 mg/dL |
|
10-11 years |
423-1080 mg/dL |
78-355 mg/dL |
17-173 mg/dL |
2.0-115 mg/dL |
|
12-13 years |
342-1150 mg/dL |
100-455 mg/dL |
28-125 mg/dL |
4.0-136 mg/dL |
|
14-17 years |
315-855 mg/dL |
64-495 mg/dL |
23-198 mg/dL |
11-157 mg/dL |
|
≥ 18 year olds |
382-929 mg/dL |
241-700 mg/dL |
22-178 mg/dL |
4-86 mg/dL |
|
| IgG, CSF | IGGC | 0.9-5.7 mg/dL |
| IgG, serum | IGG |
| Cord Blood |
636-1606 mg/dL |
|
1 months |
251-906 mg/dL |
|
2 months |
206-601 mg/dL |
|
3 months |
176-581 mg/dL |
|
4 months |
196-558 mg/dL |
|
5 months |
172-814 mg/dL |
|
6 months |
215-704 mg/dL |
|
7-9 months |
217-904 mg/dL |
|
10-12 months |
294-1069 mg/dL |
|
1-3 years |
345-1213 mg/dL |
|
4-5 years |
463-1236 mg/dL |
|
6-10 years |
608-1572 mg/dL |
|
> 10 years |
672-1760 mg/dL |
|
| IgM, serum | IGM |
| Cord Blood |
6-25 mg/dL |
|
1 months |
20-87 mg/dL |
|
2 months |
17-105 mg/dL |
|
3 months |
24-89 mg/dL |
|
4 months |
27-101 mg/dL |
|
5 months |
33-108 mg/dL |
|
6 months |
35-102 mg/dL |
|
7-9 months |
34-126 mg/dL |
|
10-12 months |
41-149 mg/dL |
|
1-3 years |
43-200 mg/dL |
|
4-5 years |
43-196 mg/dL |
|
6-10 years |
48-242 mg/dL |
|
> 10 years |
39-333 mg/dL |
|
| Imipramine | IMIP |
| Therapeutic |
150-250 µg/L for the SUM of active drugs. |
|
Toxic |
≥ 500 µg/L |
|
| Immune Cell Function (New test) | ICF |
| ≤ 225 ng/mL ATP |
Low Immune Cell Response |
|
226-524 ng/mL ATP |
Moderate Immune Cell Response |
|
≥ 525 ng/mL ATP |
Strong Immune Cell Response |
|
| Immune Complexes | IC |
| Negative |
≤ 25.1 µg Eq/mL (mcg Eq/mL) |
|
| Immunofixation Electrophoresis, serum | IFE | |
| Immunofixation Electrophoresis, urine | IFEU | |
| Influenza A virus antibody | FLUA | Negative titer < 1:8 |
| Influenza B antibody | FLUB | Negative titer < 1:8 |
| Inhibin A (New test) | INHNA | |
| Inhibin B (New test) | INHNB | |
| Insect Venom IgG Antibody | MOLT | Interpretation:
< 1.0-3.4 mg/L Low level of IgG antibody indicatcating a significant risk of reaction in patients with a history of systemic anaphylaxis from hymenoptera sting and/or positive skin test to venom.
≥ 3.5 mg/L Moderate level of IgG antibody to venom associated with a reduced risk, depending on history. |
| Insulin | INS |
Reference range was adopted from UC Davis Clinical Labs based on in-house validation studies performed using the same instrument-methodology (Siemens Centaur) on samples from adult subjects with normal FBS (70-99 mg/dL) and A1c (4.3-5.6%).
Note: if patient was not fasting the normal ranges may not apply.
Pediatric reference ranges not available for this immunoassay platform. |
| Insulin Autoantibody | INHS | < 0.4 U/mL |
| Insulin, C-peptide | CPEP |
Reference range was adopted from Quest Diagnostics-San Juan Capistrano based on in-house validation studies performed using the same instrument-methodology (Siemens Centaur) on samples from adult subjects with normal FBS (70-99 mg/dL) and A1c (4.3-5.6%).
Note: if patient was not fasting the normal ranges may not apply.
Pediatric reference ranges not available for this immunoassay platform. |
| Interleukin-6 | IL6 | 0.31-5.00 pg/mL |
| Intracellular Kappa & Lambda Light Chains (New test) | ICKL | Positive |
| Intrinsic Factor Blocking Antibody | IFBA | Negative |
| Inversion, Deletion or Translocation 16q (New test) | INV16Q | No inversion, deletion or translocation identified |
| Iodine, 24 hour urine (New test) | IODI | 70-500 µg/24Hr |
| Iodine, Random Urine (New test) | IODUR | 34-523 µg/mL |
| Iron, Transferrin and % Transferrin Saturation | FE | Iron:
|
Age |
Male |
Female |
|
0 - 1 week |
100 - 250 µg/dL |
100 - 250 µg/dL |
|
1 week - 1 year |
40 - 100 µg/dL |
40 - 100 µg/dL |
|
1 - 6 years |
22 - 136 µg/dL |
22 - 136 µg/dL |
|
6 - 10 years |
39 - 136 µg/dL 39 - 136 µg/dL |
|
10 - 14 years |
28 - 134 µg/dL |
45 - 145 µg/dL |
|
14 - 18 years |
34 - 162 µg/dL |
28 - 184 µg/dL |
|
> 18 years |
42 - 175 µg/dL |
29 - 189 µg/dL |
|
Transferrin |
182-360 mg/dL |
|
Transferrin Saturation |
10-47% |
Note:
1. Normal range for infants 0-1 year adapted from "Fundamentals of Clinical Chemistry" Tietz, 5th edition, 2001.
2. Normal range for children 1-18 years adopted from Soldin, Steven J, "Pediatric Reference Intervals", 6th edition, AACC Press, 2007, method 1.
3. Normal range for adults was determined by testing 271 male and female healthy blood donors at UCSF. |
| Iron, liver | FEBX |
| Males |
200-2400 µg per g dry wt of liver Females |
400-1600 µg per g dry wt of liver Iron Index |
< 1.0 |
|
| Iron, serum | IRON |
| Age |
Male |
Female |
|
0 - 6 days |
100 - 250 µg/dL |
100 - 250 µg/dL |
|
7 days - 11 months |
40 - 100 µg/dL |
40 - 100 µg/dL |
|
1 - 5 years |
22 - 136 µg/dL |
22 - 136 µg/dL |
|
6 - 9 years |
39 - 136 µg/dL 39 - 136 µg/dL |
|
10 - 13 years |
28 - 134 µg/dL |
45 - 145 µg/dL |
|
14 - 17 years |
34 - 162 µg/dL |
28 - 184 µg/dL |
|
≥ 18 years |
42 - 175 µg/dL |
29 - 189 µg/dL |
Note:
1. Normal range for infants 0-1 year adapted from "Fundamentals of Clinical Chemistry" Tietz, 5th edition, 2001.
2. Normal range for children 1-18 years adopted from Soldin, Steven J, "Pediatric Reference Intervals", 6th edition, AACC Press, 2007, method 1.
3. Normal range for adults was determined by testing 271 male and female healthy blood donors at UCSF. |
| Iron, urine | FEU | 100-300 µg/specimen |
| Islet Cell Antibody | ICAB | Negative |
| Islet Cell Antigen 512 Antibody | ICA | Children and adults positive result: 0.070 or greater (Index) |
| Isochrome 17q FISH (New test) | |
| 17p:17q |
0.97 +/- 0.07 |
|
%17p deleted cells |
< 20% |
|
%isochromosome 17q cells |
<2% |
|
| Isohemagglutinin Titer | ISO | |
| Itraconazole (New test) | ITRC | < 0.1 µg/mL |
| JC Virus DNA, Quantitative | JCV | Not detected |
| JC virus Antibody (New test) | JCAB | Negative |
| Janus kinase 2 Mutation, Qualitative PCR | JAK2 | Negative |
| Janus kinase 2 Mutation, Quantitative PCR (New test) | JAK2QT | Negative |
| Jo-1 Antibody (New test) | JO1 | < 1.0 AI |
| Juvenile Myelomonocytic Leukemia Associated Associated Exon Panel – Family F/U (New test) | FJMML | Negative |
| Juvenile Myelomonocytic Leukemia Associated Exon Panel (New test) | JMML | Negative |
| KIR Genotype – Low Resolution (New Test) | ILKIR | |
| KRAS Sequencing | Test is ordered in CoPath | Negative for KRAS mutations at codons 12 and 13. |
| Kappa and Lambda Free light Chains, serum | FKL |
| Kappa light chains |
3.3-19.4 mg/L |
|
Lambda light chains |
5.7-26.3 mg/L |
|
Kappa/Lambda ratio |
0.26-1.65 |
|
| Ketones, Qualitative, urine | UA or UAWM | Negative |
| Ketosteroids, 17- | 17KS |
| Age(years) |
Male |
Female |
|
0 |
< 1.0 mg/d |
< 1.0 mg/d |
|
1 |
< 2.0 mg/d |
< 2.0 mg/d |
|
5 |
< 3.0 mg/d |
< 3.0 mg/d |
|
9 |
3.0-10.0 mg/d |
3.0-10.0 mg/d |
|
13 |
5.0-12.0 mg/d |
5.0-12.0 mg/d |
|
17 |
9.0-22.0 mg/d |
6.0-15.0 mg/d |
|
21 |
8.0-20.0 mg/d |
|
> 21 |
8.0-20.0 mg/d |
6.0-15.0 mg/d |
|
| LCM Virus Antibody | LCM | Negative titer < 8 |
| LRF Test | | |
| Lactate Dehydrogenase, Body Fluid | LDB | |
| Lactate Dehydrogenase, CSF | LDCF | 5-10% of serum level |
| Lactate Dehydrogenase, Serum / Plasma | LD |
| Age |
Male & Female |
Male |
Female |
|
< 1 month |
125-735 U/L |
--- |
--- |
|
1 month - 11 months |
170-450 U/L |
--- |
--- |
|
1 year - 4 years |
-- |
140-304 U/L |
142-297 U/L |
|
5 years - 9 years |
-- |
155-290 U/L |
142-261 U/L |
|
10 years - 14 years |
-- |
115-257 U/L |
122-234 U/L |
|
≥ 15 years |
102-199 U/L |
|
|
1. Pediatric reference ranges for children <1 year adapted from Soldin, Steven J. Pediatric Reference Intervals (method 3), 6th edition, AACC Press, 2007.
2. Normal range for children 1 to less than 15 years old adapted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
3. Normal range for adults was determined by testing 271 male and female healthy blood donors at UCSF. Adult range used for pediatric patients >15 years. |
| Lactate, CSF | LACS | 1.1-2.8 mmol/L |
| Lactate, plasma | LACT |
| Age |
Normal Range |
|
0 - 2 months |
1.0-3.5 mmol/L |
|
3 months - 1 year |
1.0-3.3 mmol/L |
|
2 - 18 years |
1.0-2.4 mmol/L |
|
≥ 18 years |
0.5-2.2 mmol/L |
Adult reference range from Beckman's Lactate Information Sheet which references Tietz, N. W., Clinical Guide to Laboratory Tests, 3rd Edition, Philadelphia, PA (1995). Adult range verified by testing 24 laboratory staff (July 2011).
Pediatric reference ranges adopted from Soldin, Steven J. Pediatric Reference Intervals (method 3), 6th edition, 2007. |
| Lactate, whole blood (NCPL only) | LACTWB | 0.0-2.0 mmol/L |
| Lactoferrin, stool | LACTOF | Negative |
| Lamellar Body Count (New test) | LBC |
| > 50 x 10e9/L |
Mature |
|
15 - 50 x 10e9/L |
Transitional |
|
< 15 x 10e9/L |
Immature |
|
| Lamotrigine | LAMI | 4.0-18.0 µg/mL |
| Laxative screen, stool | LAXS | |
| Lead, 24 hour urine | PBUR | < 80 µg/L |
| Lead, blood | LEAD | < 5 µg/dL
Source of reference ranges:
The Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables, September 2012,
Department of Health and Human Services (based on NHANES 2009- 2010)
California Management Guidelines on Childhood Lead Poisoning for Health Care Providers
http://www.cdph.ca.gov/programs/CLPPB/Pages/ScreenRegs-CLPPB.aspx
For OSHA guidelines on monitoring lead levels in the workplace and for information on lead levels that require removal of an employee from work (workplace exposure to lead), see http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=standards&p_id=10030
|
| Lead, random urine | PBURR |
| Nonexposed |
< 10 µg/g creatinine |
|
| Leflunomide | LEFL | See Additional Information |
| Legionella Antigen (DFA) | P124 | Negative |
| Legionella pneumophila urinary antigen | LEGAU | Negative |
| Legionella pneumophilia Antibodies (IgG and IgM) (New test) | LEGAB | Titer < 1:64 |
| Legionella species Culture | P125 | Negative |
| Leishmania species Antibodies | LEISH | Negative |
| Leishmania, Culture | P406 | See Additional Information |
| Leishmania, Giemsa Stain | P403L | No Leishmania seen |
| Leptin | LEPN | Adult Lean Subjects (18-61years) with BMI range of 18-25:
|
Males |
1.2 - 9.5 ng/mL |
|
Females |
4.1 - 25.0 ng/mL |
Adult Subjects (19-60 years) with BMI range 25-30:
|
Males |
1.6 - 20.9 ng/mL |
|
Females |
13.1 - 40.8 ng/mL |
|
Pediatric: |
Male |
Female |
|
Prepubertal |
1.6-10.8 ng/mL |
1.7-10.6 ng/mL |
|
Tanner Stages II-III |
2.1-11.6 ng/mL |
2.6-11.5 ng/mL |
|
Tanner Stages IV-V |
3.4-10.2 ng/mL |
3.4-13.0 ng/mL |
|
| Leptospira Antibody | LEPT |
| Negative |
< 1:50 |
|
Borderline |
1:50 |
|
Positive |
≥1:100 |
|
| Leukemia Minimal Residual Disease Testing | MOLT | |
| Leukemia/Lymphoma Markers | LEUM | See Additional Information |
| Leukocyte Phenotyping | See individual tests in 'Additional information' | |
| Levetiracetam | LEV |
| Dosage |
Trough |
Peak |
|
500 mg BID |
3.1-10.0 µg/mL |
10.0-25.0 µg/mL |
|
1000 mg BID |
4.9-37.1 µg/mL |
30.0-40.0 µg/mL |
|
1500 mg BID |
7.0-34.0 µg/mL |
36.1-70.0 µg/mL |
Note: Toxic levels not established |
| Lidocaine | LIDO |
|
| Lipase | LIPA | 19-56 U/L
Normal range was determined by testing 271 male and female healthy adult blood donors at UCSF. |
| Lipoprotein (a) | LPA | < 75 nmol/L |
| Lipoprotein-PLA2 | LPLA | < 235 ng/mL |
| Listeria Antibodies | MOLT |
|
| Lithium | LI |
| Therapeutic |
0.5-1.5 mmol/L |
|
| Liver Kidney Microsome Antibody, IgG | LKM |
| Negative |
≤ 20.0 units |
|
Equivocal |
20-1-24.9 units |
|
Positive |
≥ 25 units |
|
| Lung Biopsy and Bronchoalveolar Lavage | | |
| Lupus Anticoagulant Information | LUPUS | |
| Lupus Anticoagulant by HEXA | HEXA | Negative |
| Luteinizing Hormone | LH |
| Males 20-70 years |
0.7-7.9 IU/L |
|
Males > 70 years |
3.1-34.6 IU/L |
Females
|
Follicular phase |
1.9-12.5 IU/L |
|
Mid-cycle peak |
8.7-76.3 IU/L |
|
Luteal phase |
0.5-16.9 IU/L |
|
Pregnant |
<0.1-1.5 |
|
Post-menopausal |
15.9-54.0 IU/L |
|
| Luteinizing hormone, Pediatric | PLH | Results are expressed in terms of W.H.O. 2nd Int'l Standard, Human Pituitary LH 80/552
Infants 2 weeks-11 months: Values increase about two weeks after birth to a range of 0.02-7.0 mIU/mL within the first three months, then decline to prepubertal values by the end of the first year.
Prepubertal children 12 mo-8 years: 0.02-0.3 mIU/mL
Male Normal Range-Puberty
|
Tanner Stage |
Age (years) |
Range |
|
1 |
< 9.8 |
0.02-0.3 mIU/mL |
|
2 |
9.8-14.5 |
0.2-4.9 mIU/mL |
|
3 |
10.7-15.4 |
0.2-5.0 mIU/mL |
|
4 |
11.8-17.3 |
0.4-7.0 mIU/mL |
Female Normal Ranges-Puberty
|
Tanner Stage |
Age (years) |
Range |
|
1 |
< 9.2 |
0.02-0.18 mIU/mL |
|
2 |
9.2-13.7 |
0.02-4.7 mIU/mL |
|
3 |
10.0-14.4 |
0.10-12.0 mIU/mL |
|
4 |
10.7-18.6 |
0.4-11.7 mIU/mL |
|
| Lyme Disease Ab Confirmation (WB) | LYMEWB | Negative |
| Lyme Disease Antibody Total (EIA) | LYMET | Negative |
| Lyme Disease Antibody, CSF (New test) | LYMC | No bands detected |
| Lymphocyte Antigen Stimulation | LPAG |
| Viability of lymphocytes at day 0 |
≥ 75.0% |
|
Maximum proliferation of Candida albicans as % CD45 |
≥ 5.7% |
|
Maximum proliferation of Candida albicans as % CD3 |
≥ 3.0% |
|
Maximum proliferation of tetanus toxoid as % CD45 |
≥ 5.2% |
|
Maximum proliferation of tetanus toxoid as % CD3 |
≥ 3.3% |
|
| Lymphocyte Mitogen Stimulation | LPMG |
| Viability of lymphocytes at day 0 |
≥ 75.0% |
|
Maximum proliferation of phytohemagglutinin as % CD45 |
≥ 49.9% |
|
Maximum proliferation of phytohemagglutinin as % CD3 |
≥ 58.5% |
|
Maximum proliferation of pokeweed mitogen as % CD45 |
≥ 4.5% |
|
Maximum proliferation of pokeweed mitogen as % CD3 |
≥ 3.5% |
|
Maximum proliferation of pokeweed mitogen as % CD19 |
≥ 3.9% |
|
| Lymphocyte T-cell subsets, Naive and Memory | RARO | ≥ 18 year olds:
|
Subset |
Percentage |
Absolute |
|
CD4+ CD45 RA+ |
3-59% of CD4 T cells of CD4 T-cells |
48-632 x106cells/L |
|
CD4+ CD45 RO+ |
31-76% of CD4 T cells |
220-833 x106cells/L |
|
CD8+ CD45 RA+ |
15-75% of CD8 T cells |
27-457 x106cells/L |
|
CD8+ CD45 RO+ |
11-65% of CD8 T cells |
48-400 x106cells/L |
For pediatric ranges please see following ranges established by Mayo Clinic - Department of Laboratory Medicine and Pathology; Rochester, MN 55905 (Laboratory Test Abstract Form - F 006284)
Pediatric:
|
CD4+ CD45 RA+ |
21-75% of CD4 T cells |
138-893 x106cells/L |
|
CD4+ CD45 RO+ |
11-44% of CD4 T cells |
56-411 x106cells/L |
|
CD8+ CD45 RA+ |
23-88% of CD8 T cells |
83-653 x106cells/L |
|
CD8+ CD45 RO+ |
2-26% of CD8 T cells |
10-142 x106cells/L |
|
| Lymphocyte subsets | TBHS |
| Subset |
Percentage |
Absolute |
|
CD3 (T) Cells |
55-84% |
690-2540 x106 cells/L |
|
CD4 (helper-inducer) T Cells |
31-60% |
410-1590 x106 cells/L |
|
CD8 (cytotoxic-suppressor) T Cells |
13-41% |
190-1140 x106 cells/L |
|
CD19 (B) Cells |
6-25% |
90-660 x106 cells/L |
|
CD16, CD56 Natural Killer (NK) cells |
5-27% |
90-590 x106 cells/L |
CD4/CD8 (H/S) Ratio: 0.8-4.2
Note: Reference values are for ≥ 18 year olds. For pediatric ranges please see:
Kotylo, PA, et al. 1993. Reference ranges for Lymphocyte Subsets in Pediatric Patients. Am. J. Clin. Pathol 100:111-115
Lin, S-C., et al. 1998. Age-Related Changes in Blood Lymphocytes of Chinese Children. Ped. Allergy Immunol. 9:215-220
Melaranci, C., et al. 1992. T. Cell Subpopulations in Pediatric Healthy Children: age-normal values. J. Clin. Lab. Immunol. 30:143-149 |
| Lymphocytic choriomeningitis virus antibodies, CSF | LCMC |
| Negative IgG |
<1:1 |
|
Negative IgM |
<1:1 |
|
| Lymphocytic choriomeningitis virus antibodies, serum | LCMS |
| Negative IgG |
<1:16 |
|
Negative IgM |
<1:20 |
|
| Lymphogranuloma venereum Antibody Panel (New test) | LGV |
| IgG |
<1:64 |
|
IgA |
<1:16 |
|
IgM |
<1:10 |
|
| Lysosomal Disease Screen | LYDX | |
| Lysozyme, serum | LYSO | 4.0-10.3 ug/mL |
| Lysozyme, urine | MOLT | < 4.0 mg/L |
| MGMT Promoter Methylation Assay (New test) | | Normal: No methylation (less than two CpG methylation sites) |
| MLL 11q23 (New test) | MLLQ23 | No deletion detected |
| MYC FISH (New test) | | 1.03 +/- 0.19 |
| MYCN FISH (New test) | | 1.09 +/- 0.21 |
| MaTa Antibody (New test) | MATAB | Negative |
| Magnesium, 24 hour urine | MGU | 73-122 mg/D
See Additional information. |
| Magnesium, Serum / Plasma | MG | 1.8 - 2.4 mg/dL
Normal range was determined by testing 271 male and female adult healthy blood donors at UCSF. Pediatric patients will use adult range due to comparable ranges between UCSF's normal study and Soldin, Steven J. Pediatric Reference Intervals, 6th edition, AACC Press, 2007. |
| Magnesium, random urine | MGUR | See additional information |
| Malaria Antibodies | MOLT | Negative |
| Malaria Smear | P403M | Negative |
| Manganese, blood | MN | 7-19 µg/L |
| Manganese, urine | MOLT |
| M |
0.5-3.0 µg/L |
|
F |
0.5-1.8 µg/L |
|
| Mannose Binding Lectin (New test) | MBL | ≥ 100 ng/mL |
| Maternal Cell Contamination | MCC | Negative |
| Measles Antibody, CSF, IgG | MOLT |
|
| Measles Antibody, CSF. Total | MOLT |
| Negative IgG |
< 1:64 Negative IgM |
< 1:1 |
|
| Measles Antibody, IgG, serum | MEAI | Non-immune: Negative |
| Measles PCR (New test) | P319 | No virus detected |
| Meperidine, serum | MEPE | Meperidine:
|
Therapeuitc |
0.20-0.80 mg/L |
|
Potentially Toxic |
> 1.50 mg/L |
Nomeperidine:
|
Therapeutic |
Not established |
|
Potentially Toxic |
> 1.00 mg/L |
|
| Mercury, 24 hour urine | HGU |
| Normal |
≥ 20 µg/L (Varies w/diet) |
|
Toxic |
≥ 150 µg/L |
|
| Mercury, blood | HG | ≤ 10 µg/L |
| Mercury, random urine | HGUR |
| Nonexposed ≥ 18 year olds |
≤ 4 µg/g creatinine |
|
Biologic exposure Index (preshift) |
≤ 35 µg/g creatinine |
|
| Metanephrines, 24 hour urine | METN | Metanephrine
|
3 months-4 years |
25-117 µg/d |
|
5-9 years |
11-139 µg/d |
|
10-13 years |
51-275 µg/d |
|
14-17 years |
40-189 µg/d |
|
18-29 years |
25-222 µg/d |
|
30-39 years |
36-190 µg/d |
|
40-49 years |
58-203 µg/d |
|
≥ 50 years |
90-315 µg/d |
Normetanephrine
|
3 months-4 years |
54-249 µg/d |
|
5-9 years |
31-398 µg/d |
|
10-13 years |
67-503 µg/d |
|
14-17 years |
69-531 µg/d |
|
18-29 years |
40-412 µg/d |
|
30-39 years |
35-482 µg/d |
|
40-49 years |
88-649 µg/d |
|
≥ 50 years |
122-676 µg/d |
Metanephrine, Total
|
3 months-4 years |
79-345 µg/d |
|
5-9 years |
49-408 µg/d |
|
10-13 years |
110-714 µg/d |
|
14-17 years |
107-741 µg/d |
|
18-29 years |
94-604 µg/d |
|
30-39 years |
115-695 µg/d |
|
40-49 years |
182-739 µg/d |
|
≥ 50 years |
224-832 µg/d |
|
| Metanephrines, Free, fractionated, plasma | METNF |
| Metanephrine |
≤ 57 pg/mL |
|
Normetanephrine |
≤ 148 pg/mL |
|
Total |
≤ 205 pg/mL |
|
| Metanephrines, random urine | METNR | Metanephrine:
|
3 mo-4 years |
Not established |
|
5-9 years |
106-257 µg/g creatinine |
|
10-13 years |
34-357 µg/g creatinine |
|
14-17 years |
24-302 µg/g creatinine |
|
18-29 years |
39-146 µg/g creatinine |
|
30-39 years |
32-134 µg/g creatinine |
|
40-49 years |
33-192 µg/g creatinine |
|
≥50 years |
21-153 µg/g creatinine |
Normetanephrine:
|
3 months-4 years |
Not Established |
|
5-9 years |
149-781 µg/g creatinine |
|
10-13 years |
38-523 µg/g creatinine |
|
14-17 years |
14-302 µg/g creatinine |
|
18-29 years |
91-365 µg/g creatinine |
|
30-39 years |
67-390 µg/g creatinine |
|
40-49 years |
85-514 µg/g creatinine |
|
≥50 years |
108-524 µg/g creatinine |
Total metanephrines:
3 months-4 years Not Established
|
5-9 years |
255-1167 µg/g creatinine |
|
10-13 years |
86-845 µg/g creatinine |
|
14-17 years |
39-578 µg/g creatinine |
|
18-29 years |
156-442 µg/g creatinine |
|
30-39 years |
94-445 µg/g creatinine |
|
40-49 years |
155-608 µg/g creatinine |
|
≥50 years |
149-603 µg/g creatinine |
|
| Metaphase / Interphase FISH | CYFMB | Normal. See Additional Information |
| Methadone screen, urine | METHA | |
| Methadone, serum | MOLT |
| Therapeutic |
0.05-1.0 mg/L |
|
Toxic |
> 1.0 mg/L |
|
| Methicillin Resistant Staph aureus Screen | P114 | No MRSA isolated |
| Methotrexate | MTX |
|
| Methylenetetrahydrofolate Reductase mutations | MTR | Negative |
| Methylmalonic Acid, serum | MMA | < 0.3 µmole/L |
| Methylmalonic Acid, urine | MOLT | < 2.1 mmol/mol creatinine |
| Mexiletine | MEXL |
| Therapeutic |
0.5-2.0 µg/mL |
|
Toxic |
≥ 1.5 µg/mL |
|
| Mi-2 Antibody (New test) | MI2 | Not detected |
| Microsatellite Instability by PCR | |
| Microsatellite stable |
No loci show instability |
|
MSI-Low |
Instability in only one locus |
|
MSI-High |
Instability in ≥ 2 loci |
|
| Microsporidia | P414 | Negative |
| Miscellaneous Toxicology Test | MTOX | |
| Mitochondrial Antibody | AMITO |
|
| Modified Inhibitor Titer | MODIT | < 0.25 BU |
| Molybdenum, blood | MOLY | < 2.1 µg/L |
| Monitoring Anticoagulation | | |
| Monosomy 5 / Del5q FISH (new test) | M5D5Q | Not detected |
| Monosomy 7 / Deletion 7q FISH | M7D7Q | Not detected |
| Mucoploysaccharide Enzyme Analysis | MOLT | |
| Mucopolysaccharides, urine Quantitation | MPSQNT | < 48 mg/mmol creatinine |
| Mucopolysaccharides, urine by TLC | MPSTLC | |
| Mumps PCR (New test) | P319 | No virus detected |
| Mumps virus Antibody, IgG | MUMG | See Additional Information |
| Mumps virus Antibody, IgM | MOLT |
|
| Mycobacterial Culture | P285 | No AFB isolated |
| Mycophenolic Acid | MYCPA |
| Mycophenolic acid |
1.0-3.5 µg/mL (trough) |
|
MPA Glucuronide |
35.0-100.0 µg/mL (trough) |
|
| Mycoplasma pneumoniae Antibody | MYCOP | < 0.5 Index |
| Mycoplasma pneumoniae DNA by PCR | P319 | Not detected |
| Myelin associated glycoprotein antibody, IgM | MAGM |
| Normal |
< 1:1600 |
|
Moderately Elevated |
1:1600-1:3200 |
|
Highly Elevated |
≥ 1:6400 |
|
| Myeloma Prognostic Risk Score (New test) | MYPRS | |
| Myeloperoxidase detection by flow cytometry | MPO | |
| Myositis Assessment Plus Jo-1 Ab Panel (New test) | MYOABS | Not detected |
| N-Telopeptide, 24 hour urine | MOLT |
| ≥ 18 year old premenopausal females |
5-79 nmol BCE/mmol creatinine |
≥ 18 year old males:
|
18-29 years |
5-88 nmol BCE/mmol creatinine |
|
30-39 years |
7-51 nmol BCE/mmol creatinine |
|
40-49 years |
5-47 nmol BCE/mmol creatinine |
|
50-60 years |
6-43 nmol BCE/mmol creatinine |
|
| N-Telopeptide, random urine | NTX | Pediatric:
|
0-6 months |
2-32 nmol BCE/mmol creatinine |
|
7-11 months |
2-36 nmol BCE/mmol creatinine |
|
1-2 years |
2-128 nmol BCE/mmol creatinine |
|
3-8 years |
2-149 nmol BCE/mmol creatinine |
|
9-12 years |
2-183 nmol BCE/mmol creatinine |
|
12-18 years male |
20-370 nmol BCE/mmol creatinine |
|
> 12 years female |
20-320 nmol BCE/mmol creatinine |
|
Premenopausal Females |
4-64 nmol BCE/mmol creatinine |
Males:
|
18-29 years |
12-99 nmol BCE/mmol creatinine |
|
30-59 years |
9-60 nmol BCE/mmol creatinine |
|
| N-acetylaspartate quantitation | MOLT | |
| N-methyl-D-aspartate Receptor Antibody (New test) | NMDA | Negative |
| NMO/AQP-4 Antibody, IgG (New test) | NMO | < 1.6 U/mL |
| NPM1 Exon 12 Mutations, Qualitative PCR (New test) | NPM1 | Negative |
| Neisseria gonorrhoea Culture, Any Site | P128 | |
| Neisseria gonorrhoea Culture, Male Urethral Specimens | P128S | |
| Neisseria gonorrhoeae DNA Detection for Throat & Rectal Samples (New test) | P361 | Not detected |
| Neonatal Alloimmune Thrombocytopenia - Parental evaluation | MOLT | |
| Neonatal Alloimmune Thrombocytopenia-Fetal evaluation | MOLT | |
| Neonatal Screen | NNEO | Acylcarnitine profile:
|
FC |
12-220 µmol/L |
|
FC/(C16+C18) ratio |
0-100 |
|
C-2 |
5-85 µmol/L |
|
C-3 |
0-6.5 µmol/L |
|
CO3/CO2 ratio |
0.025 |
|
C-3DC |
0-0.3 µmol/L |
|
C-4 |
0-1.8 µmol/L |
|
C-4DC |
0-2.6 µmol/L |
|
C-5 |
0-1.2 µmol/L |
|
C5:1 |
0-0.4 µmol/L |
|
C-5OH |
0-1.2 µmol/L |
|
C-5DC |
0-0.35 µmol/L |
|
C-6 |
0-0.7 µmol/L |
|
C-8 |
0-0.5 µmol/L |
|
CO8/C10 ratio |
Not given |
|
C-8.1 |
0-0.9 µmol/L |
|
C-10 |
0-0.6 µmol/L |
|
C10:1 |
0-0.45 µmol/L |
|
C-12 |
0-2 µmol/L |
|
C-12:1 |
Not given |
|
C-14 |
0-1.1 µmol/L |
|
C14:1 |
0-0.8 µmol/L |
|
C14:1/C12:1 ratio |
Not given |
|
C-14OH |
0-0.4 µmol/L |
|
C-16 |
0-10 µmol/L |
|
C-16:1 |
0-1.2 µmol/L |
|
C-16OH |
0-0.3 µmol/L |
|
C-18 |
0-3.5 µmol/L |
|
C-18:1 |
0-4 µmol/L |
|
C-18:2 |
Not given |
|
C-18OH |
0-0.4 µmol/L |
|
C18:1OH |
0-0.35 µmol/L |
Amino acids:
|
Glycine |
Not given |
|
Alanine |
0-900 µmol/L |
|
Valine |
Not given |
|
Leucine/Isoleucine |
0-200 µmol/L |
|
Leucine/Alanine ratio |
0-1.5 |
|
Phenylalanine |
0-140 µmol/L |
|
Phenylalanine/Tyrosine ratio |
0-2.3 |
|
Tyrosine |
0-700 µmol/L |
|
Methionine |
0-100 µmol/L |
|
Citrulline |
0-90 µmol/L |
|
Citrulline/Arginine ratio |
Not given |
|
Ornithine |
0-500 µmol/L |
|
Ornithine/Citrulline ratio |
Not given |
|
Arginine |
0-200 µmol/L |
|
Arginine/Ornithine ratio |
Not given |
|
Proline |
0-100 µmol/L |
|
5-Oxoproline |
Not given |
Other analytes:
|
Immunoreactive trypsinogen |
< 62 ng/mL |
|
Biotinidase |
> 10 ERU |
|
Gal-1-Uridyl Transferase |
> 50 enzyme units |
|
TSH |
0-25 mIU/L |
|
17 Hydroxyprogesterone |
< 180 nmol/L |
|
T-cell Receptor Excision Circle (TREC) |
> 25 copies/µL |
|
| Neuron Specific Enolase, CSF | NSECSF |
| Normal |
<20 ng/mL |
|
Mildly elevated |
20-35 ng/mL |
|
Indicative of CJD |
>35 ng/ml |
|
| Neuron Specific Enolase, serum | NSE |
| Age |
Normal range |
|
Newborn |
4.8-19.5 µg/L |
|
12-17 years |
≤ 12.0 µg/L |
|
≥ 18 year olds |
< 8.6 µg/L |
|
| Neutrophil Antibodies | NEUAB | None detected |
| Neutrophil Cytoplasmic Antibodies | ANCA | Myeloperoxidase Antibody (MPO) and Proteinase-3 Antibody (PR3)
:
|
Negative |
< 21 Units |
|
Equivocal |
21-30 Units |
|
Positive |
> 30 Units |
|
| Neutrophil Oxidative Index | NOI | |
| Nicotine and Cotinine, urine (New test) | NICUR | Nicotine:
|
Smokers |
200-700 ng/mL |
|
Non-Smokers |
≤ 17 ng/mL |
Cotinine:
|
Smokers |
300-1300 ng/mL |
|
Non-Smokers |
≤ 20 ng/mL |
|
| Nonsyndromic Deafness | CNXN | Mutations not detected |
| Norovirus PCR | P319 | Not detected |
| Nortriptyline | NRT |
| Therapeutic |
50-150 µg/L |
|
Potentially toxic |
> 500 µg/L |
|
| Nucleated Bone Marrow Cell Count | BMNC | Anticoagulated bone marrow sample (usually heparinized and submitted in a Red top) |
| Nucleated red cells | NRBCB |
| At birth |
< 10 per 100 WBC |
|
24 hours |
< 5 per 100 WBC |
|
48 hours |
< 1 per 100 WBC |
|
96 hours |
None |
|
| O.D. 450 Peak, Delta | OD45 | Method of Freda:
|
1+ |
Normal or possibly affected |
< 0.20 |
|
2+ |
Affected but not in jeopardy within 7 days |
0.20-0.34 |
|
3+ |
Distressed and probably in failure |
0.35-0.70 |
|
4+ |
Impending fetal death |
> 0.70 |
Method of Liley:
|
Week of gestation |
Normal |
Borderline |
|
25 |
< 0.08 |
0.08-0.33 |
|
30 |
< 0.05 |
0.05-0.21 |
|
35 |
< 0.03 |
0.03-0.13 |
|
40 |
< 0.02 |
0.02-0.08 |
|
| OR Coagulation Panel 1 (New test) | ORCO | |
| OR Coagulation Panel 2 | ORCO2 | |
| Oligoclonal Bands, CSF (Includes serum testing) | OLIG | Negative (No bands) |
| Oligosaccharides | OSTLC | |
| Onchocerca volvulus | P412 | |
| Opiate confirmation, urine | OPIAC | Not detected |
| Opiates Screen, Urine | OPI | Negative
Note: a negative result indicates that this class of drugs is not present, or they are present at a concentration below the cut-off concentration of 300 µg/L |
| Organic Acids, Qualitative | OAX | Negative |
| Orotic Acid, Urine | OROT | < 4.4 mmol/mol creatinine |
| Osmolality, serum | OSM | 283-301 mmol/kg |
| Osmolality, stool (New test) | OSMST | |
| Osmolality, urine | OSMU | 300-900 mmol/kg |
| Osteocalcin | OCAL |
| 5-9 years |
47-142 ng/mL |
|
10-13 years |
49-167 ng/mL |
|
14-17 year old males |
26-203 ng/mL |
|
14-17 year old females |
14-85 ng/mL |
|
Males > 17 years |
9-38 ng/mL |
|
Females > 17 years |
8-32 ng/mL |
|
| Oxacarbazepine (New test) | OXCBP |
| Therapeutic |
8.0-35.0 mcg/mL |
|
Toxic |
> 35.0 mcg/mL |
|
Lower Detection limit |
0.5 mcg/mL |
|
| Oxalic acid, 24 hour urine | OXAU | 3.6-38 mg/24 h |
| Oxalic acid, plasma | OXALP | < 1.8 µmol/L |
| Oxalic acid, random urine | OXALR |
| Male |
3-30 mg/g Creatinine |
|
Female |
3-40 mg/g Creatinine |
|
| Oxycodone Confirmation, urine (New test) | OXYUC | |
| Oxycodone screen, urine (New test) | OXYU | Negative
(Note: a negative result indicates that oxycodone is not present, or it is present at a concentration below the cut-off concentration of 100 µg/L) |
| PML-RARA PCR, Qualitative | PMLR | No PML-RARA bcr1 or bcr3 fusion transcripts |
| PML-RARA PCR, Quantitative | PMLQ | No PML-RARA bcr1 or bcr3 fusion transcripts |
| PMP22 Gene | MOLT | Two copies |
| POCT Activated Clotting Time | | Testing is used to monitor anticoagulation during invasive procedures. ACT levels during anticoagulation are compared to patient baseline values.
|
Cartridge |
Normal range |
|
LR cartridge |
99-187 sec |
|
Plus (+) cartridge |
98-139 sec |
See Additional Information for reportable ranges and heparin ranges appropriate for each cartridge. |
| POCT Blood Gases & Electrolytes | EG7P |
| Analyte |
Ages |
Arterial |
Venous |
|
pH |
All |
7.35-7.45 |
7.31-7.41 |
|
pCO2 |
< 1 year |
27-41 mmHg |
41-51 mmHg |
|
|
≥ 1 year |
32-48 mmHg |
41-51 mmHg |
|
pO2 |
< 30 days |
80-100 mmHg |
35-40 mmHg |
|
|
≥ 30 days |
83-108 mmHg |
35-40 mmHg |
|
Na+ |
All |
136-146 mmol/L |
136-146 mmol/L |
|
K+ |
≤ 1 year |
3.0-5.4 mmol/L |
3.0-5.4 mmol/L |
|
|
> 1 year |
3.4-4.5 mmol/L |
3.4-4.5 mmol/L |
|
iCa++ |
< 6 mo. |
0.95-1.50 mmol/L |
0.95-1.50 mmol/L |
|
|
≥ 6 mo. |
1.15-1.29 mmol/L |
1.15-1.29 mmol/L |
|
HCO3- |
All |
22-27 mmol/L |
|
Base Excess |
All |
-2 to +2 |
|
O2 Sat. |
All |
95-99% |
|
| POCT Coloscreen | | Negative |
| POCT Creatinine with eGFR | CREG | Creatinine
|
Age |
Male & Female |
|
≥ 19 years |
0.6-1.3 mg/dL |
eGFR
|
Age |
Male & Female |
|
< 18 years |
> 60 mL/min/1.73 m2 |
|
≥ 18 years |
> 60 mL/min/1.73 m2 |
|
| POCT Gastric Occult Blood | | Negative |
| POCT Glucose, Fingerstick | GLUPOC |
| Neonate |
55-115 mg/dL |
|
Adult & Pediatric |
70-199 mg/dL |
See Additional information for information on interferences with POCT glucose determinations |
| POCT Hemoglobin | |
| 0-7 days |
14.5-22.5 g/dL |
|
8-14 days |
13.5-21.5 g/dL |
|
2-4 weeks |
12.5-20.5 g/dL |
|
1-2 months |
10.0-18.0 g/dL |
|
2-3 months |
9.0-14.0 g/dL |
|
3-6 os |
9.5-13.5 g/dL |
|
6-24 months |
11.0-13.5 g/dL |
|
2-5 years |
11.2-13.5 g/dL |
|
5-8 years |
11.4-15.5 g/dL |
|
8-12 years |
11.6-15.5 g/dL |
|
Male 12-15 years |
12.3-16.0 g/dL |
|
Male 15-18 years |
12.6 -17.0 g/dL |
|
Male > 18 years |
13.6-17.5 g/dL |
|
Female 12-15 years |
11.8-15.5 g/dL |
|
Female > 15 years |
12.0-15.5 g/dL |
|
| POCT Hemoglobin A1c | | 4.2-6.0% |
| POCT Influenza Virus | | Negative |
| POCT Lipid Testing | | Total cholesterol:
Children and Adolescents (< 20 y/o):
|
Acceptable |
< 170 mg/dL |
|
Borderline |
170-199 mg/dL |
|
High |
> 199 mg/dL |
Adults (≥ 20 y/o):
|
Desirable |
< 200 mg/dL |
|
Borderline |
200-239 mg/dL |
|
High |
> 239 mg/dL |
HDL Cholesterol:
|
Acceptable |
> 39 mg/dL |
|
Higher risk |
< 40 mg/dL |
|
Lower risk |
> 59 mg/dL |
Triglycerides:
|
Desirable |
< 150 mg/dL |
|
Borderline high |
150-199 mg/dL |
|
High |
200-499 mg/dL |
|
Very high |
≥ 500 mg/dL |
LDL cholesterol:
|
Children and Adolescents (< 20 y/o): Acceptable |
< 110 mg/dL |
|
Borderline high |
110-129 mg/dL |
|
High |
> 129 mg/dL |
Adults: (≥ 20 y/o):
|
Optimal |
< 100 mg/dL |
|
Near or above optimal |
100-129 mg/dL |
|
Borderline high-risk |
130-159 mg/dL |
|
High-risk |
160-189 mg/dL |
|
Very high-risk |
> 189 mg/dL |
|
| POCT Microalbumin Urinalysis Dipstick (New test) | |
| Albumin-to-Creatinine Ratio |
<30 mg/g creatinine |
|
| POCT Multistix 10SG Urinalysis Dipstick (New test) | |
| Protein |
Negative |
|
Glucose |
Negative |
|
Ketones |
Negative |
|
Bilirubin |
Negative |
|
Hemoglobin (Myoglobin) |
Negative |
|
Nitrite |
Negative |
|
Leukocyte Esterase |
Negative |
|
pH |
4.5-8.0 |
|
Specific Gravity |
1.002-1.030 |
|
Urobilinogen |
≤ 1.0 mg/dL |
|
| POCT Multistix 9SG Urinalysis dipstick | |
| Protein |
Negative |
|
Glucose |
Negative |
|
Ketones |
Negative |
|
Bilirubin |
Negative |
|
Hemoglobin (Myoglobin) |
Negative |
|
Nitrite |
Negative |
|
Leukocyte Esterase |
Negative |
|
pH |
4.5-8.0 |
|
Specific Gravity |
1.002-1.030 |
|
| POCT Prothrombin Time, Fingerstick | |
| Normal (untreated) |
0.9-1.2 |
|
| POCT Respiratory Syncytial Virus antigen | | Negative |
| POCT Streptococcus Group A Antigen | | Negative |
| POCT Urine Pregnancy | | Negative (non-pregnant) |
| POCT iStat CG8 (New test) | CG8 |
| pH |
Arterial |
7.35-7.45 |
|
|
Venous |
7.31-7.41 |
|
pCO2 |
Arterial < 1 year |
27-41 mmHg |
|
|
Arterial > 1 year |
32-48 mmHg |
|
|
Venous |
41-51 mmHg |
|
pO2 |
Arterial < 30 days |
80-100 mmHg |
|
|
Arterial > 30 days |
83-108 mmHg |
|
|
Venous |
35-40 mmHg |
|
Na+ |
|
136-146 mmol/L |
|
K+ |
≤ 1 year |
3.0-5.4 mmol/L |
|
|
> 1 year |
3.4-4.5 mmol/L |
|
Ca++ |
< 6 months |
0.95-1.50 mmol/L |
|
|
≥ 6 months |
1.15-1.29 mmol/L |
|
Glucose |
Neonate |
55-115 mg/dL |
|
|
Pediatric/Adult |
70-199 mg/dL |
|
Lactate |
|
0.0-2.0 mmol/L |
|
Hct |
Adult male |
41-53% |
|
|
Adult female |
36-46% |
|
HCO3- |
Arterial |
22-27 mmol/L |
|
Base Excess |
Arterial |
-2 to +2 |
|
O2 Sat |
Arterial |
95-99% |
|
| POCT pH, fluid | | Results are reported in pH units as indicated from the color reaction of the paper. The colors below are descriptive only. The paper must be read against the pH color chart in the dispenser
|
Color |
Approx. pH |
|
Red |
1 |
|
Red |
2 |
|
Orange-Red |
3 |
|
Orange |
4 |
|
Orange |
5 |
|
Light Orange |
6 |
|
Yellow-Green |
7 |
|
Light Green |
8 |
|
Green |
9 |
|
Blue-Green |
10 |
|
Blue |
11 |
|
Blue-Black |
12 |
For vaginal fluid a pH > 6 indicates the presence of amniotic fluid and possible rupture of membranes. |
| PTEN Deletion by FISH | | Normal Range: Ratio >0.8 (no deletion of PTEN); Signals >1.6 (no loss of chromosome 10) |
| Pain Management Panel | PMPU | Negative
See Additional Information for confirmatory testing on positive samples |
| Pancreatic Elastase | ELAS |
| Normal |
> 200 µg/g stool |
|
Slight to Moderate insufficiency |
100-200 µg/g stool |
|
Severe insufficiency |
< 100 µg/g stool |
|
| Pancreatic Polypeptide | PPEP |
| Age |
Reference Range |
|
< 3 years |
Not established |
|
3-9 years |
≤ 519 pg/mL |
|
10-13 years |
≤ 361 pg/mL |
|
14-17 years |
≤ 297 pg/mL |
|
18-29 years |
< 480 pg/mL |
|
30-39 years |
70-400 pg/mL |
|
40-49 years |
70-430 pg/mL |
|
60-52 years |
100-780 pg/mL |
|
| Para-Aminobenzoic Acid | MOLT | > 250 mg (50%) excretion |
| Paracoccidioides Serology | MOLT | Negative |
| Paragonimus Antibody | MOLT | Negative |
| Paragonimus westermani | P412 (for respiratory specimens) or P401 (for stool) | |
| Parainfluenza Antibodies | PFL1 |
|
| Paraneoplastic Antibody Evaluation, CSF (New test) | PAECSF |
| Antibody |
Titer |
|
Antineuronal Nuclear Antibody-Type 1 (ANNA-1) |
Negative at <1:2 |
|
Antineuronal Nuclear Antibody-Type 2 (ANNA-2) |
Negative at <1:2 |
|
Antineuronal Nuclear Antibody-Type 3 (ANNA-3) |
Negative at <1:2 |
|
Anti-Glial/Neuronal Nuclear Antibody, Type 1 (AGNA-1) |
Negative at <1:2 |
|
Purkinje Cell Cytoplasmic Antibody, Type 1 (PCA-1) |
Negative at <1:2 |
|
Purkinje Cell Cytoplasmic Antibody, Type 2 (PCA-2) |
Negative at <1:2 |
|
Purkinje Cell Cytoplasmic Antibody, Type Tr (PCA-Tr) |
Negative at <1:2 |
|
Amphiphysin Antibody |
Negative at <1:2 |
|
CRMP-5-IgG |
Negative at <1:2 |
Note: Titers lower than 1:2 are detectable by recombinant CRMP-5 Western blot analysis. CRMP-5 Western blot analysis will be done on request on stored spinal fluid (held 4 weeks). This supplemental testing is recommended in cases of chorea, vision loss, cranial neuropathy, and myelopathy. Call the Neuroimmunology Laboratory at 800-533-1710 or 507-266-5700 to request CRMP-5 Western blot. |
| Paraneoplastic Antibody Evaluation, Serum (New test) | PAE |
| Antibody |
Titer |
|
Antineuronal Nuclear Antibody-Type 1 (ANNA-1) |
<1:240 |
Antineuronal Nuclear Antibody -Type 2 (ANNA-2) <1:240
|
Antineuronal Nuclear Antibody -Type 3 (ANNA-3) |
<1:240 |
|
Anti-Glial/Neuronal Nuclear Antibody-Type 1 (AGNA-1) |
<1:240 |
|
Purkinje Cell Cytoplasmic Antibody, Type 1 (PCA-1) |
<1:240 |
|
Purkinje Cell Cytoplasmic Antibody, Type 2 (PCA-2) |
<1:240 |
|
Purkinje Cell Cytoplasmic Antibody, Type Tr (PCA-Tr) |
<1:240 |
|
Amphiphysin Antibody |
<1:240 |
|
CRMP-5-IgG |
<1:240* |
|
Striational (Striated Muscle) Antibodies |
<1:60 |
|
N-Type Calcium Channel Antibody |
≤ 0.03 nmol/L |
|
P/Q-Type Calcium Channel Antibody |
≤ 0.02 nmol/L |
|
ACh Receptor (Muscle) Binding Antibody |
≤ 0.02 nmol/L |
|
AChR Ganglionic Neuronal Antibody |
≤ 0.02 nmol/L |
|
Neuronal VGKC Autoantibody |
≤ 0.02 nmol/L |
*Note: Titers lower than 1:240 are detectable by recombinant CRMP-5 Western blot analysis. CRMP-5 Western blot analysis will be done on request on stored serum (held 4 weeks). This supplemental testing is recommended in cases of chorea, vision loss, cranial neuropathy, and myelopathy. Call the Neuroimmunology Laboratory at 800-533-1710 or 507-266-5700 to request CRMP-5 Western blot.
Neuron-restricted patterns of IgG staining that do not fulfill criteria for amphiphysin, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, PCA-Tr, or CRMP-5-IgG may be reported as "unclassified antineuronal IgG." Complex patterns that include non-neuronal elements may be reported as "uninterpretable." |
| Parasite culture | P406 | Negative |
| Parasites, Duodenal and Colonic / Stool Aspirates | P401 | Negative |
| Parasites, Hepatic Abscess Aspirate | P401 | |
| Parasites, Rectal or Bladder Biopsy | P412 | |
| Parasites, Respiratory | Wet Mount (P412), Coccidia Exam (P407), Microsporidium Stain (P414), Intracellular Parasite Stain (P403) | Negative |
| Parasites, Skin biopsy | P406 | |
| Parasites, Stool | P401 | Negative |
| Parasites, Urine | P412 | |
| Parasites, Worm identification | P404 | |
| Parasites, blood | | |
| Parathormone Related Protein | PTHRP | < 2.0 pmol/L |
| Parathormone, Body fluid (FNA) | PTHB | |
| Parathormone, Intraoperative | PTHPR (Pre) & PTHPO (post) | |
| Parathormone, intact | PTH (PTHI for additional samples) | 12-65 ng/L |
| Paroxysmal Nocturnal Hemoglobinuria Cell Markers | PNHM |
| Normal |
≤ 3% WBC's & RBC's are CD59- |
|
| Parvovirus B19 Antibodies | PB19 |
| Negative |
< 0.9 index |
|
Equivocal |
0.9-1.1 index |
|
Positive |
> 1.1 index |
|
| Parvovirus B19 DNA | P338 | Not detected |
| Pentobarbital | PENT |
| Therapeutic |
1.0-5.0 mg/L |
|
Potentially toxic |
> 10 mg/L |
|
| Phenobarbital | PBAR | Therapeutic levels:
|
0-17 years |
15-40 mg/L |
|
≥ 18 years |
20-40 mg/L |
Source: Phenobarbital: Drug information copyright 1978-2012, Lexicomp, Inc. Accessed at UpToDate www.uptodate.com August 2012.
Therapeutic ranges adopted or modified from the literature based on recommendations of UCSF Pharmacists |
| Phenylalanine | PALA |
| ≤ 30 days |
30-79 µmol/L |
|
31 days-23 months |
31-92 µmol/L |
|
2-18 years |
38-86 µmol/L |
|
> 18 years |
40-74 µmol/L |
|
| Phenytoin, Free | PHNYF |
| Therapeutic |
1.0-2.0 µg/mL |
|
Potentially toxic |
> 3.0 µg/mL |
|
| Phenytoin, total | PHNY |
Source: Phenytoin: Drug information, Copyright 1978-2012 Lexicomp, Inc. Accessed in UpToDate, August 2012
Therapeutic ranges adopted or modified from the literature based on recommendations of UCSF Pharmacists |
| Phosphatidylglycerol | PGAG |
|
| Phospholipids | PLIP | 151-264 mg/dL |
| Phosphorus, 24 hour (or timed) urine | PO4U | 400-1300 mg/D |
| Phosphorus, Serum / Plasma | PO4 |
| < 1 month |
3.9-7.7 mg/dL |
|
1 month - 11 months |
3.5-6.6 mg/dL |
|
1 year - 3 years |
3.1-6.0 mg/dL |
|
4 years - 12 years |
3.0-5.7 mg/dL |
|
13 years - 15 years |
2.9-5.1 mg/dL |
|
≥ 16 years |
2.6-4.9 mg/dL |
1. Normal range for pediatric patients adapted from Soldin, Steven J., "Pediatric Reference Ranges", 6th edition, AACC Press, 2007, method 1.
2. Normal range for adults was determined by testing 271 male and female healthy blood donors at UCSF.
|
| Phosphorus, random urine | PO4UR | |
| Pinworm Examination | P405 | Negative |
| Pipecolic Acid | MOLT | Negative |
| Plasma Renin Activity | REN | 0.25-5.82 ng/mL/hour
Pediatric ranges have not been established for this assay. Please see 'Additional Information' |
| Plasminogen Activator Inhibitor - 1 antigen | PAI1AG | 4-43 ng/mL |
| Plasminogen Activity | PLMA | 65-176% |
| Plasminogen Antigen | PLMI | 8-14 mg/dL |
| Platelet Aggregation | AGGR | |
| Platelet Antigen Typing | MOLT | |
| Platelet Count | PLT, CBC , CBCD, PLTM | 140-450 x109/L |
| Platelet Crossmatch | XMPLAT | |
| Platelet Function Analysis (PFA-100) | PFA100 | Closure times:
|
Collagen/Epinephrine |
84-184 sec |
|
Collagen/ADP |
58-112 sec |
|
| Platelet Glycoprotein Antibody | PGAB | Negative |
| Pm-Scl Antibody (New test) | PMSCL | Negative |
| Pneumococcal IgG Antibodies (14 serotypes) | APN14 | See additional Information |
| Pneumococcal IgG Antibodies (23 serotypes) | APN23 | See additional information |
| Pneumococcal IgG Antibodies (6 serotypes) | APN6 | See additional information |
| Pneumocystis carinii stain | | |
| Poliovirus Antibodies | POLIO | Negative titer < 8 |
| Porphobilinogen deaminase, RBC | UPGS |
| Normal |
>6.9 nmol/L/sec |
|
Indeterminate |
6.0-6.9 nmol/L/sec |
|
Decreased |
<6.0 nmol/L/sec |
|
| Porphobilinogen, Quantitative, 24 hour urine | PBQT | < 2.8 mg/d |
| Porphobilinogen, Quantitative, random urine | PBQTR |
| 1-8 years |
0.9-2.8 mg/g creatinine |
|
9-17 years |
0.5-2.0 mg/g creatinine |
|
≥ 18 years |
≤ 1.5 mg/g creatinine |
|
| Porphyrins Evaluation, RBC | EPQTS | < 80 µg/dL |
Porphyrins, Fractionated, Fecal
| MOLT |
| Octacarboxyporphyrins (Uroporphyrins) |
< 80 µg/d |
|
Heptacarboxyporphyrins |
< 20 µg/d |
|
Tetracarboxyporphyrins (Coproporphyrins) |
< 640 µg/d |
|
Dicarboxyporphyrins (Protoporphyrins) |
< 1830 µg/d |
|
| Porphyrins, Fractionated, Urine | PORFU |
| Tetracarboxylporphyrins (Coproporphyrins) |
≤ 155 µg/d |
|
Pentacarboxylporphyrins |
≤ 4.7 µg/d |
|
Hexacarboxylporphyrins |
≤ 0.9 µg/d |
|
Heptacarboxylporphyrins |
≤ 6.8 µg/d |
|
Octacarboxylporphyrins (Uroporphyrins) |
3.3-29.5 µg/d |
|
Total porphyrins |
12-190 µg/d |
|
| Porphyrins, fractionated, random urine | PORFUR | Uroporphyrin:
|
1-10 years |
4.3-16.2 mcg/g creatinine |
|
11-17 years |
4.6-18.9 mcg/g creatinine |
|
≥ 18 years |
22.0 or less mcg/g creatinine |
Heptacarboxyporphyrin:
|
≥ 1 year |
4.6 or less mcg/g creatinine |
Hexacarboxyporphyrin:
≥ 1 year: NOT DETECTED
Pentacarboxyporphyrin:
|
1-10 years |
3.2 or less mcg/g creatinine |
|
11-17 years |
3.0 or less mcg/g creatinine |
|
≥ 18 years |
1.7 or less mcg/g creatinine |
Coproporphyrin:
|
1-10 years |
10.1-254.7 mcg/g creatinine |
|
11-17 years |
11.8-107.2 mcg/g creatinine |
|
≥ 18 years |
23.0-130.0 mcg/g creatinine |
Total Porphyrins:
|
1-10 years |
17.0-269.7 mcg/g creatinine |
|
11-17 years |
16.4-121.5 mcg/g creatinine |
|
≥ 18 years |
31.0-139.0 mcg/g creatinine |
|
| Posaconazole | PSCA |
| Single 200 mg dose, fasting |
0.05 – 0.27 mcg/mL |
|
Single 200 mg dose high fat diet |
0.24 – 1.02 mcg/mL |
|
Steady state, 200 mg TID |
0.02 – 3.65 mcg/mL |
|
| Post-Transfusion Purpura | MOLT | Negative |
| Post-Transfusion Study | TRXN | |
| Potassium, 24 hour (or timed) urine | KUR | 25-125 mmol/D |
| Potassium, Body Fluid | KBF | |
| Potassium, Serum / Plasma | K |
| < 1 year |
3.2-6.0 mmol/L |
|
> 1 year |
3.8-5.1 mmol/L |
1. Normal range for infants 0 to <1 year adopted from Soldin, Steven J., "Pediatric Reference Intervals", 6th edition, AACC Press, 2007, method 4.
2. Adult range used for children >1 year old.
3. Normal range for adults was determined by testing 271 male and female healthy blood donors at UCSF. |
| Potassium, Stool | KST | |
| Potassium, random urine | KU | Varies with diet, typically > 20 mmol/d |
| Potassium, whole blood (MtZ Only) | KSB |
| ≤ 1 year |
3.0-5.4 mmol/L |
|
> 1 year |
3.4-4.5 mmol/L |
|
| Prader-Willi/Angelman Syndromes | PWA | Negative |
| Pre-Surgical Type & Screen (New test) | BB14 | |
| Pre-Transplant Infectious Disease Screen-for organ, tissue and stem cell recipients | BMID | |
| Prealbumin | PAB | 20-37 mg/dL |
| Pregnanetriol | PRTL |
| Males |
71-1000 µg/24 hours |
|
Females |
47-790 µg/24 hours |
|
| Primidone | PRIM | Primidone:
Therapeutic: 5-15 mg/L
Potentially toxic: > 15 mg/L
Phenobarbital:
15.0-40.0 mg/L |
| Procainamide | MOLT |
| Therapeutic |
4.0-8.0 mg/L |
|
Potentially toxic |
> 16.0 mg/L |
|
NAPA |
< 30.0 mg/L |
|
| Progesterone | PROG |
| ≥ 18 year old males |
0.34-1.70 µg/L |
Menstruating females:
|
Follicular phase |
0.15-1.40 µg/L |
|
Luteal phase |
3.34-25.56 µg/L |
|
Mid-Luteal phase |
4.44-28.03 µg/L |
|
Postmenopausal |
< 0.73 µg/L |
Pregnant females:
|
First trimester |
11.22-90.00 µg/L |
|
Second trimester |
25.55-89.40 µg/L |
|
Third trimester |
48.40-422.50 µg/L |
|
| Progesterone, Pediatric | NPROG | Males:
|
5-9 years |
≤ 0.7 ng/mL |
|
10-13 years |
≤ 1.2 ng/mL |
|
14-17 years |
≤ 0.8 ng/mL |
|
18-29 years |
≤ 0.3 ng/mL |
|
30-39 years |
≤ 0.2 ng/mL |
|
40-49 years |
≤ 0.2 ng/mL |
|
50-59 years |
≤ 0.2 ng/mL |
Females:
|
5-9 years |
0.6 ng/mL |
|
10-13 years |
10.2 ng/mL |
|
14-17 years |
11.9 ng/mL |
|
Early Follicular Phase |
≤ 0.6 ng/mL |
|
Late Follicular Phase |
≤ 2.7 ng/mL |
|
Mid-Cycle Phase |
≤ 16.1 ng/mL |
|
Luteal Phase |
≤ 3.0-31.4 ng/mL |
|
Postmenopausal Women |
≤ 0.2 ng/mL |
|
| Proinsulin | PROINS | 3 - 20 pmol/L |
| Prolactin | PROL |
| ≥ 18 year old males |
2.1-17.7 µg/L |
|
Females |
2.8-29.2 µg/L |
|
Pregnant |
9.7-208.5 µg/L |
|
Postmenopausal |
1.8-20.3 µg/L |
|
| Prolactin-Insulin Stimulation Test | |
| Post-Stimulation peak |
≥ 2x basal |
|
| Prolactin-TRH Stimulation Test | |
| Post-Stimulation peak |
≥ 2x basal |
|
| Propranolol | PROP |
| Therapeutic for beta-blockade |
30-100 µg/L |
|
| Prostate Specific Antigen, Free | FPSA | See Additional Information |
| Prostate Specific Antigen, Total | PSAS, PRSA | Males 40 years of age and above: <4.00 ug/L.
Vendor reference range verified in-house by running 75 random male samples 40 years of age and older collected from outpatient settings.
See also 'Additional Information' |
| Prostatic Acid Phosphatase | ACPP | < 2.8 ng/mL |
| Protein C, Activity | PRC |
| Infant 0-6 months |
Not determined (See Additional information) |
|
Child 6 months - 16 years |
Not determined (See Additional information) |
|
> 16 years |
76-146% |
|
| Protein C, Antigen | PRCI |
| 0-1 day |
17-53% |
|
2-5 days |
20-64% |
|
6-30 days |
21-65% |
|
31-90 days |
28-80% |
|
91-180 days |
37-81% |
|
| Protein Electrophoresis, serum | PE | All values are in g/dL
|
Age |
albumin |
alpha-1 |
alpha-2 |
beta |
gamma |
|
0-1mo |
2.9-5.5 |
0.1-0.3 |
0.2-0.6 |
0.3-0.6 |
0.6-1.2 |
|
1mo-1year |
2.8-5.0 |
0.1-0.3 |
0.3-0.7 |
0.3-0.7 |
0.2-0.7 |
|
1-4years |
3.9-5.1 |
0.1-0.3 |
0.5-1.1 |
0.4-1.0 |
0.2-0.9 |
|
4-18years |
3.8-5.4 |
0.1-0.3 |
0.4-1.0 |
0.3-1.2 |
0.4-1.4 |
|
18+years |
3.1-5.4 |
0.1-0.3 |
0.4-1.2 |
0.6-1.2 |
0.6-1.6 |
|
| Protein Electrophoresis, urine | PEU | |
| Protein S Activity | PSACT | Age
|
Newborn - Day 4 |
12-60% |
|
Day 5 - 1 Month |
22-78% |
|
1 Month - 3 Months |
33-93% |
|
3 Months - 6 Months |
54-118% |
|
> 6 Months |
70-119% |
|
| Protein S, free | PRSI |
| 0-6 month old |
Not established (see Additional information) |
|
> 6 mo |
53-137% |
|
| Protein, Total, 24 hour (or timed) urine | TPU | < 160 mg/D |
| Protein, Total, Body Fluid | TPBF |
|
| Protein, Total, CSF | TPCF | 15-50 mg/dL |
| Protein, Total, Serum / Plasma | TP |
| < 1 year |
4.3 – 6.9 g/dL |
|
1 year - 2 years |
5.2-7.4 g/dL |
|
3 years - 5 years |
5.6-7.7 g/dL |
|
6 years- 9 years |
6.5-8.3 g/dL |
|
≥ 10 years |
6.0-8.1 g/dL |
Normal range for children less than 10 years old adopted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345.
Normal range for adults: low end of 6.0 determined by testing 271 normal male and female UCSF blood donors and referenced by Beckman as the low end of adult recumbent patients. High end of 8.1 adapted from Beckman Synchron's ambulatory upper limit.
Adult range used for children 10-18 years old. Adult range comparable to Beckman's range for age group 10-19 years (Bulletin 9345). |
| Protein, Total, random urine | TPCUR | < 0.16 mg/mg creatinine |
| Prothrombin (20210) mutation | PTTR | Negative |
| Prothrombin Time | PT |
| PT |
12.0-15.4 seconds |
|
INR |
0.9-1.2 |
The PT of full-term normal infants does not appear to differ significantly from adults, although factor levels are somewhat lower in the first six months of life (Andrew, M et al. Development of the human coagulation system in the full-term infant. Blood. 70:165-172). |
| Prothrombin fragment 1+2 | PROF | 0.4-1.8 nmol/L |
| Pteridine Profile | MOLT | Normals:
|
Age |
Biopterin |
Neopterin |
%Biopterin |
mmol/mol creat |
mmol/mol creat |
|
0-2 months |
0.46-1.17 |
1.02-4.46 |
20-41 |
|
4 months -13 years |
0.78-2.68 |
0.40-1.33 |
49-74 |
|
Dihydropteridine Reductase activity (nmol/min/spot) |
1.96-7.51 |
Phenylketonuria:
|
Age |
Biopterin |
Neopterin |
%Biopterin |
mmol/mol creat |
mmol/mol creat |
|
0-4 months |
2.03-10.3 |
2.06-15.5 |
19-65 |
|
8 months -18 years |
0.85-4.23 |
0.31-1.59 |
60-83 |
From: Nederwieser A et al. 1980. Acta Helv Paediat. 25;335 and Blau, N. 1988. Ann REv Nutr. 8;185 |
| Pyruvate Kinase, RBC | MOLT | 6.7 - 14.3 U/g of hemoglobin |
| Pyruvate, CSF | PYRUC | 0.50-1.70 mg/dL |
Pyruvate, plasma
Important: Read Collection Instructions BEFORE obtaining samples. | PYRU | 0.30 - 1.50 mg/dL |
| QuantiFERON Gold TB | QNTFP | Not detected |
| Quantitative Amino Acids, Plasma | AMACP |
| Phosphatidyl Serine |
0 - 5 nmol/mL |
|
Taurine |
35 - 120 nmol/mL |
|
Phosphatidyl Ethanolamine |
0 - 30 nmol/mL |
|
Aspartate |
3 - 20 nmol/mL |
|
Threonine |
75 - 200 nmol/mL |
|
Serine |
65 - 200 nmol/mL |
|
Asparagine |
29 - 90 nmol/mL |
|
Glutamate |
380 - 750 nmol/mL |
|
Glutamine |
380 - 750 nmol/mL |
|
Sarcosine |
Not established |
|
Alpha Amino Adipate |
Not established |
|
Glycine |
130 - 450 nmol/mL |
|
Alanine |
140 - 480 nmol/mL |
|
Citrulline |
10 - 40 nmol/mL |
|
Alpha Amino-N-Butyrate |
4 - 40 nmol/mL |
|
Valine |
110-300 nmol/mL |
|
Cystine |
17 - 70 nmol/mL |
|
Methionine |
9- 35 nmol/mL |
|
Cystathionine |
Not established |
|
Isoleucine |
35 - 100 nmol/mL |
|
Leucine |
65 - 180 nmol/mL |
|
Tyrosine |
35 - 90 nmol/mL |
|
Phenylalanine |
35 -120 nmol/mL |
|
Beta Alanine |
Not established |
|
Beta Amino Isobutyrate |
0 - 5 nmol/mL |
|
Gamma Amino Butyrate |
Not established |
|
Homocysteine |
Not established |
|
Ethanolamine |
0 - 15 nmol/mL |
|
Tryptophan |
34 - 82 nmol/mL |
|
Hydroxylisine |
0 - 10 nmol/mL |
|
Ornithine |
30 - 120 nmol/mL |
|
Lysine |
80 - 250 nmol/mL |
|
1-Met-Histidine |
0 - 10 nmol/mL |
|
Histidine |
Not established |
|
3-Met-Histidine |
Not established |
|
Anserine |
Not established |
|
Carnosine |
Not established |
|
Arginine |
38 - 130 nmol/mL |
|
Hydroxyproline |
0 - 10 nmol/mL |
|
Proline |
85 - 350 nmol/mL |
|
Alloisoleucine |
Not established |
|
Arginosuccinic acid |
Not established |
|
| Quantitative Amino Acids, Plasma (to Stanford, see Utilization Guidelines) (New test) | AAQTS | See report |
| Quinidine | QUIND |
|
| RBC Associated Drug Antibodies | DRBC | Negative |
| RBC Count | CBC, CBCD, RBC |
| Age |
Count |
|
0-7 days |
4.0-6.6 x1012/L |
|
8-14 days |
3.9-6.3 x1012/L |
|
2-4 weeks |
3.6-6.2 x1012/L |
|
1-2 months |
3.0-5.4 x1012/L |
|
2-3 months |
2.7-4.9 x1012/L |
|
3-6 months |
3.1-4.5 x1012/L |
|
6-24 months |
3.7-4.7 x1012/L |
|
2-6 years |
3.9-4.9 x1012/L |
|
6-12 years |
4.0-5.0 x1012/L |
|
Male 12-18 years |
4.2-5.6 x1012/L |
|
Male >18 years |
4.4-5.9 x1012/L |
|
Female >12 years |
4.0-5.2 x1012/L |
|
| RET Proto-oncogene | MOLT | No mutations detected |
| RNA Polymerase III Antibody (New test) | RNAP | < 20 Units |
| Rabies Vaccine Response | RABET | A result ≥ 0.1 IU/mL is considered acceptable per ACIP. |
| Rabies, Antibody, Post-exposure immunization | RAB |
| Negative |
< 8 |
|
Protective |
≥ 8 |
|
| Rabies, Antigen (DFA) & Culture | MOLT | Negative |
| Rapid Influenza A / B / RSV PCR (New test) | P352 | Not detected |
| Rapid Plasma Reagin | RPRN, RPRNO, RPR, RPRO | Non-reactive |
| Red Cell Osmotic Fragility | EKTA | See Additional Information |
| Red cell Indices | CBC, CBCD |
| Age |
MCV |
MCH |
MCHC |
|
0-7 days |
95-121 fL |
31-37 pg |
29-37 g/dL |
|
1-2 weeks |
88-120 fL |
28-40 pg |
28-38 g/dL |
|
2-4 weeks |
86-118 fL |
28-40 pg |
28-38 g/dL |
|
1-2 months |
85-117 fL |
28-40 pg |
29-37 g/dL |
|
2-3 months |
77-115 fL |
26-34 pg |
29-37 g/dL |
|
3-6 months |
74-108 fL |
25-34 pg |
30-36 g/dL |
|
6-24 months |
70-86 fL |
23-31 pg |
30-36 g/dL |
|
2-6 years |
75-87 fL |
24-30 pg |
31-36 g/dL |
|
6-12 years |
77-95 fL |
25-33 pg |
31-36 g/dL |
|
12-18 years |
78-98 fL |
25-34 pg |
31-36 g/dL |
|
18+ years |
80-100 fL |
26-34 pg |
31-36 g/dL |
|
| Red cell Phenotype | PHEN | |
| Reducing Substances, stool | RSST | < 500 mg/dL |
| Reducing Substances, urine | RSUU | Negative |
| Relapsing Fever | P409 | Negative |
| Reptilase Time | REPT | 15-19 seconds |
| Respiratory Syncytial Virus Antibody | RSV |
|
| Respiratory Virus Panel by PCR | P350 | Not detected |
| Reticulocyte Count | RET |
| Age |
Count |
|
≤ 4 days |
65-230 x109/L |
|
Males ≥ 18 year old |
29.0-121.4 x109/L |
|
Females ≥ 18 year old |
25.6-96.9 x109/L |
|
| Rh Phenotyping | RHGT | |
| Rh only | RH | |
| Rheumatoid Factor, serum | RF | < 40 IU/mL |
| Ribosomal P Antibody (New test) | RIBP | < 1.0 AI |
| Rickettsia Antibody | MOLT | Negative titer < 1:64 |
| Ristocetin Aggregation | RIST | |
| Ristocetin Cofactor | RCOF | 42-191% |
| Rocky Mountain Spotted Fever Antibodies (IgG & IgM) | MOLT | Negative |
| Rotavirus Antigen | P333 | Negative |
| Rubella Antibody | RUBI | Positive result indicates immunity |
| Rubella Culture | P319 | |
| Russell's Viper Venom Test | RVVTM |
| RVVT |
31.2-43.2 seconds |
|
RVVT Inhibitor Ratio |
0.90-1.09 |
|
Phospholipid Confirmatory Ratio |
0.95-1.17 |
|
| SS18 FISH (New test) | | <10% |
| Saccharomyces cerevisiae Antibody | MOLT | |
| Salicylate | SAL |
|
| Salmonella Only Culture | P156 | |
| Schistosoma Ab, CSF (IgG) | SCHIST |
|
| Schistosoma Antibodies | SCHISS | < 1.00 = Antibody not detected |
| Schistosoma species |
| Stool |
P401 |
|
Urine |
P412 |
|
Tissue |
P404 |
| Negative |
| Scl-70 Antibody | SCL70 |
| Negative |
≤ 0.8 index |
|
Positive |
> 0.8 index |
|
| Second Trimester Screen | STS | |
| Sedimentation Rate | ESR |
| Male |
0-10 mm/h |
|
Female |
0-15 mm/h |
|
| Selenium, plasma | SE |
| < 2 years |
16-71 µg/L |
|
2-3 years |
40-103 µg/L |
|
4-16 years |
55-134 µg/L |
|
> 16 years |
63-160 µg/L |
|
| Selenium, urine | SELRU |
| Selenium |
≤ 200 µg/L |
|
Corrected for Creatinine |
< 25 µg/g Creatinine |
|
| Semen Analysis | SEMN |
| Volume |
> 2.0 mL |
|
Viscosity |
Normal |
|
Sperm Count |
> 20 x109/L |
|
Motility at 2 hours |
> 50% |
|
Morphology |
> 30% normal oval, Round: < 4/HPF |
|
Liquifaction |
Complete |
|
Agglutination |
None |
|
| Serotonin | SERO |
| ≥ 18 year olds |
55-260 µg/L |
|
| Serotonin Release Assay | SRAU | Negative |
| Serum Preparation & Storage (New test) | ILSPS | |
| Serum Viscosity | VISCO | 1.4-1.8 |
| Severe Acute Respiratory Syndrome | P319 | |
| Sex Hormone-Binding Globulin | SHBG |
| 1 mo-2 years |
60-252 nmol/L |
|
1-8 years |
72-220 nmol/L |
|
Pubertal males |
16-100 nmol/L |
|
Pubertal females |
36-125 nmol/L |
|
≥ 18 year old males |
20-60 nmol/L |
|
≥ 18 year old females |
40-120 nmol/L |
|
Postmenopausal females |
28-112 nmol/L |
|
| Shiga Toxin Assay | T315 | No toxin detected |
| Sialic Acid Containing Oligosaccharides | MOLT | Negative |
| Sirolimus | SIRO |
| Therapeutic trough |
5 - 15 µg/L |
|
| Sjogren's Antibodies | SSAB | anti-SSA and anti-SSB:
|
Negative |
< 20 Units |
|
Weak Positive |
20-39 Units Index |
|
Moderate Positive |
40-80 Units |
|
Stron Positive |
> 80 Units |
|
| Smooth Muscle Antibodies | ASMA | Negative titer < 40 |
| Sodium, 24 hour (or timed) urine | NAUR | Usually 40-220 mmol/D |
| Sodium, Body Fluid | NABF | |
| Sodium, Serum / Plasma | NA |
| < 1 year |
131 - 145 mmol/L |
|
≥ 1 year |
135 - 145 mmol/L |
1. Normal range for children less than 1 year old adapted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
2. Normal range for adults was determined by testing 271 male and female healthy blood donors at UCSF. |
| Sodium, random urine | NAU | Output varies with diet, but the concentration usually exceeds 20 mmol/L. |
| Sodium, stool | NASTL | |
| Sodium, whole blood (MtZ Only) | NAWB | 136-146 mmol/L |
| Solid Tumor Cytogenetics (New test) | CYSTU | |
| Sperm Count and Motility | SPMO |
| Count |
> 20 x109/L |
|
Motility at 2 hours |
> 50% |
|
| Sperm Count, Post Vasectomy | PSCT | Negative |
| Spinal Muscular Atrophy (New test) | SMAPCR |
| SMN1 |
2 copies or more |
|
SMN2 |
0 to 5 copies |
|
| Sporotrichosis Serology | MOLT | |
| St. Louis Equine Encephalitis Antibody | SLOUB |
| IgG |
<1:16 titer |
|
igM |
<1:20 titer |
|
| Staphylococcous aureus Culture (New test) | P115 | |
| Stone Analysis | STONE | |
| Stool Analysis | STAN, P221 |
| pH |
> 6.5 |
|
WBC |
None seen |
|
Reducing substances |
negative |
|
| Streptococcus Group A Antigen | P116 | Negative |
| Streptococcus Group A Culture | P118 | Negative |
| Streptococcus Group B Culture | P138 | |
| Streptococcus pneumoniae Antigen, urine TEST NOT OFFERED AT UCSF | None - Do Not Order | |
| Strongyloides Antibody (IgG) | STRONG | Negative |
| Strongyloides species | P412 | Negative |
| Subtelomere FISH | CYSUB | Normal. See Additional Information |
| Sulfamethoxazole | SULF |
| Therapeutic |
50-150 mg/L |
|
Toxic |
> 400 mg/L |
|
| Sulfatide Antibodies | MOLT |
|
IgM |
IgG |
|
Normal |
< 1100 |
< 900 Elevated |
1100 |
900 Very High |
1700 |
1500 |
|
| Syphilis serologic testing | | |
| T Cell Receptor, Gamma, Gene Rearrangement | MOLT | Negative for clonal gene rearrangement |
| T&B-Cell Crossmatch by Flow Cytometry (For Donor) (New test) | ILTXFD | |
| T&B-Cell Crossmatch by Flow Cytometry (Recipient) (New test) | ILTXFR | |
| T-Cell Crossmatch by Cytotoxicity (For Donor) (New test) | ILTXCD | |
| T-Cell Crossmatch by Cytotoxicity (Recipient) (New test) | ILTXCR | |
| T-Cell Crossmatch by Cytotoxicity w/ DTT (Recipient) (New test) | ILTXDT | |
| T-Cell Receptor Rearrangement, Qualitative (New test) | TCRR | |
| T3, Reverse | T3RV |
| Male |
9-28 ng/dL |
|
Female |
7-24 ng/dL |
|
| T3, Total | T3 |
| Age |
Male |
Female |
|
0-12 months |
0.9-3.1 nmol/L |
1.6-3.5 nmol/L |
|
Age |
Male & Female |
|
1-5 years |
1.6-3.1 nmol/L |
|
6-10 years |
1.6-2.8 nmol/L |
|
11-14 years |
1.0-2.9 nmol/L |
|
15-18 years |
1.1-2.7 nmol/L |
|
>18 years |
0.9-2.4 nmol/L |
Adult reference ranges adopted from manufacturer reference range studies (95% CI) and verified in-house using blood donor samples (N=124) (excluding autologous donors) on no medications and negative for anti-Tg and TPO antibodies.
Pediatric reference ranges adopted from Clinical Biochemistry 42 (2009) 885-891. Canadian Laboratory Initiative on Pediatric Reference Interval Database (CALIPER). |
| T4, Total | TT4 |
| 1-8 Years |
5.9-11.5 mcg/dL |
|
9-13 Years |
4.7-10.4 mcg/dL |
|
14-17 Years |
5.0-9.8 mcg/dL |
|
≥ 18 year old |
4.8-10.4 mcg/dL |
Pregnancy:
|
1st Trimester |
6.4-15.2 mcg/dL |
|
2nd Trimester |
7.4-15.2 mcg/dL |
|
3rd Trimester |
7.7-13.8 mcg/dL |
|
All Trimesters Together |
7.0-14.7 mcg/dL |
|
| TH/TO Auoantibodies (New test) | THTO | Negative |
| TRH Stimulation Test | | TSH 2-4x basal and > 10 mIU/L 15-30 min post-TRH |
| Tacrolimus | TAC |
| Therapeutic trough |
5 -15 µg/L |
|
| Tapeworm Segments | P404 | |
| TdT | TDT | Negative |
Temporarily unavailable as of 11/21/2011
Plasminogen Activator Inhibitor -1 Activity | PAI1 |
| ≥ 18 year old males |
2.0-47.1 IU/mL |
|
≥ 18 year old females |
2.0-40.7 IU/mL |
|
| Testosterone, Free (includes Total Testosterone) | FTST | Testosterone, Total:
|
Age |
Males |
Females |
|
Cord Blood |
17-61 ng/dL |
16-44 ng/dL |
|
1-10 days |
≤ 187 ng/dL |
≤ 24 ng/dL |
|
1-3 months |
72-344 ng/dL |
≤ 17 ng/dL |
|
3-5 months |
≤ 201 ng/dL |
≤ 12 ng/dL |
|
5-7 months |
≤ 59 ng/dL |
≤ 13 ng/dL |
|
7-12 months |
≤ 16 ng/dL |
≤ 11 ng/dL |
|
1-5.9 years |
≤ 5 ng/dL |
≤ 8 or less |
|
6-7.9 years |
≤ 25 ng/dL |
≤ 20 or less |
|
8-10.9 years |
≤ 42 ng/dL |
≤ 35 or less |
|
11-11.9 years |
≤ 260 ng/dL |
≤ 40 ng/dL |
|
12-13.9 years |
≤ 420 ng/dL |
≤ 40 ng/dL |
|
14-17.9 years |
≤ 1000 ng/dL |
≤ 40 ng/dL |
|
18-69 years |
250 - 1100 ng/dL |
2 - 45 ng/dL |
|
70-89 years |
90 - 890 ng/dL |
2 - 40 ng/dL |
Pediatric Reference Ranges by Pubertal Stage :
|
Stages |
Males |
Females |
|
I |
≤ 5 ng/dL |
≤ 8 ng/dL |
|
II |
≤ 167 ng/dL |
≤ 24 ng/dL |
|
III |
21-719 ng/dL |
≤ 28 ng/dL |
|
IV |
25-912 ng/dL |
≤ 31 ng/dL |
|
V |
110-975 ng/dL |
≤ 33 ng/dL |
Testosterone, Free:
|
Age |
Males |
Females |
|
5-9.9 years |
≤ 5.3 pg.mL |
0.2-5.0 pg.mL |
|
10-13.9 years |
0.7-52.0 pg/mL |
0.1-7.4 pg/mL |
|
18-69 years |
35.0-155.0 pg/mL |
0.1-6.4 pg/mL |
|
70-89 years |
30.0-135.0 pg/mL |
0.2-3.7 pg/mL |
|
14-17.9 years |
18.0-111.0 pg/mL |
0.5-3.9 pg/mL |
|
| Testosterone, Total, Pediatric | PTES |
| Age |
Males |
Females |
|
|
Premature (26-28 weeks) |
59-125 ng/dL |
5-16 ng/dL |
|
Premature (31-35 weeks) |
37-198 ng/dL |
5-22 ng/dL |
|
Newborn |
75-400 ng/dL |
20-64 ng/dL |
|
1-5 months |
14-363 ng/dL |
< 20 ng/dL |
|
6-24 months |
< 37 ng/dL |
< 9 ng/dL |
|
2-3 years |
< 15 ng/dL |
< 20 ng/dL |
|
4-5 years |
< 19 ng/dL |
< 30 ng/dL |
|
6-7 years |
< 13 ng/dL |
< 7 ng/dL |
|
8-9 years |
2-8 ng/dL |
1-11 ng/dL |
|
10-11 years |
2-165 ng/dL |
3-32 ng/dL |
|
12-13 years |
3-619 ng/dL |
6-50 ng/dL |
|
14-15 years |
31-733 ng/dL |
6-52 ng/dL |
|
16-17 years |
158-826 ng/dL |
9-58 ng/dL |
|
18-39 years |
300-1080 ng/dL |
9-55 ng/dL |
|
40-59 years |
300-890 ng/dL |
9-55 ng/dL |
|
60 years and older |
300-720 ng/dL |
5-32 ng/dL |
|
Tanner Stage |
Males |
Females |
|
|
Tanner Stage I |
2-15 ng/dL |
2-17 ng/dL |
|
Tanner Stage II |
3-303 ng/dL |
5-40 ng/dL |
|
Tanner Stage III |
10-851 ng/dL |
10-63 ng/dL |
|
Tanner Stage IV-V |
162-847 ng/dL |
11-62 ng/dL |
|
| Testosterone,Total | TTES | Males:
|
20-39 years |
241-827 ng/dL |
|
40-89 years |
141-703 ng/dL |
Females:
Male reference range for the 20-39 age group was adopted from the reagent vendor performed studies and verified by running blood donor samples (excluding autologous donors) collected from the UCSF Blood Donor Center.
Male reference range for the 40-89 ages group was adopted from Endocrine Abstracts 2006 12:104 and verified by running blood donor samples (excluding autologous donors) collected from the UCSF Blood Donor Center.
Female reference range was adopted from vendor performed studies and verified by running female donor samples (excluding autologous donors) collected from the UCSF Blood Donor Center |
| Tetanus Antitoxin | TETA |
| Detectable |
> 0.1 IU/mL |
|
Protective |
> 0.15 IU/mL |
|
| Tetrahydrocannabinol Screen, Urine | THC | Negative
Note: a negative result indicates that this class of drugs is not present, or they are present at a concentration below the cut-off concentration of 50 µg/L |
| Thallium, 24 hour urine | MOLT |
| Normal |
< 2 µg/L |
|
Toxic |
> 200 µg/L |
|
| Thallium, random urine | THALR | ≤ 0.4 µg/g creatinine |
| Theophylline | THEO |
| Therapeutic peak |
5-20 mg/L |
|
| Thiocyanate | SCN |
| Non-smokers |
< 0.4 mg/dL |
|
Smokers |
< 2.0 mg/dL |
|
Nitroprusside infusion |
< 2.9 mg/dL |
|
Toxic |
> 10 mg/dL |
|
| Thiopental | MOLT |
| Sedative |
1-5 mg/L |
|
Toxic |
> 10 mg/L |
|
Anoxic Rx |
20-60 mg/L |
|
| Thiopurine Methyltransferase, RBC | MOLT |
| >21.0 EU |
Normal Activity |
|
6.0-21.0 EU |
Intermediate Activity |
|
<6.0 EU |
Low Activity |
|
| Thiopurine methyl transferase Genotyping | TPMTGN | |
| Thrombelastograph | TEG, HEPTEG |
| Reaction time (R) |
5.0-10.4 minutes |
|
Kinetics (K) |
0.8-2.8 minutes |
|
Angle |
55.2-78.4 degrees |
|
Max. Amplitude (MA) |
50.6-69.4 mm |
|
Lysis 30 min. post-peak (LY30) |
0.0-4.3% |
Note: Although pediatric normal ranges have not been extensively evaluated the results obtained from pediatric samples do not appear to differ appreciatively from adult samples. |
| Thrombin Time | TT | 21.6-30.1 sec |
| Thyroglobulin Antibodies | TGAB | < 4.11 IU/mL
Reference range was adopted from reagent vendor (Abbott Labs) performed studies and verified in house by running 21 male samples less than 30 years of age with a TSH level between 0.5-2.0 mIU/L. This selection criteria is specified in the NACB: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease guidelines. |
| Thyroglobulin, Ultrasensitive (Tumor Marker; includes anti-Tg Ab testing) | TGA | Thyroglobulin:
|
Male |
1.4-29.2 µg/L |
|
Female |
1.5-38.5 µg/L |
|
Thyroglobulin Ab* |
< 4.11 IU/mL |
*Reference range was adopted from reagent vendor (Abbott Labs) performed studies and verified in house by running 21 male samples less than 30 years of age with a TSH level between 0.5-2.0 mIU/L. This selection criteria is specified in the NACB: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease guidelines. |
| Thyroid Stimulating Hormone | TSH | 0.45-4.12 mIU/L |
| Thyroid Stimulating Immunoglobulin | TSI | Negative <140% of baseline (See Additional information) |
| Thyroperoxidase Antibodies | ATPO |
| Negative |
< 60 U/mL |
|
Positive |
≥ 60 U/mL |
|
| Thyrotropin Binding Inhibitory Immunoglobulin | TBII |
|
| Thyroxine Binding Globulin | TBG |
| 4-6 years |
14.8-32.9 µg/mL |
|
7-8 years |
16.3-30.7 µg/mL |
|
9-10 years |
15.8-27.4 µg/mL |
|
11 years |
15.5-27.4 µg/mL |
|
12 years |
14.8-26.2 µg/mL |
|
13 years |
13.8-25.2 µg/mL |
|
14 years |
12.2-25.2 µg/mL |
|
15 years |
10.8-23.8 µg/mL |
|
16 years |
10.0-23.8 µg/mL |
|
17 years |
8.5-23.1 µg/mL |
|
Tanner Stages |
Males |
Females |
|
Stage I |
13.5-28.4 µg/mL |
14.2-28.5 µg/mL |
|
Stage II |
15.1-25.9 µg/mL |
15.0-23.1 µg/mL |
|
Stage III |
14.0-26.3 µg/mL |
13.7-23.0 µg/mL |
|
Stage IV |
13.2-25.0 µg/mL |
12.0-22.8 µg/mL |
|
Stage V |
12.2-23.7 µg/mL |
9.1-22.8 µg/mL |
|
≥ 18 year old females |
13.5-30.9 µg/mL |
|
≥ 18 year old males |
12.7-25.1 µg/mL |
To convert to nmol/L, multiply the result by 18.5.
|
| Tissue Immmunoflorescence-IgA Antibody | UCSF | Negative Titer < 1:10 |
| Tissue Transglutaminase Antibody, IgA | TTGT |
See "Additional information" |
| Tissue Transglutaminase Antibody, IgG (New test) | TTGTGG | Negative < 20.0 Units
See Additional information |
| Tobramycin | TOBPK (Peak), TOBTH (Trough), TOBRN (Random) |
| Therapeutic peak |
5-10 mg/L |
Trough levels:
|
Standard dosing |
< 2 mg/L (< 1 mg/L optimum) |
|
Once daily, high dose |
< 1 mg/L (< 0.3 mg/L optimum) |
|
ICN extended interval dosing |
< 2 mg/L (< 1.5 mg/L optimum) |
|
CF extended interval dosing |
< 1 mg/L |
Source of reference range: UCSF/SFGH/VASF joint guidelines for antimicrobial use in adults.
Click here for link |
| Tocainide | MOLT |
| Therapeutic |
4-10 mg/L |
|
Potentially toxic |
> 10 mg/L |
|
| Tocopherols | VITE |
| Age |
alpha-tocopherol |
|
Cord blood at term |
1.8-5.8 mg/L |
|
4-11 months |
< 9.1 mg/L |
|
1-2 years |
2.9-16.6 mg/L |
|
3-5 years |
5.5-11.8 mg/L |
|
6-8 years |
4.6-14.8 mg/L |
|
9-11 years |
6.2-14.3 mg/L |
|
12-17 years |
3.7-12.4 mg/L |
|
> 17 years |
5.7-19.9 mg/L |
|
Age |
beta/gamma tocopherols |
|
3-17 years |
0.5-3.8 mg/L |
|
> 17 years |
< 4.4 mg/L |
|
| Topiramate | TOPA |
| Daily dose (mg) |
Peak |
Trough |
|
100 |
6.5-9.2 µg/mL |
4.5-6.6 µg/mL |
|
200 |
12-16 µg/mL |
8-12 µg/mL |
|
400 |
20-30 µg/mL |
14-20 µg/mL |
|
| Total Tryptase (New test) | TRPT | 2-10 ng/mL |
| Toxoplasma gondii Antibody, IgG | TOXO | Negative |
| Toxoplasma gondii Antibody, IgG, CSF | TXCG |
| Negative |
< 0.90 |
|
Equivocal |
0.9-1.09 Positive |
≥ 1.10 |
|
| Toxoplasma gondii Antibody, IgM | TOGM | Negative |
| Toxoplasma gondii Antibody, IgM, CSF | TXCM and TXCG |
| Negative |
< 0.90 |
|
Equivocal |
0.9-1.09 |
|
Positive |
≥ 1.10 |
|
| Toxoplasma gondii stain | P403 | |
| Toxoplasma gondii, DNA | TXPCR | Not detected |
| Trace Metal Analysis Collection and Processing Instructions | | |
| Transferrin | TRFN | 182-360 mg/dL |
| Transferrin, beta-2- | B2TAU | Negative |
| Translocation 11 / 14 FISH (New test) | TR1114 | Absent |
| Translocation 14 / 16 FISH (New test) | TR1416 | Absent |
| Translocation 4 / 14 FISH (New test) | TR414 | Absent |
| Trazodone | TRAZ |
| Therapeutic |
800-1600 ng/mL |
|
| Treponemal Antibody | TPAB | Non-reactive |
| Trichinella spiralis Antibody, IgG | TRICG | Negative |
| Trichomonas vaginalis | P415 | Negative |
| Triene/Tetraene Ratio | EFA | |
| Triglycerides, Body fluid | TGBF | |
| Triglycerides, serum | TRIG |
| Desirable |
< 150 mg/dL |
|
Borderline high |
150-199 mg/dL |
|
High |
200-499 mg/dL |
|
Very high |
≥ 500 mg/dL |
Risk classification is according to NCEP-ATPIII guidelines (JAMA 2001;285:2486) |
| Trisomy 8 FISH | TRIS8 | Not detected |
| Troponin I | TRPI | < 0.05 µg/L |
| Troponin I at Mount Zion | TRIPOC | < 0.09 µg/L |
| Trypanosoma cruzi Antibodies (IgG & IgM) | TCAB | Negative |
| Trypanosoma cruzi, culture | P406 | |
| Trypanosoma species, Direct smears | P409 | |
| Tularemia Agglutinins | TULA | Negative titer < 20 Equivocal titer 20-80 Positive titer > 80 |
| Tumor Cytogenetics | CYTUM | |
| Type and Screen | TYSC | |
| Type and Screen, Non-patient | TSNP | |
| Type and Screen, Prenatal | ABPR | |
| Typhus (Murine) Antibodies (IgG & IgM) | MOLT | Negative |
| Tyrosine, plasma | TYRO |
| 0-30 days |
33-160 µmol/L |
|
31 days-23 months |
24-125 µmol/L 2-17 years |
31-108 µmol/L ≥ 18 years |
38-96 µmol/L |
|
| U3 RNP Autoantibody (New test) | U3RNP | Negative |
| UDP Glucuronosyltransferase 1A1 | UGT1A1 |
|
| Unstable Hemoglobin, Isopropanol screen | UHGBI | None detected |
| Urea Clearance | URCL | See additional information |
| Urea Nitrogen, 24 hour (or timed) urine | UNU | 10-20 g/D |
| Urea Nitrogen, Body Fluid | UNB | |
| Urea Nitrogen, Serum / Plasma | BUN |
| 0 - 4 years |
5-27 mg/dL |
|
≥ 5 years |
6-22 mg/dL |
Note:
1. Normal range for children 0-5 years adapted from Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345
2. Normal range for adults used for children 5-17 years. Beckman Coulter's "Pediatric Reference Range Guidelines for Synchron Systems" Bulletin 9345 for 5-15 year olds comparable to adult range.
2. Normal range for adults was determined by testing 270 male and female healthy blood donors at UCSF. |
| Urea Nitrogen, random urine | UNUR | See Additional Information |
| Urea Reduction Ratio | URR | |
| Ureaplasma / mycoplasma hominis culture | P319 | Negative |
| Uric Acid, 24 hour (or timed) urine | UCAU | 250-750mg/D |
| Uric Acid, Serum / Plasma | URIC |
| Age |
Male |
Female |
|
< 1 month |
1.2-3.9 mg/dL |
1.0-4.6 mg/dL |
|
1 month - 11 months |
1.2-5.6 mg/dL |
1.1-5.4 mg/dL |
|
1 year - 3 years |
2.1-5.6 mg/dL |
1.8-5.0 mg/dL |
|
4 years - 6 years |
1.8-5.5 mg/dL |
2.0-5.1 mg/dL |
|
7 years - 9 years |
1.8-5.4 mg/dL |
1.8-5.4 mg/dL |
|
10 years - 12 years |
2.2-5.8 mg/dL |
2.5-5.9 mg/dL |
|
13 years - 15 years |
3.1-7.0 mg/dL |
2.2-6.4 mg/dL |
|
16 years - 17 years |
2.1-7.6 mg/dL |
2.4-6.6 mg/dL |
|
≥ 18 years |
3.9-8.2 mg/dL |
2.9-6.6 mg/dL |
1. Pediatric reference ranges adopted from Soldin, Steven J. Pediatric Reference Intervals (method 3), 6th edition, AACC Press, 2007.
2. Normal range for adults was determined by testing 137 male and 129 female healthy blood donors at UCSF. |
| Uric Acid, random urine | UAUR | See Additional Information |
| Urinalysis, Macroscopic | UA (macroscopic alone) or UAWM (with microscopy) |
| Protein |
Negative |
|
Glucose |
Negative |
|
Ketones |
Negative |
|
Bilirubin |
Negative |
|
Hemoglobin (Myoglobin) |
Negative |
|
Nitrite |
Negative |
|
Leukocyte Esterase |
Negative |
|
pH |
4.5-8.0 |
|
Specific Gravity |
1.002-1.030 |
|
| Urinalysis, Microscopic | UMIO (microscopy alone) or UAWM (with macroscopic urinalysis) | See Urinalysis, Macroscopic for dipstick testing normal ranges.
Microscopy normal ranges:
< 5 WBC/HPF
< 3 RBC/HPF
Data based on minimum sample size of 10 mL and may not be applicable to samples of less than 10 mL. |
| UroVysion (TM) FISH | UROV | ≤ 3 cells showing gains for 2 or more chromosomes (3, 7 or 17) in the same cell and ≤ 11 cells showing zero 9p21 signals. |
| VAP TM Cholesterol Test | VAPP |
| Total LDL Chol. |
< 130 mg/dL |
|
Total HDL Chol. |
≥ 40 mg/dL |
|
Total VLDL Chol. |
< 30 mg/dL |
|
Total Chol. |
< 200 mg/dL |
|
Triglyceride |
< 150 mg/dL |
|
LDL + VLDL |
< 160 mg/dL |
|
ApoB100 |
< 109 mg/dL |
|
Lp(a) |
< 10 mg/dL |
|
IDL |
< 20 mg/dL |
|
LDL-R (Real)-C |
< 100 mg/dL |
|
Total LDL-C |
< 130 mg/dL |
|
Real LDL Size pattern |
A |
|
Remnant Lipo (IDL+VLDL3) |
< 30 mg/dL |
|
HDL-2 Male |
> 10 mg/dL |
|
HDL-2 Female |
> 15 mg/dL |
|
HDL-3 Male |
> 30 mg/dL |
|
HDL-3 Female |
> 25 mg/dL |
|
VLDL-3 |
< 10 mg/dL |
|
| VDRL, CSF | VDRL | Non-reactive |
| Valproic acid | VALP |
VPA therapeutic range of 50 - 125 mg/L was set based on recommendations in the literature and consultations with UCSF pharmacists and neurologists.
Source: Valproate: Drug information copyright 1978-2012, Lexicomp, Inc. Accessed at UpToDate www.uptodate.com August 2012. |
| Vancomycin | VANC |
| Therapeutic trough, standard cases |
10-20 mg/L |
|
Therapeutic trough, exceptional cases |
15-20 mg/L |
Source of reference range: UCSF/SFGH/VASF joint guidelines for antimicrobial use in adults.
Click here for link |
| Vanillylmandelic Acid, urine | VMA |
| 1-12 months |
< 36 mg/g Creatinine |
|
1-2 years |
< 31 mg/g Creatinine |
|
2-5 years |
< 17 mg/g Creatinine |
|
5-10 years |
< 15 mg/g Creatinine |
|
> 10 years |
< 11 mg/g Creatinine |
|
| Varicella-zoster Antibody, IgG | VZI | Non-immune: Negative |
| Varicella-zoster Antigen (DFA) | P346 | Negative |
| Varicella-zoster DNA | P339 | Not detected |
| Vasoactive Intestinal Peptides | VIP | 22-42 pg/mL |
| Vectra DA (New test) | VECTRA | See report |
| Verapamil | VERA |
| Therapeutic |
70-350 ng/mL for parent drug |
|
| Vibrio Culture | P159 | |
| Viral Culture, Eye | P324 | |
| Viral Culture, other | P324 | |
| Viral Serology | IDAB | Negative |
| Vitamin A | VITA | Age:
|
1-6 years |
20-43 µg/dL |
|
7-12 years |
26-49 µg/dL |
|
13-19 years |
26-72 µg/dL |
|
> 19 years |
38-98 µg/dL |
|
| Vitamin B1, blood | VIB1 | 78-185 nmol/L |
| Vitamin B12 | VB12 |
Reference range adopted from vendor performed studies and verified by running blood donor samples (excluding autologous donors) collected at the UCSF Blood Donor Center. |
| Vitamin B6 | VIB6 |
| 2-17 years |
3.0-35 ng/mL |
|
> 17 years |
2.1-21.7 ng/mL |
|
| Vitamin D, 1,25-Dihydroxy- | VDHD |
| 3-17 years |
27-71 pg/mL |
|
≥ 18 years |
15-60 pg/mL |
|
| Vitamin D, 25-Hydroxy | 25HD | 30-100 ng/mL
|
Vit. D excess |
> 150 ng/mL |
|
Vit. D sufficiency |
> 30 ng/mL |
|
Vit. D insufficiency |
10-30 ng/mL |
|
Vit. D deficiency |
< 10 ng/mL |
|
| Vitamin K | VITK | 80-1160 pg/mL |
| Voriconazole (New Test) | VORIC | Achievable steady state levels with typical dosing range from 2-6 µg/mL. |
| WBC Count | CBC, CBCD, WBC, WBCDF |
| 0-24 hours |
9.0-38.0 x109/L |
|
24 hours-1 wk |
5.0-34.0 x109/L |
|
1 wk-6 months |
5.0-21.0 x109/L |
|
6 months -4 years |
5.5-17.5 x109/L |
|
4-14 years |
4.5-15.5 x109/L |
|
14-21 years |
4.5-13.2 x109/L |
|
> 21 years |
3.4-10.0 x109/L |
|
| WBCs, Fecal | P221 | Negative (No cells) |
| Warfarin Metabolism | WARF |
| Wildtype 2C9 |
*1/*1 |
|
VKORC1 |
G/G |
|
| Water Culture | P055 | |
| West Nile Virus Antibodies, Serum (IgG & IgM) | WNVS | West Nile Virus IgG:
|
Negative |
<1.30 |
|
Equivocal |
1.30-1.49 |
|
Positive |
≥1.50 |
West Nile Virus IgM:
|
Negative |
<0.90 |
|
Equivocal |
0.90-1.10 |
|
Positive |
>1.10 |
|
| West Nile Virus Antibody, CSF | WNVC | West Nile Virus IgG, CSF:
|
Negative |
<1.30 |
|
Equivocal |
1.30-1.49 |
|
Positive |
≥1.50 |
West Nile Virus IgM, CSF:
|
Negative |
<0.90 |
|
Equivocal |
0.90-1.10 |
|
Positive |
>1.10 |
|
| West Nile Virus Nucleic Acid Testing (NAT) | Only orderable as package PTXID | Non-reactive |
| Western Equine Encephalitis Antibodies | WEEB |
| IgG |
< 1:16 titer |
|
IgM |
< 1:20 titer |
|
| White Blood Cell Antibodies | | |
| White Blood Cell Differential | CBCD, WBCDF | Normal Absolute Counts in x109/L (95% confidence interval):
|
AGE |
NEUTS |
LYMPH |
MONO |
EO |
BASO |
|
0-24 hours |
5.0-28 |
2.0-12 |
0.4-3.1 |
0.0-0.9 |
0.0-0.6 |
|
24 hours-1 wk |
1.5-21 |
2.0-17 |
0.3-2.7 |
0.1-1.1 |
0.0-0.3 |
|
1 wk-6 months |
1.0-10 |
2.0-17 |
0.2-2.7 |
0.1-1.1 |
0.0-0.3 |
|
6 months -4 years |
1.0-8.5 |
2.0-14 |
0.0-0.9 |
0.0-1.1 |
0.0-0.3 |
|
4-14 years |
1.5-8.5 |
1.2-8.0 |
0.0-1.4 |
0.0-1.1 |
0.0-0.3 |
|
14-21 years |
1.8-8.0 |
1.0-6.1 |
0.0-1.4 |
0.0-0.8 |
0.0-0.3 |
|
> 21 years |
1.8-6.8 |
1.0-3.4 |
0.2-0.8 |
0.0-0.4 |
0.0-0.1 |
|
| Whole Blood Electrolytes |
| NLYTE |
NCPL |
Na, K, Cl, iCa |
|
BLYTE |
MtZ |
Na, K, iCa |
| Sodium 136-146 mmol/L
Potassium:
|
0-6 months |
3.0-5.4 mmol/L |
|
> 6 months |
3.4-4.5 mmol/L |
Ionized Calcium:
|
0-6 months |
0.95-1.50 mmol/L |
|
> 6 months |
1.15-1.29 mmol/L |
|
| Wright's Stain, body fluid | WSBF | |
| XX/XY FISH (New test) | XXXY | |
| Yersinia Agglutinins | MOLT | Negative titer < 20 |
| Yersinia only Culture | P159 | |
| ZAP-70 (New test) | ZAP70 | ZAP-70+/CD19+ ratio < 10% |
| Zinc Protoporphyrin | ZIPP | 0-69 µmol ZPP/mol Hem
Refer to current OSHA regulations for exposure criteria. |
| Zinc, 24 hour urine | ZINU | 100-1200 µg/24 hours |
| Zinc, plasma | ZINC | 55 - 150 µg/dL (mcg/dL) |
| Zinc, random urine | ZINUR |
| 2nd voided urine in non-exposed ≥ 18 year old |
100-810 µg/g creatinine |
|
| Zonisamide | ZONI | 10-40 µg/mL |
| cKIT | MOLT | Negative for mutations of exons tested. |
| pH, Body fluid | PHB | |
| pH, stool | PHF | > 6.5 |
| pH, urine | PHU | 4.6-8.0 |
| vWF Exon 28 Gene Analysis | MOLT | NEG |
| von Willebrand Factor - Factor 8 Binding Ratio | VW2NR |
| vWF-Factor VIII binding ratio |
0.73-1.42 |
|
| von Willebrand Factor Antigen | VWFAG | 42-191%
See Additional Information |
| von Willebrand Factor Cleaving Protease | VWFCP |
| ADAMTS13 |
68-163% |
|
ADAMTS13 Inhibitor |
< 0.4 BEU |
|
| von Willebrand Factor Multimers (New test) | VWMULT | Normal pattern |
| von Willebrand Panel | VWP | |
